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Growth retardation and impaired bone health are common complications of paediatric 
inflammatory bowel disease (IBD), especially Crohn's disease (CD). Aetiology may 
include undernutrition, inflammatory impact on the hormonal growth axis, delayed 
puberty, the effect of drugs such as glucocorticoids (GC) and low muscle mass. Despite an 
increase in our knowledge of its pathogenesis, growth retardation and impaired bone health 
remain common problems for children with CD. Control of disease activity and 
minimizing the need for GC therapy are necessary measures to facilitate normal growth. 
However, in many cases these strategies are not sufficient and data on the role of adjuvant 
therapy with recombinant human growth hormone (rhGH) remain scarce. Moreover, 
currently there is conflicting evidence on the benefit of anti-tumour necrosis factor-α (anti-
TNF-α) on bone health and there are no reports on the effect of rhGH therapy on bone 
health in children with CD. 
To address this knowledge gap, this thesis studied the hypothesis that successful treatment 
of inflammation with anti-TNF-α would improve linear growth and bone health in children 
with CD. Additionally, a further objective was to examine the role of adjuvant therapy with 
rhGH on linear growth and bone health in children with quiescent CD. 
A prospective study was first carried out to assess the effect of 12-months anti-TNF-α 
therapy on linear growth, the growth hormone (GH)-insulin like growth factor (IGF) axis, 
and bone turnover. The results showed that other than depressed acid label subunit (ALS), 
markers of GH axis were not particularly abnormal in the majority. Bone turnover markers 
were also low at baseline. With therapy and improvement in disease, patient height was 
modestly improved in those with growth potential, and this was associated with increased 
bone formation but no clear change in markers of the GH-IGF axis. These findings suggest 
that if growth is of concern then adjuvant therapy combined with other forms of growth-
promoting therapy during critical periods of growth warrants further exploration. 
Further prospective analyses were conducted in this cohort to examine the effects of anti-
TNF-α therapy on bone density and structure, at the time of, and 12 months after initiation 
of treatment and also to explore the association of IGF-1 axis, cytokines and muscle with 
bone density in children with CD. These results indicated that although anti-TNF-α therapy 
was associated with an improvement in disease activity and bone formation, there was 
insufficient evidence, as assessed by imaging, to show a change in bone health. The 
observed persistent bone impairment could be related to two possible factors. Firstly, there 





deficit may partly explain the poor bone health seen in CD. These findings suggest that the 
anti-TNF-α therapy  may not be sufficient for improving musculoskeletal development in 
children with CD and the role of adjuvant therapy such as nutrition, exercise or 
manipulation of the GH/IGF axis requires further investigation.  
A subsequent analysis was conducted to investigate the effects of 24-months rhGH 
(67mg/kg/day) therapy on linear growth and insulin sensitivity in 14 children with CD, 
compared to an equal number of historical controls, matched for age, gender and duration 
of disease. The results of this analysis demonstrated that the growth-promoting effect of 
rhGH in children with CD, that were previously observed over a period of 6 months, is 
sustained over a longer period without a deleterious effect on glucose homeostasis. 
Improved growth with rhGH therapy was sustained over a two-year period, justifying the 
need for a randomised clinical trial (RCT) of this therapy. Close monitoring of glucose 
homeostasis is still recommended with the use of rhGH in children with CD and growth 
retardation. 
Chapter 5 explores a preliminary analysis of the effect of adjuvant therapy with high dose 
rhGH therapy for 24 months on bone health and body composition by DXA in 8 children 
with inactive/quiescent CD. The results showed that despite increases in the biomarkers of 
bone turnover with most children having completed pubertal growth, deficiency in bone 
mineral density persists. This finding may be explained by partial recovery of the GH-IGF-
1 axis and/or decreased muscle mass. These results also underscore the importance of 
muscle mass for bone health in CD children. 
A final set of analyses were performed in a survey conducted to examine the feasibility of 
a RCT of injectable forms of growth-promoting therapy; and to survey the attitudes of 
children with CD and their parents to it. The results of this survey showed that by 
approaching shorter children with CD, as well as alleviating their fears about injections, a 
future trial would be more likely to achieve higher recruitment rates. 
In summary, the body of work presented in this thesis depicted that anti-TNF-α therapy is 
associated with a modest clinical improvement in height but no observable beneficial effect 
on musculoskeletal health. The use of high dose rhGH therapy for 24 months was 
associated with growth-promoting effects but with no discernible influence on bone and 
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1.1 Crohn's disease  
Crohn's disease (CD) is a form of inflammatory bowel disease (IBD); a chronic lifelong 
remitting and relapsing inflammation of the gastrointestinal tract (GIT) that also includes 
ulcerative colitis (UC) (1). The findings of endoscopic, histological and radiological 
investigations, along with the clinical context, can be used to classify children with IBD as 
CD or UC (2;3). These two conditions differ in the localisation and extent of mucosal 
inflammation. Whereas UC is defined by inflammation limited to the mucosal layer of the 
colon, CD is characterized by transmural inflammation which may be localised to any part 
of the gastrointestinal tract, from oropharynx to anus, and include features such as 
dissentious inflammation “skip lesions”, stricture, and fistula (3;4). Approximately 10% of 
children present with pathology characteristics of CD but with the affecting tissues limited 
to the colon only, which can make the differentiation between UC and CD uncertain, even 
after a complete workup. Such cases are termed IBD unclassified (IBDU) or indeterminate 
colitis (IC) (1). CD may be defined by age of onset, location, or by pattern of disease (5) 
and these variables have been combined in the Montréal classification (Table 1-1) (5). 
 
Table  1-1: Definition of Crohn's disease phenotype using the Montréal classification 
 Adapted and modified from (5). 
Age at onset of CD Location Behaviour 
A1: < 17 years L1: Distal ileal B1: Non-stricturing, non-penetrating 
A2: 17–40 years L3: Colonic B2: Stricturing 
A3: > 40 years L3: Ileocolonic B3: Penetrating 
 L4: Isolated upper 
gastroenterology tract 





1.1.1 Aetiology and role of cytokines in pathogenesis of CD  
The aetiology of CD remains unclear and appears to involve interplay between genetic 
susceptibility, environmental factors and the immune system (6;7). A combination of these 
CD risk factors seems to initiate alterations in epithelial barrier function thus permitting the 
translocation of luminal antigens (for example, bacterial antigens from the commensal 
microbiota) into the bowel wall. Subsequently, abnormal and excessive cytokine responses 
to such environmental triggers cause subclinical or acute mucosal inflammation in a 
genetically susceptible host (8). Several cytokines have been identified as key factors in the 
pathogenesis of CD, particularly an imbalance between pro-inflammatory and anti-
inflammatory cytokines that hampers the resolution of inflammation and instead leads to 
disease continuation and tissue destruction (9). Naive CD4+ T cells have been shown to 
differentiate into T helper -1 (Th1), Th2, Th17 and T regulatory cells, upon recognition of 
cognate antigen in the context of associated environmental signals, as generated by 
cytokines or an inflammatory milieu (10). CD is considered a Th1-mediated disease, 
characterized by increased production of interferon-γ (IFN-γ) and interleukin (IL) -12, 
activating macrophages and driving the release of key cytokines include tumour necrosis 
factor-α (TNF-α), IL-1 and IL-6 that contribute to mucosal inflammation in CD (10). TNF-
α influences the production of IL-22, which has also been found to be associated with the 
Th1 pathway (11). In recent years, an additional distinct subset of T cells characterized by 
secretion of IL-17 (Th-17) under stimulation of IL-23 has been identified and linked to CD 
pathogenesis. Furthermore, Th17 cells are an important source of IL-21, an IL-22-related 
cytokine that is up-regulated in inflamed CD mucosa (10;11). T regulatory cells exert a 
potent anti-inflammatory action through production of IL-10 and transforming growth 
factor-β (TGFβ) in experimental colitis, and they are depleted in peripheral blood of 
patients with active CD, relative to quiescent CD patients and control subjects (10). 
Cytokines not only drive intestinal inflammation and associated symptoms, such as 
diarrhoea, but may also regulate extra-intestinal disease manifestations (for example, 
growth failure) and systemic effects in CD, such as impairment of bone health. A more 
detailed explanation of the role of cytokines in pathogenesis of growth and bone 






1.1.2 Epidemiology of CD 
Approximately 25% of CD cases present during childhood and adolescence (12). Among 
children with CD, 4% present before the age of 5 years and 20% before the age of 10 years 
(12), with the peak onset in adolescence between 10-14 years (12-14). Thus, the disease 
commonly presents during a short but important period of growth acceleration, which 
might play a crucial role in final height and peak bone mass. The incidence of CD 
continues to increase worldwide, with an estimated incidence of 7–10 children per 100,000 
developing CD in any given year from studies in UK, Sweden, Norway and the United 
States (15-19). 
 
1.1.3 Clinical features  
Clinical manifestation of CD in children and adolescents can exemplify many similarities 
to the disease in adults. For instance, typically, CD most commonly presents with 
abdominal pain, diarrhoea and weight loss (12). However paediatric CD can exhibit 
diverse symptoms, such that growth impairment and pubertal delay can be the presenting 
features, without any or only minimal gastrointestinal and other systemic symptoms. 
Conversely, impaired linear growth is rarely present at diagnosis in UC (20;21). Extra-
intestinal manifestations occur in 28-35% of children with CD that can present before, at 
time of diagnosis, or later during the course of disease. The most common extra-intestinal 
manifestation in children are arthritis (axial or peripheral), cutaneous disorders (erythema 
nodosum and pyoderma gangrenosum), eye diseases (such as episcleritis and uveitis), liver 
disease (primary sclerosing cholangitis, autoimmune hepatitis), impaired bone health 
(osteopenia /osteoporosis) and disorders of growth and pubertal development (22;23). An 
in-depth review of impaired growth and bone health in children with CD, the underlying 
mechanism, and management detailed later in this Chapter (Section 1.3, 1.4, and 1.5). 
 
1.1.4 Assessment of disease activity in CD 
The Paediatric Crohn’s Disease Activity Index (PCDAI) is the oldest paediatric CD 
activity score and serves as the primary outcome measure for induction and maintenance of 
remission (24). PCDAI is based on symptoms (abdominal pain, stool pattern and general 
wellbeing), physical examination (abdominal and perianal region, growth parameters 
including weight gain and height velocity), laboratory parameters (serum haematocrit, ESR 





100 (25). Since linear growth is a component of the PCDAI, the interpretation of growth 
and disease parameters based on PCDAI may confound the finding. Furthermore, the 
correlation of PCDAI and mucosal inflammation is poor (24). Weighted Paediatric Crohn’s 
Disease Activity Index (wPCDAI) is a multi-measure of disease activity based on a one-
week recall of subjective symptoms (abdominal pain, stool pattern and general wellbeing), 
laboratory parameters (erythrocyte sedimentation rate (ESR) and albumin) and physical 
examination (presence of extra-intestinal disease e.g. fever, arthritis, rash and ileitis, 
perirectal disease, and weight), with scores ranging from 0–125 (26). The cut-off point to 
identify clinical remission is < 12.5, from 12.5-40 for mild, > 40–57.5 for moderate and > 
57.5 for severe disease. Improvement (i.e. ‘response’) is defined by a reduction of 17.5 
points or more (26). Since growth is not a parameter of wPCDAI it might be considered 
more accurate to assess the relationship between disease and growth parameters. In 
addition, the wPCDAI is shorter, appears more feasible than PCDAI, and it is better at 
discriminating between the disease activity categories (26). However, none of the PCDAI 
versions are able to give a valid assessment of mucosal healing (27).  
 
1.1.5 Management  
There are two phases of management: active treatment to induce remission and 
maintenance treatments aimed at keeping the condition in remission and preventing 
relapse. There are a variety of treatments strategies for each phase supported by national 
(1;28) and international guidelines (29). Some therapies are effective only for remission 
induction or maintenance, whereas others are appropriate for both phases. However, due to 
the differing responses of patients, treatment should be tailored to each individual (1). 
Medications used for induction and maintenance of CD are summarised in Figure 1-1 
based on British Society of Paediatric Gastroenterology, Hepatology and Nutrition 
(BSPGHAN) guidelines (1). BSPGHAN recommended that surgery should only be 
considered for those for whom medical treatment has failed or who present with stricture 
(1). As paediatric IBD occurs during a critical period of growth and development, special 
considerations in treatment are needed to reverse linear growth failure, delayed puberty, 
and deficits of bone mineralization. 
To better understand the literature on CD-related growth and bone disease and their 
management, the next part of the introduction will firstly summarise normal bone structure 
and development, followed by a comprehensive review of the prevalence, aetiology and 






                        
Figure  1-1: Flow chart of the management approach to children with Crohn's disease according to British Society of Paediatric Gastroenterology, Hepatology 
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1.2 Bone structure and function  
Bone is a complex and dynamic tissue that act as biomechanical support and protection of 
soft tissue, provides an environment for marrow (both blood forming and fat storage), and  
plays a key role in mineral homeostasis (30). Bone is composed of type I collagen fibres 
(25% of bone) packed with hydroxyapatite crystals (65% of bone) that ensures resistance 
to fracture through an optimal balance of flexibility and stiffness (30). 
Morphologically, bone has two components: cortical or compact (external layer) bone 
making up approximately 80%, and trabecular (internal layer) bone encompassing 20% of 
total bone mass (Figure 1-2) (31;32). Cortical bone is found in the diaphysis of the shaft of 
long bones. It also forms the outer shell around trabecular bone at the end of long bones 
and the vertebrae. Cortical bone serves a structural and protective role. It has a low 
porosity of between 5% and 10% and a slower turnover rate (annual rate of 3-5%), which 
gives it a harder structure, with less vulnerability to fracture than trabecular bone (31;32). 
Trabecular bone is found within the cortical bone in the metaphysis and epiphysis of long 
bones and in the vertebrae. Trabecular bone has a significantly higher porosity than cortical 
bone, of between 50-90%. Due to its porosity, trabecular bone has a large surface that 
makes the bone tissue more metabolically active, with a remodelling rate of 20–25% 
annually. Trabecular bone is therefore more sensitive to disturbances in bone formation or 
bone resorption, and osteoporosis-induced fractures occur mainly in trabecular bone 
(31;32).  
There are two bone surfaces: the periosteum, which is a fibrous connective tissue sheath 
that surrounds the outer cortical surface of bone, with the exception of joints, and the 
endosteum, which is a membranous structure on the internal surface of bone covering the 














































Figure  1-2: Structure of tibia bone illustrating different structures 
 
 
1.2.1 Bone cells  
Bone is a highly metabolic connective tissue and its material is constantly in a state of 
turnover. There are three main cell types in bone tissue that are responsible for its 
biological activity: bone-forming osteoblasts, bone-resorbing osteoclasts, and osteocytes 
















1.2.1.1 Osteoblasts  
Osteoblasts are derived from mesenchymal stem cells (33). Osteoblasts are found on the 
bone surface and synthesise bone matrix (osteoid) by secreting collagen, non-collagen 
proteins (osteocalcin (OC), bone sialoprotein (BSP), osteopontin (OP) and osteonectin 
(ON)), bone specific alkaline phosphatase (BSAP) and ultimately stimulate bone 
mineralization (34). Whereas BSAP is used as an early marker, OC is considered to be a 
late marker for osteoblast differentiation. Osteoblasts also function as regulators for 
osteoclastogenesis by secreting OPG (ostpeprotegerin; inhibitory) and an activator of 
nuclear factor- κB ligand (RANKL; stimulatory) (35). Mechanical load, oestrogen, insulin-
like growth factor-1 (IGF-1) and parathyroid hormone have been shown to play key roles 
in stimulating osteoblast function (36). 
 
1.2.1.2  Osteocytes 
Osteocytes are derived from osteoblasts and are the most abundant cells in bone (37;38). 
Osteocytes are found embedded in the bone matrix within lacunae and have several roles. 
Because of their location and their complex dendritic network, osteocytes act as 
mechanosensors. They respond to mechanical load by sending inhibitory signals to 
osteoclasts and stimulatory signals to osteoblasts. Osteocytes are involved in the bone 
remodelling process through a number of different mechanisms. Apoptotic osteocytes 
trigger signals that attract osteoclast precursors to specific areas of bone, which in turn 
differentiate to mature, bone-resorbing osteoclasts and initiate the bone remodelling cycle. 
Osteocytes are also the source of molecules that regulate the generation and activity of 
osteoclasts, such as OPG and RANKL. Osteocytes can also inhibit bone formation by 
secretion of sclerostin (37-39).  
 
1.2.1.3 Osteoclasts 
Osteoclasts are found on the bone surface and within lacuna. They are unique cells that 
possess an ability to resorb both the organic and inorganic matrices of bone tissue by 
secreting acid, proteolytic enzymes (cathepsin K), and collagenase (36). RANKL and OPG 
are the master regulators of osteoclastogenesis (36). RANKL stimulates osteoclast 
differentiation and activation and inhibits osteoclast apoptosis, thereby dramatically 
prolonging osteoclast survival (36). Moreover, there are several other factors that are 





dihydroxyvitamin D3, macrophage-colony stimulating factor (M-CSF), IL-1 and TNF-α 
and parathyroid hormone (PTH). 
 
1.2.2 Bone growth and development 
During childhood, bones increase in length and width, and undergo modelling and 
remodelling. These processes work to develop and maintain bone mass and health (31). 
Longitudinal bone growth is the result of a process called endochondral ossification, by 
which the embryonic cartilaginous model of most bones is gradually substituted by 
calcified bone (40;41). Longitudinal bone growth occurs at the growth plate (Figure 1-2) 
(40-42).  
The growth plate encompasses one cell type, the chondrocyte, distributed at various points 
of differentiation within zones designated as resting; proliferative or hypertrophic (Figure 
1-3). The resting zone is situated adjacent to the epiphyseal bone and as the name implies, 
consists of resting chondrocytes that do not have a function in bone growth. The resting 
chondrocytes are found in a scattered pattern, proliferate at a slow rate, and store nutrients 
for proliferative chondrocytes (43;44). The proliferative zone contains chondrocytes in a 
high rate of propagation. This region has a characteristic histological appearance wherein 
chondrocytes are arranged in a manner akin to stacked coins. The thickness of this zone is 
proportional to the growth rate, with wider zones displaying an increased level of growth 
(44;45). In the hypertrophic zone, chondrocytes are hypertrophied and increase their height 
about 6-10 fold, arranged in column-like structures (40;44;46). The newly formed cartilage 
is invaded by blood vessels and bone cell precursors, which remodel the hypertrophic zone 
cartilage into bone (40;41). 
The process of longitudinal bone growth is complex and tightly regulated by several 
factors. Hormones play a major role in the regulation of longitudinal bone growth and most 
central are the growth hormone/insulin like growth factor-1 (GH/IGF-1) axis, thyroid 
hormone, and sex steroids. Nutrition is also an imperative regulator of growth (47).  
Growth is rapid in infancy, followed by slower rate until puberty (47;48). Linear growth 
increases again at puberty, characterised as the individual’s growth spurt or peak height 
velocity (PHV). PHV accounts for 20-25 % of adult height (47;48) and during the pubertal 
growth spurt almost half of adult bone mass is acquired (49), with the attainment of peak 
height velocity preceding peak mineral accumulation by about 7 months (50). The 
relationship between bone mineral gain during childhood and adolescence, and bone 






The rate and timing of PHV is different between the genders. In healthy girls, PHV is 
attained 2 years earlier than boys, at approximately 12 years, coinciding with early onset of 
puberty (breast stage-2), whereas in healthy boys it occur late in mid-puberty, 
corresponding to genital stage 4 (47;48). Generally, sex steroids accelerate growth through 
an increase production of GH and IGF-1 (48). Since the chronological age does not mirror 
the pubertal maturity, the recommendation is to consider puberty and the potential to grow 






















Figure  1-3: Histological structure of a growth plate 









1.2.3  Bone modelling and remodelling  
Table 1-2 summarises the important characteristics of bone modelling and remodelling 
(54-56). Bone modelling is defined as either the formation of bone by osteoblasts or 
resorption of bone by osteoclasts, on a given surface, in an uncoupled manner (54-56). 
Bone modelling is responsible for changes in the shape and size of the bone, such as those 
observed during growth, or adaptive responses to a change in mechanical loading patterns 
(54-56). For example, modelling activity on the diaphyseal cortices during growth, 
characterised by rapid periosteal formation modelling, is countered by resorptive 
modelling on the endocortical surface, resulting in a relatively consistent cortical thickness 
over time while increasing the width of the bone (54-56).  
In contrast, remodelling occurs in a coupling manner at the same site on the same bone 
surface to conserve the bone without any net increase in bone mass (54-56). This process is 
coordinated by multiple cell types, including osteoclasts, osteoblasts, osteocytes and 
osteoblast-derived lining cells, which form small packets called basic multicellular units 
(BMU) under the control of the OPG-RANKL system (54-56). The remodelling cycle 
includs five basic phases (Figure 1-4). The first stage is the “activation phase” and involves 
recruitment of osteoclast precursors to an area of bone, differentiation and activation, 
followed by the “resorption phase”, where the mature osteoclast dissolve minerals and 
liberate collagen fragments to form small cavities in the bone surface. The third, “reversal 
phase”, is characterized by the cessation of osteoclast resorption and the initiation of bone 
formation, leading directly into the “bone formation phase”, where the osteoblasts deposit 
new un-mineralised bone matrix (osteoid), followed by mineralisation. Osteoblasts 
incorporated into bone matrix transform into osteocytes to complete bone formation. In the 
final “resting phase” the bone surface is covered with bone lining cells and the majority of 
bone surfaces within the bone are in a state of quiescence (54;55). Any interruption in the 
coupling remodelling process can lead to pathology of the bone such as osteoporosis (54-
56). In cortical bone, increased remodelling results in increased cortical porosity and 
decreased intracortical bone density, whereas in trabecular bone, the net negative balance 











Table  1-2: Characteristic of bone modelling and remodelling 










  Modelling  Remodelling  
Function  Shape bone and size during childhood 
Increase bone density 
Renew bone after micro-damage  
Maintain bone density 
Maintain mineral haemostasis  
 
Bone component Periosteal, endocortical 
and trabecular 
Periosteal, endocortical, trabecular, and 
intracortical 
 
Cells involved Osteoclasts and osteoblasts and precursors Osteoclasts and osteoblasts and precursors 
 
Mechanism  Uncoupling activation of bone resorption 
or formation  
Coupling activation of bone formation and 
resorption  
 
Time Mainly childhood but continues 
throughout life 













































Figure  1-4: Bone remodelling cycle 
Activation phase, osteoclasts are attracted to the resorption site; Resorption phase, osteoclasts dissolve 
bone matrix; Reversal phase, osteoblast precursors differentiate into mature osteoblasts and migrate into the 
resorption area; Formation phase, osteoblast initiate bone formation; Resting phase, the osteoblast initiate 
bone formation. Adapted and modified from (57).












1.2.4 Biomarkers of bone turnover  
Several biomarkers of bone turnover are released into the circulation during the process of 
bone formation and resorption, reflecting information about the dynamic bone metabolism 
process (58;59). These biomarkers can be measured in blood or urine (58;59). In adults, it 
has been documented that accelerated bone turnover is associated with an increased 
fracture risk (60). However, in children, biomarkers of bone turnover not only reflect bone 
remodelling but also growth in bone length (endochondral ossification at growth plate), 
growth in bone width (bone modelling), and pubertal growth spurt. Therefore, an accurate 
interpretation of bone biomarkers in children should take growth and pubertal maturation 
in to consideration (61), and this is particularly crucial for children who receive growth-
promoting therapy. Additionally, pubertal delay is common in the cohort of IBD children, 
so the age and gender matched control, without taking puberty in consideration, may not be 
precise (62). Generally, in children, biomarkers of bone turnover are mostly investigation 
tools for short-term longitudinal studies to assess the impact of specific intervention and 
not used for prediction of fracture risk (61). Bone biomarkers complement bone mass 
evaluation by dual energy x-ray absorptiometry or quantitative computed tomography in 
children by providing a dynamic picture of whole body bone turnover that can be repeated 
regularly. This dynamic evaluation allows early detection of disease or therapy 
consequences, long before changes in bone mass or progression in bone disease can be 
precisely ascertained (63). 
 
1.2.4.1 Marker of bone formation 
Markers of bone formation are either by-products of active osteoblasts expressed during 
the various phases of their development or osteoblastic enzymes. The most widely used 
markers of bone formation are measured in serum or plasma and include: bone specific 
alkaline phosphatase (BSAP), osteocalcin, and the carboxy- and amino-terminal 
propeptides of type 1 collagen (58;59;64). BSAP has a long half-life, low diurnal variation, 
clearance is not dependent on the kidney, and food has little effect. In combination with 
sample stability and a cheap-to-perform assay with lower intraindividual variability than 
other bone turnover markers, it makes BSAP a valuable and sensitive bone formation 
marker (58;60). However, BSAP is affected by cross-reactivity with the liver form of 
alkaline phosphatase, limiting its use in patients with liver disease (58;60). Theoretically, 
osteocalcin should be the most accurate marker of osteoblast activity. However, diagnostic 





and by difficulties in differentiating between the several molecular forms that are found in 
the circulation (65). Collagen type 1 is by far the most abundant protein synthesized by 
osteoblasts. Procollagen type 1 Amino terminal Propeptide (P1NP) and Procollagen type 1 
Carboxy -terminal Propeptide (P1CP) are propeptides cleaved from type I procollagen 
during collagen formation and released into circulation (59;60). The advantage of P1NP 
and P1CP as markers of bone formation is that they reflect the activity of a crucial and 
well-characterized step of bone formation - the synthesis of collagen type 1. Thus, P1NP 
represents a real bone formation marker, is stable, its levels are reproducible and 
independent of the timing of sampling, and no circadian variation has been documented. 
However, P1NP has a higher cost of measurement compared with other bone turnover 
markers (58;60). 
 
1.2.4.2 Markers of bone resorption  
The majority of markers of bone resorption such as pyridinoline (PYD) and 
deoxypyridinoline (DPD), and cross-linking telopeptides of collagen type 1 including the 
C-terminal and N-terminal cross-linking telopeptides are degradation products of bone 
collagen, whereas tartrateresistant acid phosphatase (TRAP5b) is an enzyme of osteoclast 
origin (58;59;64). Telopeptides of type 1 collagen are the most extensively studied and 
used as bone resorption markers. Depending on the cross-link forming site with collagen 
there are two types, which are released during collagen degradation, Carboxy-terminal 
(CTX) and amino-terminal (NTX) cross-linking telopeptides. CTX is considered the 
marker of choice and the international Osteoporosis Foundation has selected serum CTX as 
the reference marker for bone resorption (60). CTX is released by cathepsin-K cleavage of 
type I collagen during bone resorption (58). However, CTX is subjected to large circadian 
variation, thus repeated sampling must be done at the same time of day, under fasting 
conditions, and immediate freezing is required to minimise degradation (58;60).  
 
1.2.5 Growth hormone–insulin-like growth factor (GH–IGF)-1 axis 
GH is secreted from the anterior pituitary gland in a pulsatile manner under control of 
hypothalamic growth hormone-releasing hormone (GHRH), which stimulates its secretion. 
GH circulates in the body bound to GH-binding protein (GHBP), where it interacts with 
hepatic GH receptor to generate IGF-1, the main mediator of GH action. The liver 
contributes up to 75% of circulating IGF-1 (66). Hepatic-produced IGF-1 circulates bound 
to one of the six binding proteins, collectively called the insulin-like growth factor binding 





abundant IGFBP in serum is IGFBP-3. In serum, most of the IGF-1 is found in a complex 
formed by IGFs, IGFBP-3, and a non-IGF binding glycoprotein known as the acid labile 
subunit (ALS) (66). IGFBP-2 is known to be a negative regulator for GH- IGF-1 (67). 
 
1.2.5.1 GH-IGF-1 axis regulation of bone growth and bone mass  
Figure 1-5 illustrates the effect of the GH-IGF-1 axis on growth and bone mass. GH–IGF-1 
axis is the major regulator of linear growth from postnatal life to throughout puberty (47). 
GH may acts directly on the growth plate to stimulate the differentiation of chondrocytes 
or through the intensification of local and systemic IGF-1 secretion (68). Although most of 
the circulating IGF-1 is produced by the liver under influence of GH, it seems that locally 
derived IGF-1 may be more important for postnatal growth (69). However, conflicting data 
exists to challenge this hypothesis (68). In one study, when hepatic IGF-1 secretion was 
restored in IGF-1 null mice, some growth was also restored (68). Furthermore, GH can 
promote longitudinal bone growth through IGF-independent mechanisms (70-72). A role 
for GH acting directly on growth plate cartilage is also suggested by data from suppressor 
of cytokine signalling 2 (SOCS2) null mice. SOCS2 is expressed by epiphyseal 
chondrocytes, and is a recognised negative regulator of GH signalling via inhibition of the 
Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway (72). 
On the other hand, it is well documented that the GH/IGF-1 pathway is a critical regulator 
of osteoblast function, bone homeostasis, and ultimately, bone mass (66;73-75). The GH 
action on bone mass can be direct (IGF-1 independent) or indirect (IGF-1 dependent). 
Furthermore, the close connection between GH and IGF-1 hinders deciphering the relative 
contributions of the systemic and locally derived IGF1 on bone attainment. Based on the 
data obtained from animal models, systemic IGF-1 appears to predominantly influence 
cortical bone. Conversely, local IGF1 is important in regulating trabecular architecture, 
with minimal effects on cortical geometry (76-79). Animal data also provides compelling 
evidence to support the concept that GH can regulate osteoblast function, and ultimately 





































Figure  1-5: The GH-IGF axis and its role in linear growth and bone mass 
GH is released from the pituitary. GH receptor is expressed throughout the body, including within the liver 
and at growth plates and bone cells. GH is the prime regulator of the IGF-1 gene in the liver. The liver is a 
major contributor to serum IGF-1. The majority of circulating IGF-1 forms a ternary complex with IGFBP-3 
and ALS, which regulate its half-life and deliver it to the tissues. GH also stimulates local production of IGF-
1 within bone. Adapted and modified from (66). GH, growth hormone; IGF-1, insulin like growth factor-1; 
IGFBP-3, insulin like growth factor binding protein-3; ALS, acid label subunit.
GH 
Increase linear 










1.3 Growth impairment in children with CD 
As described earlier in this chapter, CD is not limited to the GI tract. The disease can also 
exhibit extensive and varied extra-intestinal manifestations, such as impaired growth and 
bone health. Given the age of presentation of IBD, there is a limited window of 
opportunity for improvement of growth and bone health before skeletal maturation. 
 
1.3.1 Definition of growth failure 
As yet there is no universal agreement to define growth failure (81). One commonly used 
definition is a height (Ht) lower than the third percentile (≤ -2 standard deviation scores 
(SDS)) (81). However, the formal definitions may underestimate the prevalence of 
individuals with subnormal growth velocity, that experience a decline in their growth 
within a certain period of time, but still obtain a height above defined lower limits (82). 
Another pitfall of these definitions is that static height is primarily influenced by genetic 
determinants, reflecting both parents' height and thus needs to be interpreted in the context 
of the child’s midparental height (MPH) (83). Whilst some have suggested that growth rate 
(height velocity, HV) and HV SDS, adjusted for age and gender, are a valid method of 
identifying growth failure (83), HV represents growth status at a particular point of time 
and might present a more sensitive marker for the impact of disease on normal growth. 
However, in a cohort of children where the extent of pubertal delay may be relatively 
common, comparing HV purely based on age and gender may be deceptive as it varies 
according to pubertal status. Thus, an understanding of pubertal staging or bone age is 
needed to interpret HV. Furthermore, the available normative data for HV is based on a 
small and old reference dataset (84). The use of change in Ht SDS ( Δ Ht SDS) has been 
suggested as a more robust way to report response to growth promoting therapy in children 
with chronic disease in longitudinal studies, particularly when there is a high prevalence of 
children of peripubertal age (84). Growth impairment has been defined by some as HV 
SDS below -1 with Ht SDS below -1 or a reduction from MPH SDS of more than 1.0, and 
severe growth impairment as reduction from MPH SDS of more than 1.0 combined with a 
Ht SDS of less than -2 (85). Measurements of bone age may improve the interpretation of 






1.3.2 Growth failure in children with CD 
Growth failure is twice as common in CD compared with UC and may be the first 
manifestation of disease (87). At diagnosis, growth failure may be present in up to 56 % of 
children with CD and 10 % of children with UC (20). Ht SDS < -2.0 is present in 
approximately 10% of children with CD at diagnosis (84;88;89). Furthermore, a quarter of 
affected children may continue to grow slowly and remain short as adults (90;91). The 
duration of CD disease negatively correlates with degree of growth retardation, and, in 
turn, is subsequently associated with reduced adult height (90;91). Thus, early 
identification and treatment of CD is of the utmost importance in IBD clinics in order to 
improve growth outcomes (21;91;92). Another factor that studies have consistently shown 
to correlate with growth failure is disease location, in particular, the proximal small bowel 
was associated with reduced linear growth, and this may be principally related to a 
malabsorption of micronutrients and disaccharide intolerance, resulting in shorter gut 
transit times, pain, and exacerbation of diarrhoea (88;91;93).  
Evidence as to whether gender has an influence on growth failure is conflicting. Some 
reports have demonstrated that males are more likely to be associated with reduced linear 
growth, and that this may be due to an effect on the pubertal growth spurt which occurs 
later and lasts longer in boys (94;95). In contrast, other studies have detected no difference 
in growth between the genders (88;91;96).  
Both adults and children with a chronic inflammatory condition such as CD are now living 
longer, and the adverse effects of chronic inflammation on growth and skeletal 
development have been ranked by the Crohn’s and Colitis Foundation of America as one 
of the top areas that require further attention (97). A recent study in a cohort of 
contemporary children and adolescents with IBD demonstrated a negative association of 
Ht SDS with the body image domain of the pediatric IBD specific quality of life score 
IMPACT III, with higher scores indicating poorer quality of life (98). However, quality of 
life is a challenging area in which to obtain meaningful data as there needs to be distinction 






1.3.3 Pathophysiology of growth impairment in CD 
The mechanisms of growth failure are multifactorial and involve the GH–IGF axis at a 
peripheral and central level (Figure 1-6) (99). Although the exact mechanisms of 
disturbance of the GH–IGF axis in CD children are still debatable (99-101), there is 
evidence to show that some children have low levels of IGF-1 despite normal GH secretion 
(102;103). These findings point to growth hormone resistance as a possible mechanism 
that may explain growth failure in short children with CD. Recent data has suggested that 
systemic GH–IGF-1 axis is affected to a variable extent in poorly growing children with 
CD, and that the abnormalities may range from functional GH deficiency to GH resistance 
and low IGF-1 level (100;101). A retrospective review of 28 patients with IBD reported 
that peak GH levels following insulin-induced hypoglycaemia were variable and 
subnormal in some cases (peak GH˂3 mcg/l and IGF-1 SDS˂0) but IGF-1 concentrations 
were almost universally low (101). 
The role of specific genetic and immunological factors in growth variation in children with 
CD continues to be an area of active research (90;93;104). Evidence from an in vivo study 
reported polymorphisms in the dymeclin gene (DYM) are associated with growth failure in 
CD children (90). Further evidence to the importance of specific gene polymorphisms 
comes from a study that investigated genetic variants associated with disease susceptibility 
that were also associated with growth impairment. They found that patients with a specific 
organic cation transporter 1/2 (OCTN1/2) haplotype had a significantly lower height at 
diagnosis (104). 
A study of 153 children with CD at time of diagnosis reported that the IL-6 174GG 
genotype was correlated with a lower Ht SDS score and higher circulating level of C-
reactive protein (105). Also, data from Levine et al (106) showed that variations in the 
TNFα promoter region of the TNFα gene might independently modify linear growth and 
disease severity in paediatric onset CD. They suggested that the presence of either the TNF 
238G/A or 863C/A polymorphism, which is linked to a reduced level of TNFα, was 
associated with higher mean Ht SDS, and thus had a protective effect on growth 
retardation, whereas two other polymorphisms were associated with disease severity. A 
recent in vitro study shows that defects in innate immunity due to granulocyte macrophage 
colony stimulating factors autoantibodies (GM-CSF Ab) in a CARD15 deficient host is 
associated with growth impairment in CD and hepatic GH resistance in murine ileitis (93). 
It is possible that these genetic polymorphisms are associated with variable immune 




















Figure  1-6: Possible mechanism of growth failure in children with Crohn's disease 
GH, Growth hormone; IGF-1 insulin-like growth factor-1; LH, luteinizing hormone; FSH, follicle-





1.3.3.1  Nutrition 
Over 80 % of children with CD are malnourished at the time of diagnosis (107) due to 
decreased nutrient intake, decreased gut nutrient absorption, increased loss, and increased 
requirements (108). An abnormal level of serum GH is often found in a state of 
malnutrition, being high in acute status, but reduced in chronic nutritional deficit. 
However, in protein-restricted rats, administration of GH was not associated with 
normalisation of IGF-1 levels, suggesting a degree of GH resistance (109). The nutrition 
disturbance that occurs in CD may contribute to GH resistance by several mechanisms. 
Reduced lean body mass is one consequence for children with CD, similar to that seen in 
cystic fibrosis. Sermet-Gaudelus et al. (110) showed a strong correlation between low 
serum IGF-1 levels and reduced lean body mass in cystic fibrosis patients. Furthermore, 
both lower circulatory IGF-1 and IGFBP-3 levels were found in children and adults with 
restricted energy and protein intake (111). The reduction in both IGF-1 and IGFBP-3 was 
observed to be associated with high GH levels and the authors suggest a degree of GH 
resistance at the receptor level in human subjects with energy restriction (111). Thus, 
nutritional deficit can contribute to both functional GH deficiency and resistance seen in 
those children. However, improving nutrition has been shown to be associated with only a 
partial improvement in growth in animal studies, suggesting that poor growth is not solely 
due to poor nutrition, with over 40 % of impairment in growth explained by inflammation 
(112).  
 
1.3.3.2 Effect of inflammatory cytokines on the GH-IGF-1 axis 
The effect of pro-inflammatory cytokines on growth has been extensively studied (113). A 
negative correlation between cytokine and IGF-1 levels indicate that cytokines may impair 
growth through disturbance of the GH–IGF-1 axis in CD and induction of a level of GH 
resistance (112;114;115). Drug-induced colitis in pair-fed rats is associated with 
impairment in growth, a normal GH level, and a low IGF-1 level, suggestive of a state of 
GH resistance. Administration of IGF-1 to the colitis group was associated with an 
increase in the circulating IGF-1 level and linear growth by approximately 44–60 %, 
suggesting that the effect of disease on growth due to systemic GH resistance could be 
partially overcome by increasing IGF-1 (112). The cellular mechanisms by which 
inflammatory cytokines modulate the GH axis remain unclear but the possible role of 
suppressor of SOCS has been suggested (116). The existing evidence shows a role for IL-6 





relationship between plasma IL-6 and IGF-1 levels (114). It is of interest to note that 
administration of IL-6 antibodies to rats with colitis and growth failure was associated with 
a significant improvement in linear growth and IGF-1 level but that administration of TNF-
α had no effect on circulatory IGF-1 levels (105). An association has also been 
demonstrated in children with IBD between cytokines and physical growth as well as 
markers of the GH-IGF axis. In 37 children with IBD (17 CD), IGF-1 levels were lower, 
whilst IGFBP-2 was higher during relapse, compared with controls. IL-1β levels were 
related to IGF-1 and IGFBP-2 (117). There is also evidence that TNFα may reduce 
expression of GH receptors by hepatocytes and thus reduce circulatory IGF-1.Furthermore, 
IL-6 may decrease circulatory IGF-1 half-life by increasing the breakdown of IGFBP-3 
and interfering with formation of the IGF-1/IGFBP-3/acid labile subunit (ALS) complex 
(Figure 1-7) (85). IL-1B may also inhibit local production of IGF-1 (118). An in vivo study 
showed that greater increases in IGF-1, and decreases in TNF-α and IL-6 levels, were 
associated with increases in height-SDS in paediatric CD (115). The researchers proposed 
the possibility of immune-mediated mechanisms in growth failure. However, treatment 
with IGF-1 could only partially normalise the growth suppressive effects, suggesting that 








Figure  1-7: Possible mechanism of effect of inflammatory cytokines on systemic GH-IGF1 
axis 
Tumour necrosis factor (TNFα) may reduce expression of growth hormone (GHR) receptors by hepatocytes 
and thus reduce circulatory insulin-like growth factor-1 (IGF-1). Interleukin-6 (IL-6) may decrease 
circulatory IGF-1 half-life by increasing the breakdown of insulin-like growth factor binding protein-3 
(IGFBP-3) and interfering with formation of the IGF-1/IGFBP-3/acid labile subunit (ALS) complex. 
Interleukin-1β (IL-1β) may also inhibit local production of IGF-1. TNF-α may suppress growth by inducing 
anorexia in patients with chronic inflammation by acting through the appetite regulatory centre at the 






1.3.3.3 Effect of inflammatory cytokines on the growth plate 
Animal studies show that both TNF-α and IL-1β inhibit growth plate chondrocyte 
differentiation and increase apoptosis, and inhibit cartilage-specific proteoglycan synthesis 
(119;120). TNFα and IL-1β have both synergistic and additive consequences as when 
combined; they more severely hinder longitudinal growth in the rodent metatarsal model 
(119;120). Additionally, data from a culture model showed that the duration of exposure to 
pro-inflammatory cytokines is critical, such that dramatic irreversible decrease in growth 
was associated with longer duration of exposure (120). This may reflect the clinical 
findings of greater growth impairment in those children who have a longer period of 
symptoms prior to diagnosis (21;91;92). In addition, TNF-α may suppress growth by 
inducing anorexia in patients with chronic inflammation by acting through the appetite 
regulatory centre at the hypothalamic level (121).  
 
1.3.3.4 Effect of glucocorticoid on GH–IGF axis 
The negative effect of glucocorticoid (GC) on growth occurs through multiple mechanisms 
and is an important drawback of using this medication in children with CD (87). Growth 
recovery is poorer following the use of GC as compared with enteral nutrition in the early 
phase of treatment for paediatric CD (122;123). GC can interfere with the GH–IGF axis 
through attenuation of GH secretion by increasing hypothalamic somatostatin tone and a 
loss of pulsatile release (124). Steroid exposure can also lead to functional IGF-1 
deficiency through downregulation of liver GH receptors, thus suppressing IGF-1 
production and inhibiting IGF-1 bioactivity (125). However, it is difficult to separate the 
effect of GC therapy on growth, weighing its anti-inflammatory properties against its 
defined adverse impacts. Indeed, no association were found between GC and linear growth 
in some clinical studies in children with CD (126;127). 
 
1.3.3.5 Effect of glucocorticoid on the growth plate 
GC may also inhibit linear growth through pathways that are independent of the systemic 
GH–IGF axis. They may impair GH receptor expression at the level of the growth plate 
thus decreasing GH action and local IGF-1 production (128). They may also restrict 
chondrogenesis by reduced chondrocyte proliferation and increased apoptosis rates, 






1.3.3.6 Pubertal delay  
Delayed puberty is a commonly encountered issue in children with CD (14;98;132;133), 
with potential sequelae, such as poor linear growth (14;98;132;133). Studies of children 
and adolescents with CD have reported delays in bone age (134), breast development 
(135), menarche (134;135), testicular enlargement (135), and the pubertal growth spurt 
(14). The abnormalities of the hypothalamic–pituitary–gonadal (HPG) axis include 
hypogonadotropic hypogonadism and abnormalities of sex steroid synthesis or action of 
sex steroid (136-138). Preclinical data has suggested a mechanism in which both under-
nutrition and inflammation are postulated to induce central and peripheral hypogonadism 
(136-138). Generally, it is documented that under nutrition is associated with decreased fat 
tissue, with a subsequent reduction in levels of leptin, an essential hormone for the normal 
initiation of puberty (87). However, investigations in rat models with colitis revealed that 
inflammation appears to have a detrimental effect on pubertal development and either 
directly inhibits puberty or potentiates the effects of under nutrition (136). A recent study 
in rats with induced colitis showed that pubertal delay in colitis cannot solely be explained 
by reduction in leptin level only. They suggest the inhibition of gonadotrophins secretion 
by inflammatory cytokines as a conceivable explanation of pubertal delay in mice with 
colitis (137;138). In mice with experimental colitis, treatment with a monoclonal antibody 
against TNF-α resulted in partial normalization of oestrogen production, as evidenced by 
earlier vaginal opening, an oestrogen-dependent marker of pubertal progression in murine 
models (139). This finding was supported by a recent clinical study that showed 
improvements in disease activity and cytokine levels in children with CD during induction 
therapy were associated with rapid and significant increases in sex hormone and 
gonadotropin levels, independent of body mass index or fat mass. The authors suggest a 
role of inflammatory cytokines in this regulation among individuals with an inflammatory 
condition (140). Thus, the negative effect of inflammation on the growth axis and puberty 
may provide a plausible explanation for poor growth and short adult height seen in children 
with IBD. 
In summary, significant growth impairment is often seen in children with CD leading to a 
short stature at adult height. Depending on how growth failure is defined, approximately 
10% of children with CD are considered short at the time of diagnosis. Current data 
suggests that a proportion of children with CD will not achieve their expected final height. 
The underlying mechanism is multifactorial and includes poor nutrition, chronic 





in the GH-IGF axis exist in these children, although emerging evidence points to 
perturbations at the level of the growth plate as a result of cytokine-driven insult and also 
effects of GC treatment. Given the multifactorial pathogenesis of growth impairment in 
children with CD, a multifaceted approach may be needed to improve growth. 
 
1.4 Impairment of bone health in children with CD 
 
1.4.1 Definition of osteoporosis  
Osteoporosis is a skeletal condition characterised by decreased bone mass and 
deterioration of the microarchitectures and quality of the skeleton, with a consequental 
reduction in bone strength and predisposition to fractures (141). An accepted clinical 
definition of osteoporosis is an adult areal bone mineral density (aBMD) T-score measured 
by Dual-energy X-ray absorptiometry (DXA) of less than -2.5 (142), however, the 
interpretation of the standard deviation score (SDS) is less established for assessment of 
osteoporosis in paediatrics (143). Current paediatric densitometry guidelines (the 
International Society for Clinical Densitometry (ISCD)) agreed that the presence of one or 
more vertebral compression fracture (decrease of vertebral height at any point of more than 
20%) in the absence of disease or high energy trauma is established as an indicator for the 
diagnosis of osteoporosis in children and adolescents. In the absence of vertebral fracture, 
the ISCD stated that the diagnosis of osteoporosis requires the presence of both a clinically 
significant history of fracture (two or more long bone fractures by the age of ten years or 
three or more long bone fracture at any age up to 19 years), combined with low BMD or 
bone mineral content (BMC) (of less than -2) adjusted for age and or body size as 
appropriate (144). Recently, the expert consensus recommended defining sub-optimal 
BMD as BMD SDS of less than -1 in children and adolescents with IBD (145).  
Bone strength depends not only on bone mineral density (BMD) but also on bone quality 
(141). Bone quality is determined by microarchitecture, mineralization, and geometry of 
bone. Bone microarchitecture is determined as width, number and spatial organization of 
bone trabeculae, and by cortical porosity (146). Bone geometry is determined as persioteal, 
endosteal circumference, cortical thickness and cortical cross-sectional area (146). Imaging 
techniques such as peripheral quantitative computed tomography (pQCT), high-resolution 
pQCT, and micro-MRI that can measure one or more of the determinants of bone strength 





Osteoporosis in childhood and adolescence can be primary or secondary due to chronic 
disease (141). The pathogenesis of secondary osteoporosis is multifactorial. The 
underlying mechanism of osteoporosis in CD will be detailed in the next section. 
 
1.4.2 Bone health impairment in CD 
Poor bone health is a documented complication in children with CD (147-149). Evidence 
from laboratory, clinical, imaging, and bone biopsy studies suggest that at the time of 
diagnosis both bone formation and bone resorption are reduced in children with CD, with a 
significant reduction in markers of bone formation (62;149-151). Recent studies have 
reported that 43-46% of children with CD had BMD SDS < -1 SD at diagnosis (149;152). 
In children with newly diagnosed CD, both tibia and radius exhibit decreased trabecular 
bone mineral density, expanded endocortical surface, and reduced periosteal 
circumference, resulting in bone that is predicted to be mechanically weaker (153-155). 
In children with CD, bone mass deficits are apparent at diagnosis, with an incomplete 
improvement in bone mass after median 12 to 24 months follow-up (149;153-
155;155;156). This impairment in bone health may result in an increased risk of fractures. 
Nevertheless, studies investigating the non-vertebral fracture rate are inconclusive 
(157;158) and data on vertebral fractures are scarce (145). However, growing evidence 
suggests an increase rate of vertebral fracture, which may be subclinical in children and 
adolescents with CD (159;160). The prevalence of vertebral fractures in a cohort of 80 
children with IBD was 11% after of an average of three years post-diagnosis, compared to 
3% in healthy controls (159). Accordingly, the ISCD Pediatric Official Positions 
concluded that children with CD should undergo DXA assessment of lumbar spine BMD 
at diagnosis, and annually thereafter, as indicated (161).  
Furthermore, given that paediatric CD most frequently presents during late childhood or 
early adolescence, at the time when bone mass is acquired at the fastest rate, it may effect 
bone mass accrual. Premenopausal women with childhood onset CD demonstrated 
significantly reduced BMD (162). Thus, uncontrolled disease during those years may lead 
to a reduction in peak bone mass accrual and therefore increased lifetime fracture risk 
(163;164). Overall, studies addressed the impact of childhood IBD on peak bone mass are 
still lacking and currently, there is little data on fracture history of adults with paediatric-






1.4.3 Pathophysiology of bone impairment in CD 
The pathophysiology of skeletal morbidity in CD is complex and may contribute to 
























Figure  1-8: Possible mechanism of bone mass impairment in children with Crohn's disease 
GH, Growth hormone; IGF-1 insulin-like growth factor-1; LH, luteinizing hormone; FSH, follicle-
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Changes in calcium and vitamin D homeostasis may contribute to bone deficits. Vitamin 
and mineral deficiencies have been described in patients with CD and are attributed to gut 
mucosa inflammation and a reduced oral intake (147-149;166-170). Vitamin D and 
calcium are important for maintaining adequate bone homeostasis and facilitating bone 
modelling, remodelling and linear growth. However, there is still no strong evidence in the 
literature of an association between circulating vitamin D levels and bone health outcomes, 
in particular, improvement in BMD in healthy children (171) as well as children with CD 
(147-149;172;173). Although randomised controlled trials showed the effectiveness of 
vitamin D supplementation in treatment of vitamin D deficiency in CD children (174;175), 
to date, the only experimental study of the effect of vitamin D supplementation on bone 
mineral density in paediatric CD did not show any benefit (176;177). Based on available 
data, vitamin D deficiency does not appear to explain the bone health deficient seen in 
children with IBD. However, BSPGHAN recommended that calcium and vitamin D 
supplementation should be considered in children with significant nutritional impairment, 
during the pubertal growth spurt and during steroid treatment (1). 
 
1.4.3.2 Pro-inflammatory cytokines  
Evidence from human and experimental studies shows that bone mass deficits present in 
children with CD, even before treatment is started, suggested the central role of 
inflammation in the pathogenesis of bone disease (150;178;179). Pro-inflammatory 
cytokines such as TNF-α, IL-1, and IL-6, are commonly dysregulated in inflammatory 
disease (10), and can alter osteoblast and osteoclast differentiation and function, resulting 
in altered bone modelling and remodelling (180). These pro-inflammatory cytokines 
promote osteoclastogenesis by acting on cells of the osteoclast lineage, or indirectly, by 
modulating expression in target cells of key molecules such as RANK-L (181;182). TNF-α 
can also decrease the expression of osteoprotegerin (OPG), a decoy receptor that blocks 
RANKL (182;183). In addition, TNF-α can directly inhibits osteoblast differentiation and 
collagen synthesis, and promotes osteoblast and osteocyte apoptosis (Figure 1-9) 
(181;182;184). Evidence from preclinical data showed that serum from patients with CD 
impairs osteoblast differentiation and function in vitro, presumably due to these cytokines 
(178;179;185). Antibody neutralization of serum cytokines has yielded conflicting results 
for the effects of serum in this model (178;179;185). Limited human studies in children 





Thus, pro-inflammatory cytokines potentially cause bone loss by inhibition of osteoblast 
differentiation and stimulation of osteoclastogenesis. Chronic inflammation in CD may 
also impair bone via other mechanisms such as an increase in renal phosphate excretion 
and inhibition of renal 25 hydroxyvitamin D3 1 α hydroxylase (187;188), and acute 
inflammation may increase locally active GC or local GC sensitivity (189). In summary, 
inflammatory bone loss is a result of the upregulation (and thus hyperactivity) of 
osteoclasts as well as the downregulation (and thus hypoactivity) of osteoblasts, which 




























Figure  1-9: Possible mechanism of effect of inflammatory cytokines on bone 
Tumour necrosis factor (TNFα, interleukin-6 (IL-6) and interleukin-1β (IL-1β) may alter osteoblast and 
osteoclast functions through RANKL-OPG system. TNFα can also directly promote osteoclastogenesis and 























1.4.3.3 Glucocorticoid  
GC is widely used in the treatment of UC and they are also used in children and 
adolescents with CD, although exclusive enteral nutrition is considered the first line 
approach for induction of remission in those with mild–moderate CD (1). GC can affect 
bone health via various mechanisms (190-192). GC can be directly toxic to bone cells by 
hampering bone formation and stimulating excess bone resorption through inhibition of 
osteoblastogenesis, promotion of osteoblast/osteocyte apoptosis, prolongation of osteoclast 
survival (191;192), and promotion of osteoclastogenesis through increased expression of 
RANKL and decreasing OPG (180). Indirectly, GC use may act to inhibit calcium 
absorption leading to secondary hyperparathyroidism, impair linear growth, and delay 
puberty through reduced sex hormone production (190;191). GC also adversely affect bone 
through their negative effect on muscle function and mass weakness, which may lead to a 
reduction in bone strain and mechanical stimuli (193;194). GC effects on the growing 
skeleton may be rather different from their effects in adults due to their influence on bone 
modelling and remodelling (153;195). A longitudinal cohort study of children with new-
onset CD, who subsequently received GC therapy, revealed normal cortical BMD but 
reduced trabecular BMD and cortical area at baseline. At follow-up, greater linear growth 
was associated with a greater cortical area improvement, especially among participants 
with less glucocorticoid exposure and inflammation (153). These findings demonstrate the 
effect of disease and GC exposure on bone modelling during childhood. Studies of GC 
effects on BMD in paediatric CD have reported differing observations. Some investigators 
have found a negative relationship between cumulative GC dose and BMD 
(62;147;159;196-198). The minimum duration and dose of GC therapy that may cause 
damage to bones in paediatric patients with CD are currently unresolved from available 
data. In one study, a cumulative weight-adjusted prednisolone dose of more than 150mg/kg 
during the preceding 3 years was found to increase the risk of low aBMD at lumbar spine 
and total body in IBD children (159). Alternately, others investigators failed to confirm a 
link between GC and BMD in children with CD (149;152-155;186;199). However, in 
children with CD, the negative effect of GC therapy on bone may be offset to a degree by 
their ability to combat inflammation, which in itself is detrimental for bone. It is 
challenging to identify the independent effect of GC. For this reason the role of GC in 
inducing bone deficits in CD remains controversial and provokes the question of whether 








1.4.3.4 Muscle mass and strength  
Low muscle mass and strength are a common finding in children with CD compared to 
healthy controls (115;147;150;153;154;199-203). Low muscle mass may be a consequence 
of inflammation, malnutrition, glucocorticoid use, or decreased physical activity (204). 
Some longitudinal evidence demonstrated that CD children might have persistent 
deficiencies in lean mass, despite treatment and a marked improvement in disease activity 
(153;155;200;205). Both newly diagnosed young patients and those with a history of CD 
have demonstrated reduced muscle strength compared to healthy controls, which was 
reflected in reduced muscle cross-sectional area (154;199). Bone increases in mass, 
strength and dimension as the muscle mass and strength increase (mechanostat theory) 
(206). Thus muscle deficit may partly explain the poor bone health seen in CD. 
 
1.4.3.5 The GH-IGF-1 axis and sex steroid  
As previously discussed, the GH-IGF-1 axis and sex steroids are frequently disturbed in 
CD. These hormonal disturbances can affect bone development and maintenance. It has 
long been known that GH-IGF-1 controls growth, remodelling, and mineralization of the 
skeleton, in part via their direct actions on bone (68). A close relation between height SD 
score and BMD is documented based on cross-sectional studies in young patients with CD 
(147;196;198). In girls during puberty, oestrogen inhibits periosteal apposition of bone 
while stimulating endocortical bone formation, with consequent narrowing of the 
medullary cavity. Testosterone enlarges bone size by apposition on the periosteal surface 
(207). Given the requirement of sex steroids for normal bone mineralization, the absence 
of sex steroids during early adolescence is likely to worsen BMD accrual (208-211). So 
far, only one study showing no improvement in bone mass accrual was observed during 
puberty in children with IBD. Furthermore, postpubertal patients showed significantly 
decreased aBMD, indicating suboptimal peak bone mass attainment during puberty (165). 
Although more studies are needed to confirm compromised bone mass accrual in children, 
puberty may offer a window of opportunity to improve BMD. It is recommended to 
monitor linear growth and growth velocity, and pubertal development regularly in children 
or adolescents with CD (145;205). Prompt intervention with GH and sex steroid 





In summary, children with IBD, particularly CD, are at risk for low bone mass because of 
the complex effects of malnutrition, glucocorticoid therapy, cytokines, low muscle mass, 
physical inactivity, impaired growth, and delayed puberty.  
 
1.5  Therapeutic strategies to improve growth and bone in 
paediatric Crohn's disease 
Based on the described pathophysiology of growth and bone impairment in children with 
CD it is intuitive that optimization of growth should rely on restoration of appropriate 
nutrition, minimizing inflammation, and avoiding long-term or frequent corticosteroid 
therapy. However, the unpredictability of the insult and the limited opportunity for 
improvement of growth, at least in some adolescents, pose a challenge for decision-making 
about therapies to improve growth and bone. The first step in management of growth 
impairment is early identification of growth impairment and close collaboration between 
the clinical teams overseeing the child’s care. This will help in providing prompt 
management for children in whom growth and puberty are significant clinical issues. The 
European Society of Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) 
and the European Crohn's and Colitis Organization (ECCO) guidelines published in 2014 
outline the practical approach for treatment of children with CD related growth failure 
(Figure 1-10) (212). Currently, an expert opinion recommended that the prevention of bone 
disease is best accomplished by controlling inflammation using GC-sparing agents and 
careful attention to nutrition by providing adequate calcium and vitamin D 




































Figure  1-10: Schema for the therapeutic approach to children with active Crohn's disease 
and growth failure according to European Society of Pediatric Gastroenterology, Hepatology 
and Nutrition (ESPGHAN) and the European Crohn's and Colitis Organization (ECCO). 
Adapted and modified from (212). EEN, exclusive enteral nutrition; anti-TNF-α, anti-tumour necrosis factor-
α; GH, growth hormone  
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1.5.1  Improvement of nutritional status 
Exclusive enteral nutrition (EEN) is increasingly considered as an effective initial method 
of controlling inflammation in children with active CD (20), with reported remission rates 
of about 80 % (213). By controlling inflammation, enteral nutrition may avoid the use of 
GC and their negative impact on growth and bone (214). Over the last few years, 
improvement of nutritional status by EEN has also been associated with a short-term 
improvement in growth velocity and a reduction in inflammation and disease activity. This 
suggests that some forms of nutritional regimens may lead to growth improvement by 
mechanisms other than simply improving nutritional status (215;216). A short-term study 
of 12 children with active CD treated with EEN for 6 weeks showed early improvement in 
inflammatory markers (erythrocyte sedimentation rate (ESR), IL-6) after 3 days and in 
IGF-1 after 1 week of starting nutritional treatment, without any significant change in 
nutritional status, measured by weight SDS, mid upper arm circumference and triceps skin-
fold thickness (217). The authors linked this improvement in IGF-1 to the anti-
inflammatory effect of EEN rather than nutritional resuscitation (217). A possible 
mechanism by which EEN may improve growth and bone is induction of mucosal healing 
and reduced mucosal production of pro-inflammatory cytokines (218;219). Fell et al (218) 
reported that 8 weeks of enteral nutrition in paediatric patients with active CD was 
associated with macroscopic and histological mucosal healing. A report where mucosal 
biopsies were obtained from patients with CD and controls incubated with elemental diet, 
casein, or whey, showed that elemental diet may have a direct inhibitory effect on mucosal 
inflammation by increasing the anti-inflammatory: pro-inflammatory cytokine ratio in CD 
(219). This anti-inflammatory effect may not be particularly due to the amino acid 
composition, as diets containing casein have similar anti-inflammatory effects.  
While EEN has been shown to improve short- and medium term nutritional status, as well 
as short-term growth, velocity studies have not shown any long-term effect on height SDS 
/final adult height (220;221). However, Papadopoulou et al (214) and recently, Lambert et 
al (123) have shown a significant marginal benefit in height SDS at 1 and 2 years 
respectively, following a single course of EEN at diagnosis, compared with initial 
corticosteroid treatment. It may be concluded that where growth is concerned, EEN is 
superior to corticosteroid therapy in the short-term, and there is a need to investigate other 
therapeutic strategies to maximise height potential in paediatric CD.  
To date only two studies demonstrate an effect of EEN on bone health in children with 
IBD. Wittin et al (222) showed that an 8-week EEN therapy normalized serum markers of 





considered. A recent small study in 10 children with newly diagnosed CD, induced 
remission with EEN and maintained patients on immunomodulatory treatment, followed 
up to 52 weeks, showed that the bone biomarkers, trabecular BMD SDS, and muscle CSA 
SDS measured at radius by pQCT improved within 3 months after starting with EEN, but 
with no further normalisation thereafter and no improvement seen in grip strength(223). 
Additional prospective studies that evaluate serum bone markers and bone density 
outcomes over time are required to assess the potential impact of EEN on this complication 
of active CD. 
 
1.5.2  Control of inflammation 
Introduction of steroid-sparing immunomodulators such as thiopurines and methotrexate 
should be considered early in children with elements of growth failure, thereby reducing 
the use of corticosteroids (224). Some promising data regarding the growth-promoting 
effect of anti-TNF-α are now available, and the limited evidence about its effect on bone 
will be discussed more thoroughly in this section. 
 
1.5.3 Anti-TNF-α therapy in CD 
As previously outlined, TNF-α is a pro-inflammatory cytokine commonly dysregulated in 
inflammatory diseases, including CD. Studies investigating the role of TNF-α in CD and 
other inflammatory diseases have led to the development of therapies designed to 
neutralise to block the effect of TNF-α in pathogenesis of CD. The proposed mechanisms 
of action of anti-TNF-α in CD include neutralization of soluble and transmembrane TNF-
α, , induction of T cell apoptosis, apoptosis of transmembrane TNF-α expressing cells, 
downregulation of costimulatory molecules like CD40, reduced production of pro-
inflammatory cytokines including IL1, IL6, and IL8, and induction of T-cell population 
with a regulatory phenotype (225). It is propose that modulation of the inflammatory 
immune response of anti-TNF-α may restore mucosal integrity and inhibit mucosal 
angiogenesis in gut mucosa. 
Two anti-TNF-α agents have been approved for the induction and maintenance of 
remission in CD: infliximab (IFX) and adalimumab (ADA) (1;212;226). IFX is a chimeric 
(75% human and 25% murine sequences) IgG1 monoclonal antibody against TNF-α (227). 
IFX is typically used for the treatment of patients with moderately to severely acute CD 
and patients with fistulising CD, who have had an inadequate response to conventional 
therapy (1;212;226). IFX is also recommended as primary induction therapy for patients 





antibody directed against TNF-α (227). ADA is typically used to decrease signs and 
symptoms of CD, and to achieve and maintain clinical remission in patients with moderate 
to severe acute luminal CD who have not responded well to conventional treatments 
(1;212;226). ADA is also used to treat patients who have lost responsivity to IFX, or who 
are allergic or unable to tolerate it (1;212;226). IFX is given as a scheduled intravenous 
infusion at a dose of 5 mg/kg at 0, 2 and 6 weeks, followed by maintenance infusions every 
8 weeks. Dose escalation (to 10 mg/kg) and/or interval shortening (from 8 weeks to 6 
weeks or 4 weeks) may be implemented as needed, and ADA administrated as 
subcutaneous injection 80 mg stat followed by 40 mg every two weeks (1;212;226).  
There are a number of side effects that may occur in anti-TNFα therapy. One of the most 
common problems of IFX includes its chimeric properties and the formation of antibodies 
(ATI) to IFX, or to the murine portion of the drug (228;229). Development of ATI is can 
cause adverse reactions such as acute infusion reactions, delayed hypersensitivity reactions 
and loss of drug response (228;229). Episodic treatment with IFX is associated with a 
higher likelihood of developing ATI than maintenance treatment, while concomitant use of 
immunosuppression therapy may reduce the risk of antibody formation (227;229). Clinical 
studies, registries, and case reports have highlighted that the risk of infection, particularly 
opportunistic infections (invasive fungal infections, reactivation of latent tuberculosis), in 
patients with CD treated with anti-TNF-α, which occurs at a higher incidence when 
concomitant immunosuppression is used. Thus, screening for latent tuberculosis infection 
before initiation of anti- TNF-α therapy is mandatory (227). The long-term safety of anti- 
TNF-α regimen is heralded by a potential risk for malignancy. The overall risk to develop 
malignancies, such as lymphomas, for children with CD is low, but higher than the general 
paediatric population. Very recent data on malignancy and mortality in paediatric CD have 
been provided by an ESPGHAN survey, which retrospectively evaluated the cases of 
malignancy or mortality among paediatric IBD patients over a 6-year period (230). A total 
of 18 malignancies were identified, mainly in CD patients. None of these cases had 
received anti-TNF-α. In children on biologicals, as of April 2008, 48 cases of malignancy 
including lymphoma and skin cancers, melanoma were identified by the FDA (31 
following IFX use, 2 following ADA use, and 15 following etanercept use). This rate of 
malignancy was higher than background rates in the general U.S. paediatric population, but 
it is currently impossible to associate the risk to the anti-TNF-α and not to other 






1.5.4 Effect of anti-TNF-α therapy on growth in CD 
Current published studies point to the growth-promoting effects of anti-TNF-α therapy in 
CD (Table 1-3; 1-4). However, its effect on optimization of linear growth seems to be 
variable. A number of studies have now reported that the use of IFX is associated with 
improved growth in children with CD, whose disease improves with the introduction of 
this drug, providing treatment is undertaken early enough prior to or during puberty (232-
246). The open-label multicentre RCT (REACH study) to evaluate efficacy and safety of 
IFX therapy for treatment of moderate to severe paediatric CD in 103 children showed a 
positive impact of IFX on Ht SDS after 30 and 54 weeks of therapy (238). In addition, it 
seemed that the growth favourable effect was sustained for longer, but these conclusions 
may be somewhat guarded given that the number of children studied was 15, 10, and 4, at 
2 years, 3 years and 4 years, respectively, with a greater beneficial effect in children with 
at least 1-year delay in bone age and those who were on GC at enrolment. Furthermore, 
growth outcome was not the main objective of the study, the subjects were not blinded and 
no pubertal data were available.  
An increase in Ht SDS has also been observed after 6 months of therapy in treated subjects 
compared to an untreated cohort (233). The Assa group (232) recently elucidated that a 
tendency towards enhanced growth velocity was found in responders compared to non-
responders. Furthermore, they highlighted the gender predilection based on the observation 
that only male responders showed a considerable amplify in height velocity during 
treatment. The authors supported the need for future study that may clarify sex-specific 
growth responses during IFX treatment of CD patients. However, growth data from this 
report need to be approached with caution as a large proportion of the cohort were also 
taking glucocorticoids, which may have impaired growth. 
Interestingly, Walters et al (244) reported that IFX therapy is associated with improvement 
in mean HV SDS and Ht SDS in responder participants providing that IFX commenced 
before or during early puberty. Thus, they argued that the time of starting IFX is crucial in 
gaining control over disease when height is an issue. A comparable observation was 
reported in a small prospective study by Cezard and colleagues (234), where HV SDS was 
significantly enhanced in 10 children who had not finished their pubertal growth after one 
year of commenced IFX therapy, compared to one year before treatment. However, 
minimal amount of growth is expected for children in late puberty. 
A recent retrospective study conducted by Malik et al (239) confirmed that median Ht SDS 
and HV SDS of a group of 21 children responding to IFX treatment improved significantly 





prior and after commencing IFX, compared to non-responders whose growth rate remain 
unchanged. They verified that the growth-promoting effect of IFX in responders could be 
independent of reduction in glucocorticoid use and pubertal progress, emphasising the role 
played by controlling inflammation. This retrospective study also showed median HV in 
children who were receiving methorexate therapy before starting IFX was significantly 
increased after 6 months of commencing biologics, compared with a control group who did 
not receive methotrexate therapy. The authors suggest the beneficial effect of IFX on 
growth may be enhanced when a child is also receiving methotrexate, possibly due to their 
synergistic effect on disease activity.  
Crombe et al (235) found a significant improvement in mean Ht SDS in a group of 41 CD 
children responders over a period of follow-up compared to 41 CD children who failed to 
respond to IFX therapy. In another retrospective study of 33 children with IBD, 21/33 of 
children experienced catch-up growth, and children in remission showed significantly 
higher Ht SDS compared with those with mild or moderate-severe disease activity, 
demonstrated that inflammation has an impact on growth (241). In a study published in 
2014, children with matching baseline characteristics were compared in three treatment 
groups; 68 children receiving immunomodulators, 68 children receiving anti-TNFα, and 68 
children with no immunomodulator, within three months of diagnosis for attaining clinical 
remission and promoting growth in children with CD (245). This study highlighted the 
benefit of early initiation of anti-TNF therapy for the resumption of growth in paediatric 
CD patients. In comparison to early immunomodulators or no immunomodulators only, the 
early anti-TNF treated group increased their Ht SDS at 12 months (a significant difference 
of +0.25). The study showed that children receiving early anti-TNFα therapy were 
significantly more likely to be in remission at 1 year compared with those receiving early 
immunotherapy or no immunotherapy (remission was based on glucocorticosteroids-free 
clinical remission (PCDAI˂10) at 1 year after diagnosis without luminal resection). 
Interestingly, despite matching the three groups for important confounders (PCDAI, age, 
HtSDS, puberty, perianal disease, disease location, inflammatory biomarkers and deep 
ulceration on initial colonoscopy), the proportion of children on glucocorticosteroids in the 
immunomodulator only and no early immunomodulator groups were higher compared to 
those on early anti-TNFα at baseline and 12 months. Thus one possible explanation could 
be that glucocorticosteroids may have had a larger inhibitory effect on growth catch-up in 
the immunomodulator only and no early immunomodulator groups. 
This was not found to be the case in one recent prospective study however, examining the 





CD children after 12 months of treatment, with a greater decrease in PCDAI associated 
with greater increase in Ht SDS and this improvement was not affected by GC 
exposure(237). However, the authors did not determine whether this improvement was 
independent of progress in puberty. 
ADA has also recently been reported to be associated with an improvement in disease and 
growth. A retrospective review of 36 CD children, who started ADA at a median age of 
14.7 years, demonstrated that clinical response to ADA treatment was associated with a 
short-term improvement in linear growth. Furthermore, this improvement was more likely 
in patients who were in early puberty and on immunosuppression, but was independent of 
steroid use (240). Alternatively, a recent retrospective study failed to confirm any 
beneficial effect of ADA on growth in 18 patients received ADA for 12 months (247). 
However, it should be noted that a large proportion of this cohort was already at late 
puberty by the time of starting anti-TNF-α. 
From available evidence on the effect of anti-TNF-α on growth, it is considered the 
mainstay for therapy of growth failure in children with CD based on its ability to control 
inflammation. On the other hand, three retrospective studies failed to find any association 
between use of IFX and improvement of linear growth in CD children (236;242;246). 
Nevertheless, the retrospective nature of reports, relatively small sample size and lack of 
cohort pubertal data make it difficult to interpret the results with any certainty. A similar 
unfavourable outcome on growth was reported by the Pfefferkon group (88). The 
researchers prospectively investigated 176 newly diagnosed IBD children younger than 
sixteen with a Tanner score from 1 to 3, to evaluate growth outcomes with current regimes. 
They found that although disease activity significantly improved in 64 CD patient 
receiving IFX, height SDS remain impaired despite the improvement in HV SDS in many 
children with CD after 2 years following diagnosis (88). Malik et al (84) also found that 
slow growth and short stature remained a problem in 10% CD children, despite advances 
in treatment of paediatric CD and that this diverse group may benefit from specific growth-
promoting treatment or novel therapeutic approaches.  
In conclusion, despite the improvement on growth in some studies, there continues to be 
some controversy about the overall beneficial effects of anti-TNF-α therapy on growth. 
Prospective studies on anti-TNF-α on growth of CD children are needed as this will not 
only improve the knowledge of the effect of anti-TNF-α on growth but also might directed 
future research for elucidating mechanism and exploring novel therapeutic strategies to 






Table  1-3: Published studies of anti-TNF-α on linear growth in children with CD (retrospective studies) 
ΔHt SDS, change in Ht SDS; Ht SDS, standard deviation from the mean for height for normal children for the same age and gender; HV, height velocity (cm/year); HVSDS, standard 
deviation from the mean for height velocity for normal children for the same age and gender; NK, not known; NS, not significant. Age is represented as mean (±SD) or median (range)
Reference Study design Size Duration of study 
(months) 
Age at start of therapy 
(years) 
Tanner stage at 
start of therapy 
Results 
Pichler et al (2015)(247) 
 
Retrospective 18 12 14.4 (5.3-19.1) 1-5 ΔHt SDS: baseline: -0.1 (-2.5,0.7); 12 months: 0.0 (-2.5,1.3) 
(p=NS) 
Pichler et al (2014)(241) Retrospective 33 12 14 (4-17.7) 1-4 ΔHt SDS : baseline: -0.2±0.2; 12 months: 0±0.4 (-2.6, 2.47) 
(p=0.04) 
Church et al  (2014)(248) Retrospective 47 36 NK 1-2 Ht SD: Normalised in those received IFX within 18 months 
of diagnosis 
Assa et al (2012)(232) Retrospective 101 60 13.5±3.9 NK HV: Only male responders showed increased HV (p=0.007) 
Malik et al (2012)(240) Retrospective 36 6 14.7 (11.3-16.8) 1-5 ΔHt SDS: baseline: -0.2 (-0.7,0.2); 6 months: 0.0 (-0.5,0.8) 
(p=0.005) 
Malik et al (2011)(239) Retrospective 28 6 13.1 (9.9-15.7) 1-3 Ht SDS: baseline: -0.1 (0.00,-0.1); 6 months: 0.05 (0.00,0.4) 
(p=0.001) 
HV: baseline: 2 (0.3,7.1); 6 months: 6.4 (2.3,9.1) in 
responders (p=0.004) 
Crombe et al (2011)(235) Retrospective 82 32 18.0 (16-21) NK Ht SDS: Only responders showed an improvement 
baseline: -0.57±1.1; 32 months: -0.25± 0.99 (p=0.04) 
 
Sinitsky et al (2010)(242) Retrospective 16 12 13.0± 4.2 NK Ht SDS: baseline: -0.5(-2.5, -0.6); 12 months: -0.8 (-2.8,-1.4) 
(p=NS) 
 
Diamanti et al (2009)(236) Retrospective 14 
 
10 13.0 (11.5-15) 
 
NK Ht: Case, baseline: 146.1 cm±0.2; 10 months: 147.8 cm±0.3 
Control, baseline: 147.4 cm±0.2; 10 months: 148.5 
cm±0.1(P=NS) 
Walters et al (2007)(244) Retrospective 27 12 14.3 1-5 HV SDS (Tanner 1-3): baseline: -2.8±1.7; 12 months: 
1.1±3.6 (p<0.001) 
HV SDS (Tanner 4-5): baseline: 0.46±3.4; 12 months: 
0.68±1.1 (p=NS) 







Table  1-4: Published studies of anti-TNF-α on linear growth in children with CD (prospective studies) 
ΔHt SDS, change in Ht SDS; Ht SDS, standard deviation from the mean for height for normal children for the same age and gender; HV, height velocity (cm/year); HV SDS, number of 
standard deviation from the mean for height velocity for normal children for the same age and gender; NK, not known; NS, not significant; RCT, randomised controlled trial. Age is 













Age at start of therapy(years) 
 
Tanner stage at 
start of therapy 
 
Results 
Griffin et al (2015)(237) 
 
Prospective 74 12 14 (5-21) 1-5 Ht SDS: baseline: -0.2±0.2; 12 months: 0.0 ±0.2 
(p=0.04) 
 





12 14 (5-21) 1-3 ΔHt SDS: 0.14±0.4 on antiTNF-α (p=0.002), -
0.02±0.4 on early immunomodulator therapy only 
(p=0.6), -0.06±0.4 on neither (p=0.2) 
 
Hyams et al (2011)(249) Prospective 20 48 13.3±2.5 NK Ht SDS: baseline: -1.64; 24 months: 0.82; 36 months: 
1.01; 48 months: 1.56 
 
Thayu et al (2008)(243) Prospective 
RCT 
 
103 12 13.3±2.5 NK Ht SDS: baseline: -0.76± 1.24; 12 months: -0.49 
± -0.50 (p<0.002) 





20 12 13.3±2.5 NK Ht SDS: baseline: -1.5; 12 months: 0.5 (<0.001) 
Borreli et al (2004)(233) Prospective 18 6 13.0 (6-18) NK  
Ht SDS (treated group): baseline: -0.99±0.62;                 
6 months: -0.74±0.71(p<0.01) 
Ht SDS (untreated group): baseline: -0.86±0.42;  
6 months: -0.83±0.40 (p=NS) 
 
Cezard et al (2003)(234) 
 
Prospective 10 12 15.0±2.0 NK HV SDS: baseline -0.45 (-1; 1.3); 12 months:  






1.5.5 Effects of anti-TNF-α therapy on the GH-IGF-1 axis  
There are only a limited number of studies that have investigated the blockade of TNF-α 
on the GH-IGF-1 axis (250-252). In a murine colitis model, TNF-α neutralization up-
regulated liver GHR abundance and GH signalling and serum IGF-1 levels (250). 
Preliminary data from a controlled study of adults with active CD showed an opposite 
effect of treatment with IFX on the GH resistance occurring in active CD (251;252). 
Vespasiani et al (251) studied 14 adult IBD patients with low levels of IGF-I and IGFBP-3 
treated with IFX. IGF-1 and IGFBP-3 levels did increase during induction and IGF-1 
reached values comparable with those in healthy controls, however, the study failed to 
demonstrate normalization of IGF-1 levels during maintenance therapy. The derangement 
of the GH-IGF-1 axis during maintenance therapy is difficult to elucidate, however, the 
authors hypothesised that during this period some degree of subclinical mucosal 
inflammation might persist. The study time points were 0, 2, 6, 12, and 20 weeks after IFX 
infusion. The authors demonstrated that GH-IGF-1 axis derangement occurs in patients 
presenting a satisfactory nutritional status, comparable with that in controls, thus 
suggesting a predominant role of systemic inflammation rather than a reduced protein 
calorie intake, and the result seen is likely related to suppression of the systemic 
inflammation. The short-term effect of anti-TNF therapy on IGF-1 is supported by the 
report by Eivindson et al (252)  when 13 adult patients with therapy-refractory CD were 
treated with IFX and age- and gender-matched with 10 controls. The IGF system and 
markers of inflammation were studied at baseline, on days 2-5 and after 1, 4, and 8 weeks. 
Treatment with IFX normalized circulating levels of total IGF-I and IGFBP-3, and 
partially normalized IGFBP-2, whereas free IGF-I remained suppressed. However, 
comparable data is not yet available for any paediatric cohort. An improved understanding 
of the systemic GH-IGF-1 axis and how it is affected in chronic inflammation will lead to 
an improved rationale for developing therapeutic regimens that can improve growth and 
bone health in children with CD. 
 
1.5.6 Effect of anti-TNF-α therapy on bone health 
Consistent with the hypothesis that TNF-α contributes to bone deficits in CD, several 
studies have demonstrated the significant beneficial effect of monoclonal anti-TNF-α on 
bone metabolism in adults with CD, with some limited evidence for the effect of anti-TNF-
α on bone mineral density (253). To date, only five studies have been published that 





conflicting (Table 1-5) (186;237;241;243). The first study to suggest a beneficial effect for 
IFX on bone density in children with CD was seen in 2007 by Paganellli et al (186). They 
observed that lumbar spine BMAD, measured by DXA, in 10 children with CD treated 
with IFX (-1±0.8) was higher than for 25 children with CD not treated with IFX (-1.8±0.8). 
They matched for age, sex, puberty and age at diagnosis. However, in this study the 
authors did not look at markers of bone turnover.  
Thayu et al (2008) were the first to observe a beneficial effect with anti-TNF-α on bone 
metabolism in paediatric CD patients (243). In this study, 112 children aged between 6-17 
years, with moderate to severe CD disease based on PCDAI (˃30), received IFX induction 
(5 mg/kg/dose) at 0, 2, 6 and 10 weeks. Responders (n, 103) were randomised to IFX every 
8 or 12 weeks maintenance therapy. For the purpose of analysis of bone biomarkers, data 
was limited to 103 children. The biomarkers of bone metabolism; BSAP, P1NP, urinary 
CTX-1 and DPD were measured at baseline, and at 10 weeks. The PCDAI was also 
measured at baseline, 10 and 54 weeks as markers of biological response. In this study the 
authors observed that both BSAP and P1NP increased during 10 weeks, with median 
increases of 87% and 103% respectively. The change in BSAP was associated with 
reduction in PCDAI at 10 weeks when adjusted for bone age, gender, and height. The 
authors suggest that IFX may have beneficial effect on bone formation through primary 
inhibition of TNF-α. The CTX-1 and DPD also increased at 10 weeks, but the magnitude 
of changes (18%, 23%) was less than the change in formation markers. Biomarkers of bone 
resorption were not associated with PCDAI. This is the largest paediatric study showing 
IFX treatment is associated with an increase in biomarkers of bone formation and 
resorption; however, this study did not related changes in bone markers to subsequent 
changes in bone mass. In addition, because of the short duration of the study, questions 
remains as to whether this improvement is sustained over a longer period of time, and if 
there is any associated improvement in BMD. 
A retrospective study of the effect of IFX on bone formation (BSAP, Osteocalcin) and 
resorption markers (CTX), as well as on LS-BMD and bone mineral apparent density 
(BMAD), over a period of 1 year in 33 children with moderate to severe IBD (24CD/9 
IBDU), failed to find any improvement in these parameters (241). The only confounder 
factor taken into account was clinical response to therapy based on PCDAI, and indeed 
they found a subgroup of children with BMD SDS˂-2, had higher PCDAI. Although this 
was a 1-year study, not all children received IFX for the full duration. In addition, they did 
not categorise the patients according to steroid use despite a large proportion of children 





growth, this was not reflected in biomarkers of bone turnover. In a follow-up, data was also 
reported regarding the effect of ADA on bone health in 18 CD children. The authors 
reported no significant influence on bone biomarkers after 12 months from the start of 
ADA. LS-BMD SDS and BMAD SDS remained static in 6 children who had complete 
remission, and LS-BMD SDS significantly deteriorated in 12 children who had mild or 
moderate-severe disease at 12 months after starting ADA (254). The authors claim a 
protective role for IFX and ADA in preventing bone deterioration (241;254). 
Recently, the first study reporting bone biomarkers, pQCT measure of tibia bone density 
and structure, over 1 year after initiation of IFX therapy in 74 children with CD was 
published (237). At baseline, CD children had lower trabecular BMD, cortical area and 
muscle area SDS compared with reference data. PCDAI reduced during 10 weeks from 
induction and was associated with a significant increase in trabecular BMD, cortical area, 
and muscle area SDS over 12 months. In multivariate analysis, improvement in linear 
growth, assessed by change in tibial length, was associated with greater increase in cortical 
area in CD. The use of IFX led to mild improvement in trabecular BMD associated with 
improvement in bone turnover at follow-up. The improvement in bone parameters was 
independent of GC use over the study period. The authors conclude that anti-TNF-α during 
growth and development is associated with improvements in trabecular BMD and cortical 
structure, and this improvement was greater in younger and growing children, suggesting a 
window of opportunity for treatment of bone deficient. However, the improvement seen 
following the IFX in this group of children may largely reflect growth, as the more 
significant improvement was seen in cortical bone area with a persistent deficient in 
trabecular BMD which remained relatively low (1 SD below mean) after 1 year of therapy. 
Taken together, the limited data available thus far demonstrates contradictory results and 
the extent of benefit for anti-TNF-α with regard to bone health and architecture is unclear, 





Table  1-5: Published studies of the effect of anti-TNF-α on bone health in children with Crohn's disease 
CD, Crohn's disease; IBDU, inflammatory bowel disease unclassified; BMD, NA, not available; bone mineral density; BMAD, bone mineral apparent density; LS, lumbar spine; DXA, 
Dual-energy X-ray absorptiometry; pQCT, peripheral quantitative computed tomography; P1NP; Procollagen type 1 Amino terminal Propeptide; BSAP, bone specific alkaline 
































IFX for 2 years 
 
BMAD in 10 children with CD who treated 
with IFX was higher than 25 children with 
CD IFX naïve. 
 

















At baseline and 
10 weeks 
 
Significant increase in median BSAP, 
P1NP, CTX, DPD from baseline to week 
10. 
 




















At baseline and 1 
year 
 
Failed to find any improvement in all these 
parameters and they remained fairly static 
during study periods. 
 
Pichler et al 
(2015)(254) 
 

















At baseline and 1 
year 
No significant influence on bone 
biomarkers after 12 months of start of 
ADA. LS BMD SDS and BMAD SDS 
remained static in 6 children who had 
complete remission and significantly 
deteriorated in 12 children who had mild 
and moderate to severe disease at 12 
months after start ADA. 




















At baseline, 10 
weeks, 6 months 
and 1 year 
 
Significant increase in trabecular BMD, 
cortical area and muscle area SDS over 12 
months. 
BSAP and CTX SDS were low at baseline 
and significantly increased at 10 weeks and 






1.5.7  Effect of human recombinant growth hormone (rhGH) therapy on 
growth in CD 
GH is a potent anabolic agent known to stimulate linear growth, osteoblast activity and 
protein synthesis. In the UK, rhGH is licensed in children for treatment of GH deficiency, 
Turner syndrome, chronic renal insufficiency, Prader Willi syndrome and children who are 
born small for gestational age (255). Paediatric studies involving use of rhGH children 
with chronic inflammatory diseases such as juvenile idiopathic rheumatoid arthritis(JIA) 
and cystic fibrosis show significant improvement of linear growth (256;257). 
Table 1-6 summarises studies on the effect of rhGH therapy on linear growth in children 
with IBD (258-263). The first report that investigated the effect of rhGH on linear growth 
of IBD children was conducted in 1974 (263). In this study rhGH was used at a dose of 9 
mg/week for 6 months in 3 adolescents with IBD and poor growth, and showed no 
improvement in their height velocity compared to their prior growth rate. However, two of 
the participants had a bone age of 16 years and 18 years and would have completed most 
of their growth prior to therapy. In a preliminary study of 10 subjects with CD who 
received rhGH at dose of 0.05 mg/kg/day for a variable duration (7 for 1 year, 3 for 6 
months), the 7 children receiving therapy for 1 year showed significant improvement in 
their height standard deviation (Ht SDS) from -1.7±0.5 at baseline to -1.2±0.6 by the end 
of study (p=0.03) (261). Eight of the ten children in the study were prepubertal at time of 
commencement (n, 1; tanner stage IV, n, 2; tanner stage I). No data was given on puberty 
at follow up and the dose of GC remained unchanged during period of study (0.27 
mg/kg/day). 
In another RCT in 7 IBD children with growth impairment, participants were randomised 
to either rhGH (0.05mg/kg/day) or placebo (Phase 1 for 1 year, in phase 2 all children 
received rhGH for further 1 year). Investigators show no significant difference in mean Ht 
SDS between the two groups (258). All patients except one were not on GCs during the 
study period. Six were on early puberty and one was prepubertal and remained so during 
the study period.  
In 2008, an open labelled controlled trial in 8 children with IBD and short stature, using a 
rhGH dose of 0.043mg/kg/day for 1 year, showed a significant increase in the height SDS, 
weight SDS in rhGH treated group (p<0.01, p<0.01 respectively) compared to the control 
group of 24 individuals (260). The mean PCDAI in rhGH group was 21.9±21.2 at baseline 
and 13.1±7.5 after 1 year of treatment.  
Recently, a randomized controlled trial was performed in two UK tertiary paediatric 





to either rhGH (0.067mg/kg/day, n=11) or no rhGH (n=11) for six months. They found that 
HV increases (from 4.5 cm/year (0.6, 8.9) at baseline to 10.8 cm/year (6.1, 15) at 6 months 
p=0.003) and Ht SDS increases (from - 2.8 (-4.2, -1.5) at baseline to -2.4 (-3.7, -1.2 versus 
P = 0.003) were significant relative to baseline for the treated group, but not the untreated 
group. This study also demonstrated a considerable improvement in biomarkers of growth. 
Median IGF-1 SDS adjusted for bone age improved from -2.9 (-3.7, 2.9) at baseline to -0.1 
(-2.7, 2.2) after 6 months in the rhGH group (p = 0.04) whilst it remained unchanged in the 
control group. The use of steroids in both groups was scanty throughout the period of 
study, and puberty stayed almost unchanged.  
This study also revealed no significant change in disease activity or bone age in both 
groups at baseline and six months. This was the first study to also assess insulin sensitivity 
and showed that despite scant use of glucocorticoids, children with IBD were insulin 
resistant at baseline and the degree of resistance increased in those on rhGH. This increase 
in insulin resistance was not associated with impaired glucose tolerance as none of the 
children who had an oral glucose tolerance test 6 months after receiving rhGH injections 
was found to have asymptomatic diabetes mellitus. 
Similar results were reported by Denson and associates (259) who investigated whether 
rhGH therapy improving disease process (at dose of 0.075mg/kg/day) at 12 weeks. After 
12 weeks, 18 subjects aged between 7-18 years who experienced a clinical response 
received rhGH for 52 weeks, and linear growth was assessed. They found mean height 
SDS (-1.1(-1, -0.6) at baseline) and HV SDS (-1.3 at baseline) considerably increased 
to -0.4 (-1, -0.2), p=0.04, and 2.4, p=0.000, respectively, compared to baseline in the GH 
group. Moreover, a rise in fasting insulin level was documented without impairment in 
glucose level. The Mauras group (261) found no significant change in oral glucose 
tolerance test with a trend towards higher fasting insulin concentrations during combined 
prednisone/ rhGH therapy. 
These initial results suggest that rhGH may have a positive effect on growth over the short-
term and is not associated with any deterioration in the disease status. However, there is a 
need to be judicious in the use of this drug especially if used for extended periods given 
that there are scant data for efficacy and safety over the longer term. Children with JIA, 
and especially those who receive GC, may develop more profound impairment of glucose 
tolerance (264). Given that inflammation may itself alter insulin sensitivity, there is a need 
to perform regular assessment of insulin sensitivity and glucose tolerance in children who 






Table  1-6: Published studies of rhGH therapy in children with Crohn's disease 
RhGH: Recombinant growth hormone; RCT: Randomised controlled trial; CD: Crohn’s disease; UC: Ulcerative colitis; HV: Height velocity (cm/year); Ht SDS: Number of standard 











Duration of rhGH 
therapy (months) 
 
Duration of study 
(months) 
 
Primary end point 
 
Results 







0.067 6 6 Linear growth 
HV:baseline: 4.5 cm/yr (0.6,8.9); 6 months: 10.8( 6.1,15), 
p=0.003 
Ht SDS: baseline: -2.8 (-4.2,-1.5); 6 months: -2.4(-3.7,-1.2), 
p=0.003No significant change observed in control group 
 
Denson et al (2010)(259) 
Prospective 
 
18 CD 0.075 12 12 
Disease activity 
 
Ht SDS: baseline: -1.1(-1.6,-0.6); 12 months: -0.4(-1,0.2), 
p=0.004 





8 CD rhGH 
24 no rhGH 
0.043 12 12 Linear growth 
rhGH group: HV: baseline: 3.00±1.39 cm/yr; 12 months: 
8.32±3.20, p=0.01 Δ HtSDS 0.76±0.38, p<0.01 
Comparison group:HV: baseline: 4.00±1.39 cm/yr; 12 months: 
4.9±3.20, p=0.20 
Δ Ht SDS 0.16±0.40, p=0.07 
 







0.05 12 12 Linear growth 
rhGH: Δ Ht SDS +0.13 Placebo: Δ Ht SDS +0.23 
No change in linear growth 


















1.5.8  Effect of rhGH on bone health  
Evidence from JIA studies on the effect of rhGH on bone mass have shown that rhGH 
therapy may have a beneficial effect on bone health (265-267). There are only two studies 
investigated the effect of rhGH therapy in children with CD (261). In a pilot study by 
Mauras et al (261) in 10 children with CD, serum markers of bone formation and 
resorption were not significantly affected by rhGH treatment, except for a significant 
increase in mean BSAP from 39±8 at baseline to 54±12 at  4 months and a significant 
decrease in percent fat mass (-3.5%) as measured by DXA scanning after 4 months of 
rhGH therapy. In an open label study in CD, the authors observed that rhGH therapy for 12 
months was associated with a mean increase in LS-BMD SDS for age of 0.3 ±0.3 and 
mean percent body fat (by DXA scan) was decreased by 2.55±2.58 compared to baseline. 
Serum alkaline phosphatase level was increased from 127.3±31.4 at baseline to 200.0 
±71.3 at the end of GH treatment (260). In both these studies the increase in bone alkaline 
phosphatase may reflect linear growth. Furthermore, DXA bone outcomes were not 
adjusted for growth or puberty and both were short-term studies. Further evidence on the 
effect of rhGH on bone health in children with inflammation in general, and in CD in 
particular, are still needed.  
 
1.5.9  Effect of rhGH on disease activity 
Other than a growth promoting effect, GH therapy may have an effect on disease status as 
reported in number of human and animal studies (259;268;269). Slonim et al (269) 
conducted a randomised controlled trial to investigate the effect of rhGH on disease status 
in 37 adult patients with moderate to severe CD, allocated to either receive rhGH (n=19) 
loading dose, 5 mg/day subcutaneously for one week, followed by a maintenance dose of 
1.5 mg/day, or placebo (n=18). They found that the Crohn’s Disease Activity Index score 
decreased by mean of 143±144 points in the rhGH group, as compared with a decrease of 
19±63 points in the control group (p=0.004) suggesting a beneficial effect of GH in 
improving disease activity. In a paediatric study by Denson et al (259) 65% of CD children 
on GH therapy and corticosteroid achieved clinical remission, measured by PCDAI, by 12 
weeks, compared to only 20% of patients in control group (p= 0.03). At week 12, 40% of 
participants in rhGH and corticosteroid arm achieved steroid-free remission compared to 
20% of subjects in control group. There was a trend towards improvement in endoscopic 
disease activity in the rhGH group at week 12; however, this did not reach statistical 
significance. Furthermore, other markers of disease activity such as faecal calprotectin and 




ESR were similar in both groups. Although disease activity index improved in this study, 
Ht SDS/HVSDS is a component of the paediatric crohn’s disease activity index (PCDAI), 
and the use of PCDAI to assess disease in studies promoting growth may be flawed by a 
concurrent improvement in growth rate. It is possible that the lower PCDAI in the rhGH 
group in that study merely reflects improvement in linear growth, independent of reduction 
of inflammation. The possibility that rhGH may improve inflammation directly in 
paediatric CD remains an open question. 
Data from Wong et al(262)  reported no significant difference in disease status, based on 
an abbreviated paediatric CD activity index (APCDAI) that utilised subjective symptoms 
and physical examination after six months, between the intervention and control groups. 
Additionally, other markers of disease activity (such as ESR, CRP, Hb, HCT, albumin and 
inflammatory cytokines: TNF, IL1 and IL6) were similar between the two groups. 
However, in this study the children were in remission or had mild disease activity so it is 
difficult to conclude effect of rhGH therapy on disease activity from this study. 
  




1.6  The rationale for the present work and aims 
Impaired growth and bone health are documented detrimental consequences in children 
with IBD, particularly CD. The underlying mechanism is multifactorial and includes poor 
nutrition, inflammation, and the prolonged use of steroids. Assuming a multifactorial 
mechanism, several therapeutic approaches have been proposed that may aid in improving 
growth and bone health in children with CD. However, currently there is inconsistent 
evidence regarding the efficacy of available therapeutic agents in this cohort. Therefore, 
the overall aim of this thesis is to explore the effect of some therapeutic strategies 
particularly anti-TNF-α and rhGH therapy on growth, the GH-IGF-1 axis, and biomarkers 
of bone turnover as well as bone mineral density in children with CD. Furthermore the 
following specific hypothesis and aims are proposed under the scope of this thesis: 
 
Impact of Anti-Tumour Necrosis Factor Therapy on Linear Growth, Insulin like 
Growth Factor Axis and Bone Turnover Markers in Childhood Crohn’s Disease 
(Chapter-2).  
Hypothesis: Childhood-onset CD is associated with impaired growth, disturbance in IGF-
1 axis, and bone turnover that is potentially related to TNF-α. We hypothesized that use of 
anti-TNF-α is associated with improvement in linear growth, IGF-1 axis and biomarkers of 
bone formation. 
Aim: To examine linear growth, growth biomarkers and bone turnover in a cohort of 
children and adolescents with CD at time of, and 12 months after, initiation of treatment 
with anti-TNF-α. 
 
Persistence of Musculoskeletal Deficits in Paediatric Crohn’s Disease Following Anti-
Tumour Necrosis Factor Therapy (Chapter-3). 
Hypothesis: TNF-α contributes to deficits in BMD and bone geometry and these 
parameters would improve during anti-TNF-α therapy. 
Aim: (1) To assess change in bone density and structure in a cohort of children and 
adolescents with CD at time of, and 12 months after, initiation of treatment with anti-TNF-
α. 
(2) To explore association of IGF-1 axis, cytokines and muscle, with bone density in 
children with CD. 
 
 




The Sustained Effects of Recombinant Human Growth Hormone Therapy on Linear 
Growth in Children with Crohn's Disease (Chapter-4). 
Hypothesis: Some children with CD continue to grow slowly despite anti-TNF-α therapy. 
Poorly growing children with CD may exhibit combined abnormalities of functional GH 
insufficiency as well as GH resistance. There may, therefore, be a rationale for considering 
treatment with high dose rhGH in children with CD and ongoing growth retardation. 
Aims: To investigate the effects of prolonged rhGH therapy on linear growth and insulin 
sensitivity in children with CD. 
 
Recombinant Human Growth Hormone Therapy in Children with Crohn's Disease: 
Impacts on Bone Health (Chapter-5). 
Hypotheses: In accordance with an anabolic effect of GH, rhGH therapy may help to 
reduce detrimental effects of CD on bone health and muscle in children with quiescent CD. 
Aim: To determine the effects of prolonged rhGH therapy on BMD by DXA of total body 
and lumbar spine. 
 
Assessing the Feasibility of Injectable Growth-Promoting Therapy in Crohn's Disease 
(Chapter-6). 
Hypothesis: Dimension in attitude toward RCT in relation to height in both patients with 
CD and their families. 
Aim: To assess the feasibility of RCT of injectable forms of growth promoting therapy; 
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2.1 Abstract  
Background: Childhood onset CD is associated with impaired growth, disturbance in IGF-
1 axis, and bone turnover that is potentially related to TNF-α. 
Aims: To examine linear growth, growth biomarkers and bone turn over in a cohort of 
children and adolescents with CD at baseline and 12 months after initiation of treatment 
with anti-TNF-α. 
Design and participants: Prospective longitudinal study of 19 (12 male) participants with 
CD, aged 11.2, 17.2 (median 14.9) years, completing a 12 months study. 
Main outcomes: Anthropometric data were obtained at baseline and 12 months. IGF-1, 
IGFBP-3, ALS, BSAP and β-CTX performed at baseline, 2 weeks, 6 weeks, 6 months and 
12 months after initiation of anti-TNF-α. All were adjusted for bone age and gender.  
Results: wPCDAI decreased significantly from to 40 (0, 95) at baseline to 17.5 (0, 70) 
during the 2 weeks following induction (p=0.004 vs. baseline). Reduction in wPCDAI was 
associated with a subsequent improvement in height velocity (p=0.008 vs. baseline) and 
change in height SDS (p=0.015 vs. baseline) at 12 months in those who still had potential 
to grow. At baseline, IGF1 SDS was +0.1 (-3.8, 2.1) (p=0.80 vs. zero), IGFBP3 SDS +1.4 
(-2.9, 3.0) (p=0.02 vs. zero) and ALS SDS -0.9 (-2.2, 1.5) (p<0.0001 vs. zero). IGF1 SDS 
was <-2.0 in 5 (26%) at baseline and none at 12 months. At 12 months, IGFBP3 SDS was 
+0.5 (-1.1, 2.9) and not different from zero (p=0.09). ALS SDS was <-2.0 in 1 (5%) at 
baseline and none at 12 months. BSAP SDS of -1.7 (-3.6, 1.0) (p<0.0001 vs zero) and β-
CTX SDS of -1.1 (-2.6, 0.4) (p=0.01 vs zero) at baseline reflect a low bone turnover state. 
BSAP SDS increased significantly at 6 weeks (p=0.01), whereas β-CTX remained 
unchanged, reflecting a net increase in bone formation.  
Conclusion: Comprehensive assessment of markers of bone turnover and the IGF-1 axis in 
children starting anti-TNF-α therapy for CD shows that other than depressed ALS, markers 
of GH axis were not particularly abnormal in the majority. Bone formation was also low at 
baseline. With therapy and improvement in disease, the height of the patients improved 
and this was associated with increased bone formation but no clear change in markers of 





2.2 Introduction  
Looking at the literature, it is obvious that children with IBD, and more specifically, CD at 
risk of poor growth and short stature; both at diagnosis (84;88) and remaining short as 
adults (90;91). 
Various aetiologies have been proposed to be the cause of poor growth in CD that involves 
abnormalities of the GH-IGF-1 axis and sex steroid, malnutrition, inflammation, and 
glucocorticoid therapy (270). Clearly all those factors are interlinked, although it is 
apparent that the inflammatory process mediated by pro-inflammatory cytokines such as 
TNF-α and interleukins (IL) which are commonly elevated in active CD (10) are central 
modulating factors. Hence, the first strategy to improve or restore growth is to control 
inflammation. 
The monoclonal anti TNF-α chimeric antibody (IFX) induces and maintains remission in 
moderate to severe disease and is first line medication in refractory CD (227;249). Loss of 
the IFX effect can usually be effectively treated with humanised anti TNF-α agent (ADA) 
(271;272). However, the effect of anti-TNF-α on improvement of linear growth seems to 
be variable (232-246). 
To date, data describing the effects of in vivo and in vitro TNF-α inhibition on growth 
biomarkers in patients with CD are still limited (250-252). Currently, there is no published 
evidence about IGF-1 axis in children with CD following TNF-α therapy. Therefore, 
improvement of disease activity by directly reducing inflammatory cytokines may lead to 
improvement in linear growth of these children mediated by changes in the GH-IGF axis. 
The aim of this prospective study was: To assess linear growth, growth biomarkers, bone 
turnover in a cohort of children and adolescents with CD at the time and 12 months after 





2.3 Methods  
2.3.1 Study population 
This is a prospective cohort study of growth, growth axis and bone metabolism. Between 
June 2009 and June 2014, children with IBD who had not completed growth (Tanner stage 
1-4) attending Royal Hospital for Sick Children (RHC), Yorkhill Glasgow and 
commencing treatment with anti-TNF-α therapy were approached to see if they satisfied 
the inclusion criteria. All participants were approached prior to starting anti-TNF-α therapy 
and provided with information sheets. These participants were patients with long-lasting 
disease in clinical relapse who failed to reach inactive disease despite conventional 
therapy. Participants were excluded if received anti-TNF-α therapy in the previous 6 
months; pregnancy; and medical illnesses or therapies unrelated to CD that could 
potentially affect bone, nutrition, or growth such as kidney disease, seizure disorder, 
diabetes, or chronic liver disease. During the period 27 children with IBD (n, 25 CD: n, 1 
UC: n, 1 IBDU started anti-TNF-α therapy (IFX/ADA). 25 of the 27 participants were 
recruited (n, 24 IFX and n, 1 ADA); two participants declined to take part in the study (n, 1 
IFX, n, 1 ADA); two participants decided not to start the study after consenting; one 
participant was lost to follow up after 6 weeks as she moved to adult care and 3/25 were 
non responders and stopped IFX after 6 weeks. Therefore, 19 (12 male) participants, aged 
11-17 years CD, were included for analysis in this study (Figure 2-1). Disease phenotype 
was classified using the Montreal criteria (5). None of the participants were on growth or 
puberty promoting treatments during the period of study. The diagnosis reached in each 
participant was according to standard criteria after small bowel imaging, endoscopy and 
colonoscopy with multiple biopsies, and other investigations, as indicated in the revised 
porto criteria (3).The study protocol was approved by the local research ethics committee 
(LREC) Reference Number: 09/S0703/58 and the research and development office. 









































Figure  2-1: Consort diagram for the study. 
The total number of eligible participants who were started on anti-TNF-α between 2009 and 2014 was 27; 2 
participants declined to take part; 25 participants recruited of whom 2 participants dropped out before starting 
the study, 1 participant lost to follow up as she moved to adult care and 3 participants stopped anti-TNF-α at 
6 weeks as they were non responders. The remaining 19 participants completed 12 months study visits. 
 
 
Visit 12 months  
CD (n, 19) 
Visit 0, 2, 6 
weeks (n, 23) 
Visit 6 months  
CD (n, 19) 
Dropped out 
 (n, 2) 
Declined 
 (n, 2) 
Recruited (n, 25) 
CD (n, 23): UC (n, 1): IBDU (n, 1) 
27 Participants approached  
CD (n, 25): UC (n, 1): IBDU (n, 1) 
Lost to follow up 
at 6 weeks (n, 1) 




CD (n, 1) 
Stopped IFX  
UC (n, 1) 
IBDU (n, 1) 







2.3.2 Anti-TNF-α  
All participants received a baseline schedule of three intravenous infusions of IFX as 
inpatients (5 mg/kg at baseline, 2 and 6 weeks). Following this, infusions were usually 
administered every 8 weeks as maintenance therapy for 12 months. Of the 19 participants, 
4 had ADA therapy; one had ADA from the start, one switched to ADA after suffering a 
hypersensitive reaction to IFX; two participants lost response to IFX therapy and switched 
to ADA between 6 and 8 months. ADA was given intramuscularly (induction dose of 80 
mg followed by 40 mg 2 weeks later and the maintenance regimen was every second 
week). 
 
2.3.3 Disease activity index 
Disease activity was assessed by the wPCDAI and was determined at baseline, 2 weeks, 6 
weeks, 6 months and 12 months. Disease activity was categorized as remission <12.5, mild 
(12.5–40), and moderate (>40–57.5), severe (>57.5). These cut-off points of wPCDAI 
were used to classify the disease status at 12months. 
 
2.3.4 Concomitant medication 
At each study visit details of concomitant medication and nutritional support and surgery 
were obtained. Average oral GC dose over the 5 times points was converted into 
mg/kg/day. To identify further effects of GC use on changes in IGF-1 axis, bone turnover 
and bone health, the participants were sub-divided according to GC use during the study 
period. 
 
2.3.5 Disease biomarkers and cytokines  
At baseline, 2 weeks, 6 weeks, 6 months and 12 months the following markers of 
inflammation were analysed: erythrocyte sedimentation rate (ESR, mm/h), serum C–
reactive protein (CRP, mg/l), and albumin (g/l) concentrations, using standard methods in 
the clinical laboratory. Non fasting blood sample collections coincided with the routine 
schedule of IFX infusions/ ADA injection visits; usually between 10am-3pm. Samples 
were immediately centrifuged at 2500 rpm for 5 min, and the serum was subsequently 
stored at -80C. Numbers of cytokines (TNF-α, IL-6) measured at baseline, 6 weeks, 6 
months and 12 months by the Luminex which is a multiplex immunoassay with intra-assay 




detection of multiple cytokines in one plate. The assay principle is similar to that of an 
ELISA.  
 
2.3.6 Anthropometry  
At baseline and 12 months, the following data were obtained: Ht and sitting height (SH) 
using a Harpenden stadiometer, weight using digital weight scale. Subischial leg length 
(SILL) was calculated from the Ht and SH. Body mass index (BMI) calculated using the 
formula weight (kg) / height (m)
2
. Ht and BMI were converted to SDS using 1990 children 
standards (273;274). SH and SILL were converted to SDS using the 1978 Tanner-
Whitehouse17 standards (275). HV (cm/year) and ∆Ht SDS were calculated for baseline 
from the prior 12 months of growth before time points of starting anti-TNF-α therapy and 
for 12 months after anti-TNF-α therapy from baseline. 
 
2.3.7 Pubertal assessment and skeletal maturation  
Tanner stage was ascertained by self-assessment questionnaire (276). Pubertal status data 
were collected at baseline, 6 and 12 months and participants were categorised as pre-
pubertal (Tanner stage 1), early/mid-pubertal (Tanner stage 2-3) and late pubertal (Tanner 
stage 4-5). Bone age (BA) was determined at baseline and 12 months using the Tanner 
White House (TW2) the radius-ulna-short bones (RUS) method (277). BA was read on a 
clinical basis by a paediatric radiologist who was aware of the participant’s age but not 
Tanner stage. However, we found discordant pubertal status using self-assessment with 
HV because some participants who categorised themselves as early puberty and HV of 0 
cm/year, thus we assess the impact of puberty on growth by using BA. To evaluate the 
effect of anti-TNF- on growth and bone, participants were categorised by 2 groups based 
on BA: group (A), those with growth potential: BA<13.5 year for girl & <14.5 year for 
boys (n=9) and group (B) those with little or no growth potential: BA ≥13.5 for girl & 
≥14.5 for boys (n=10). ΔBA/ΔCA ratio (the change in bone age (ΔBA) to change in 
chronological age (ΔCA)) ratio was used as predictors of pubertal progression (52). 
 
2.3.8 Growth biomarkers  
Serum IGF-1 (ng/ml) concentration was determined by a serum IGFBP-blocked IGF-1 
ELISA kit (Mediagnost, Reutlingen, Germany) with inter- and intra-assay variation 
coefficients of 11.4% and 9.9% respectively, and low cross-reactivity of the IGF-1 with 




Reutlingen, Germany) with inter-assay and intra-assay coefficients of 5.3% and 1.6%. 
Serum ALS (mU/ml) was measured by ELISA using the Mediagnost ELISA Reutlingen, 
Germany kits with inter-assay variation of 5.1% and intra-assay variation of 14.5% and no 
cross reactivity with IGF-1 and IGFBP-3. Serum IGFBP-2, (ng/ml) was measured by 
ELISA (Mediagnost ELISA Reutlingen, Germany). This assay is specific to human 
IGFBP-2; there is no cross-reactivity with IGFBP-1 or IGFBP-3 and inter- and intra assay 
coefficients of variability (CV) are 12.6% and 0.76%. To take into account pubertal 
variation, IGF-1 and IGFBP-3 level were converted to standard deviation scores (SDS) by 
adjusting to bone age and sex using reference data available from Mediagnost (n, 388) 
(278) and ALS level was converted to standard deviation scores (SDS) by adjusting to 
bone age and sex using published reference data (n, 252) (279). The baseline bone age for 
baseline 2 and 6 week and 12 months bone age for 6 months and 12 months. As IGFBP-2 
does not vary with gender or puberty, it was adjusted only for age using published 
reference data (n, 388) (280). 
 
2.3.9 Bone Biomarkers 
Serum BSAP (µg/L) was measured by immunoenzymetric assay (EIA) (Ostase BAP assay, 
Immunodiagnostic Systems (IDS) UK) (interassay and intra-assay coefficients of variation 
of 8.9% and 4.5%). Bone age and sex specific standard deviation scores (SDS) calculated 
using reference data available from Immunodiagnostic (n, 116) (281). Current 
immunoassays for BSAP possess a low cross-reactivity with the circulating liver 
isoenzyme. Biomarkers of bone resorption, β-CTX (ng/ml) measured by the Serum 
CrossLaps® ELISA (Immunodiagnostic Systems (IDS) Ltd), with interassay and intra-
assay coefficients of variation of 7.1% and 7.4% respectively. Bone age and sex specific 
standard deviation scores (SDS) calculated using published reference data (n, 572) (282). 
Vitamin D (25(OH) vitamin D) was conducted by Mrs Susan Johnston at Glasgow Royal 
Infirmary Hospital. 25 (OH) vitamin D was measured by liquid chromatography-tandem 
mass spectrometry (Waters Corporation, Milford, MA, USA) with a sensitivity of 2.5 
nmol/L and intra-assay variation coefficients was 5.3%. 
 
2.3.10 Statistics  
Analyses were performed using SPSS software version 22 (New York, USA). Non-
parametric data were presented with medians and ranges. Changes between parameters 




signed-rank tests and subsequently adjusted for multiple comparison using a Bonferroni 
correction and p<0.05 considered as statistically significant. Mann Whitney U test was 
used for continuous and Chi-square test for categorical variable to assess inter-group 
differences divided according to disease, GC use or growth potential. The univariate 
correlation between variables was assessed using the Spearman’s correlation coefficient. 
To assess the relationship of IGF-1 axis (SDS adjusted for gender and BA) with albumin, 
wPCDAI, IL-6 and GC exposure, we used a mixed-model approach that takes into account 
intra individual correlations over the 5 time points of study visits. Linear regression 
analysis was used to assess the independent predictors for Δ Ht SDS at 12 months in group 
with growth potential. The statistical analysis was only done for those who had complete 
data. All graphs were prepared by GraphPad Prism software version 7 (San Diego 






2.4  Results  
2.4.1  Participant characteristics  
Table 2-1 summarises the characteristics of the 19 CD participants at the time of starting 
anti-TNF-α. The median (range) age at diagnosis of CD and age at anti-TNF-α initiation 
was 11.9 years (5.5, 15.5) and 14.9 years (11.2-17.2) with median interval since diagnosis 
of 3.1 years (0.2, 10.7); only 3 participants had the disease less than 18 months. 10/19 
(53%) of participants had colonic (L2) CD, two had colonic and upper gastro-intestinal 
disease (L4), 8 /19 (42%) had ileocolic disease (L3) CD and four of them had L3+ L4. 4/19 






Table  2-1: Participant characteristics at time of starting anti-TNF-α. 
Data presented as number, n; percentage, %, median (range). CA, chronological age; BA, 
bone age; Ht SDS, height SD score; BMI SDS, body mass index SD score. 
  n, 19 CD 
Male, n (%) 12 (63%) 
CA at Diagnosis (year) 11.9 (5.5, 15.5) 
CA at starting anti-TNF-α (year) 14.9 (11.2, 17.2) 
Duration of disease 3.1 (0.20, 10.7) 
BA at starting  anti-TNF-α (year) 14.2 (9.3, 16.9) 
BA delay (year) 0.5 (-0.8, 2.3) 
Tanner stage, n (%)  
Pre-puberty (tanner stage-1) 2 (11) 
Mid-puberty (tanner stage 2-3) 8 (42) 
Late puberty (tanner stage 4-5) 9 (47) 
Ht SDS at starting anti-TNF-α -0.7 (-2.7, 1.7) 
BMI SDS at starting anti-TNF-α -0.4 (-2.7, 3.2) 
Disease location, n (%)  
Ileal (L1) 1 (5) 
Colonic (L2) 10 (53) 
Ileocolonic (L3) 8 (42) 
Isolated upper disease(L4) 6 (32) 
Behaviour (non-stricturing, non-penetrating) 
19 (100) 





2.4.2 Disease and laboratory characteristics  
Table 2-2 summarises disease and treatment characteristic in 19 CD participants at each 
visit. At baseline, median (range) of wPCDAI scores was 40.0 (0.0, 95.0) and significantly 
decreased, to 17.5 (0.0, 70.0) at 2 weeks (p=0.004 vs. baseline), 7.5 (0.0, 67.0) at 6 weeks 
(p=0.008 vs. baseline), 10.0 (0.0, 42.0) at 6 months (p=0.004 vs. baseline) and 15.0 (0.0, 
47.0) at 12 months (p=0.038 vs. baseline) (Figure 2-2). Nine (47%) participants had 
moderate to severe disease activity based on wPCDAI at enrolment with marked 
improvement to three (16%) at 6 weeks and four (21%) at 12 months (Figure 2-2). ESR, 
Serum albumin, CRP improved significantly at 6 weeks with no difference between 6-
weeks and 12–month values. Overall, median (range) TNF-α (pq/ml) remained unchanged 
during the study interval. At baseline, median (range) of serum IL-6 (pq/ml) was 52.1 
(34.0, 153.0) and changed to 58.6 (21.0, 155.5) at 6 weeks (p=0.60 vs. baseline), reduced 
to 49.5 (17.5, 151.5) at 6 months (p=0.59 vs. baseline) and 44.4 (22.0, 116.0) at 12 months 





Table  2-2: Changes in disease activity, laboratory results, and treatment over the study interval. 
Data presented as number, n; percentage, %, median (range). wPCDAI, weighted paediatric disease activity index; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; IL-6, 
interleukin-6; TNF-α, tumour necrosis factor-α. Values in bold indicate statistical significance (p<0.05). 
 n, 19 Baseline 2 Weeks 6 Weeks 6 Months 12 Months p-values 
Baseline vs. 
2 weeks 






wPCDAI,  40.0 (0.0, 95.0) 17.5 (0.0, 70.0) 7.5 (0.0, 67.0) 10.0 (0.0, 42.0) 15.0 (0.0, 47.0) 0.004 0.008 0.004 0.038 
wPCDAI, n (%)          
Not active (<12.5) 3 (16) 9 (47) 11 (58) 12 (63) 9 (47)     
mild (12.5-40) 7 (37) 8 (42) 5 (26) 5 (26) 6 (32)    0.09 
Moderate-severe (>40) 9 (47) 2 (11) 3 (16) 2 (11) 4 (21) 0.012 0.036 0.012 0.09 
Albumin (g/l)  34.0 (17.0, 42.0) 35.0 (17.0, 42.0) 36.0 (25.0, 44.0) 38.0 (20.0, 44.0) 36.0 (19.0, 42.0) 0.17 0.04 0.20 0.17 
ESR (mm/hr)  25.0 (3.0, 70.0) 11.0 (3.0, 70.0) 12.0 (3.0, 86.0) 12.0 (4.0,56.0) 12.0 (2.0, 48.0) 0.000 0.075 0.071 0.12 
CRP (mg/l)  10.0 (3.0, 95.0) 5.0 (3.0, 98.0) 5.0 (3.0, 51.0) 3.0 (0.0, 39.0) 4.0 (3.0, 90.0) 0.15 0.042 0.042 0.2 
Il-6 (pg/ml)  52.0 (34.0, 153.0) - 59.0 (21.0, 
156.0) 
50.0 (18.0, 152.0) 44.0 (22.0, 116.0) - 0.60 0.59 0.05 
TNF-α (pg/ml)  14.0 (10.0, 49.0) - 19.0 (9.0, 53.0) 19 (9.0, 119.0) 18 (10.0, 92.0) - 0.13 0.13 0.16 
Medication, n (%)          
Glucocorticoid 9 (47) 9 (47) 8 (42) 2 (11) 2 (11)    0.08 
Aminosalicylates 10 (53) 9 (47) 10 (53) 8 (42) 5 (26)    0.10 
Methotrexate  13 (68) 13 (68) 12 (63) 12 (63) 11 (58)    0.50 
Mercaptopurine/Azathioprine  3 (16) 4 (21) 4 (21) 6 (32) 6 (32)    0.25 



































Figure  2-2: Individual change in weighted Paediatric Disease Activity Index (wPCDAI)  
following 12 months of anti-TNF-α.  
Red solid lines represent the median values. Black dotted lines represent the cut off values of wPCDAI. 



























Figure  2-3: Individual change in interleukin-6 (IL-6) following 12 months of anti-TNF-α. 


















To identify further effects of disease status (based on wPCDAI) on changes in, IGF-1 axis, 
bone turnover and growth, the participants were sub-divided into two groups according to 
their disease status at 12 months following the treatment with anti- TNF-α agents (Table 2-
3). There was no significance in gender distribution, duration of disease, GC use and 





Table  2-3: Participant characteristics according to disease status based on wPCDAI at 12 
months. 
Data presented as number, n; percentage, %, median (range). CA, chronological age; BA, bone age, Ht SDS, 









  Remission 
(n, 9) 
Non-remission 
(mild/ moderate+ severe 
disease) (n, 10) 
p-value 
Male, n (%) 6 (67%) 6 (60%) 0.76 
CA at Diagnosis (year) 12.2 (6.5, 15.5) 11.0 (5.5, 15.1) 0.60 
CA at starting anti-TNF-α (year) 14.8 (11.6, 16.3) 15.5 (11.2, 17.2) 0.35 
Duration of disease 3.0 (0.17, 5.5) 3.6 (0.7, 10.7) 0.39 
BA at starting anti-TNF-α (year) 13.5 (11.4, 16.9) 14.4 (9.3, 16.5) 0.65 
BA delay (year) 0.1 (-0.9, 1.3) 0.6 (-0.6, 2.3) 0.49 
Tanner stage, n (%)    
Pre-puberty (tanner stage-1) 1 (11) 1 (10)  
Mid-puberty (tanner stage2-3) 4 (44) 4 (40)  
Late puberty (tanner stage4-5) 4 (44) 5 (50)  
Ht SDS at starting anti-TNF-α 
(year) 
-0.7 (-2.7, 1.8) -0.7 (-1.6, 1.5) 0.78 
BMI SDS at starting anti-TNF-α 
(year) 
-0.4 (-2.7, 3.2) -0.1 (-1.4, 1.4) 0.27 
Glucocorticoid at baseline 6 (67%) 3 (30%) 0.11 
Disease location, n (%)    
Ileal  0 (0) 1 (10)  
Colonic  6 (67) 4 (40)  
Ileocolonic  3 (33) 5 (50)  
Isolated upper disease 2 (22) 4 (40)  
Behaviour (non-stricturing, non-
penetrating) 
9 (100) 10 (100)  




2.4.3 Treatment characteristics  
All participants started the study on anti-TNF-α and all were responders at 6 weeks and 
had anti-TNF-α for 12 months. Nine (47%) participants were treated with GC at baseline 
and corresponding data were 9/19 (47%) at 2 weeks, 9/19 (47%) at 6 weeks, 2/19 (10%) at 
6 months and 2/19 (10%) at 12 months respectively. None of the participants had surgery 
during the 12 months of the study interval (Table 2-2). 
To identify further effects of GC use on changes in IGF-1 axis, bone turnover, the 
participants were sub-divided according to GC exposure during the study period into GC 
naïve (n,10), GC at baseline but stopped at 6 months (n,7), GC at baseline and throughout 
12 months (n,2) (Table 2-4). The participants who were on GC had lower BA and all of 
them were on tanner stage between 1-3. Of the two who were on GC throughout 12 
months, one was female (ID18) and another was male (ID19) aged 15.6 and 16 years 
respectively at the time of starting anti-TNF-α and both were on tanner stage 4. Both of 








Table  2-4: Participant characteristics according to GC exposure during study.  
Data presented as number, n; percentage, %, median (range). CA, chronological age; BA, bone age, Ht SDS, 
height SD score; BMI SDS, body mass index SDS; GC, glucocorticoid; +/-, GC at baseline and stopped at 6 
months. Values in bold indicate statistical significance (p<0.05).
  GC naïve 
(n, 10) 
GC at baseline and 
stopped at 6 months (n, 
7) 
p-value 
Male, n (%) 6 (60%) 5 (71%) 0.63 
CA at Diagnosis (year) 11.5 (5.5, 13.1) 10.6 (6.3, 15.1) 0.73 
CA at starting anti-TNF-α (year) 15.3 (12.2, 17.2) 12.8 (11.2, 15.8) 0.06 
Duration of disease 3.1 (2.7, 10.7) 2.2 (0.73, 5.5) 0.35 
BA at starting  anti-TNF-α (year) 15.0 (11.4, 16.5) 12.9 (9.3, 15.4) 0.06 
BA delay (yr) 0.6 (-0.85, 2.3) 0.5 (-0.5, 1.9) 0.73 
Tanner stage, n (%)    
Pre-puberty (tanner stage -1) 1 (10) 1 (14) 0.79 
Mid-puberty (tanner stage 2-3) 2 (20) 6 (86) 0.008 
Late puberty (tanner stage 4-5) 7 (70) 0 (0) 0.004 
Ht SDS at starting anti-TNF-α 0.2 (-1.5, 1.5) -0.9 (-2.7, -0.7) 0.007 
BMI SDS at starting anti-TNF-α -0.4 (-2.3, 3.2) -0.03 (-2.3, 0.6) 0.73 
wPCDAI 38.0 (0.0, 58.0) 40.0 (7.5, 83.0)  
Disease location, n (%)    
Ileal (L1) 1 (10) 0 (0) 0.39 
Colonic (L2) 3 (30) 7 (100) 0.19 
Ileocolonic (L3) 6 (60) 0 (50) 0.011 




7 (100)  





2.4.4 Anthropometric characteristics 
Table 2-5 summarises anthropometry and pubertal outcomes and figure 2-4 shows 
individual data at baseline, 2 weeks, 6 weeks, 6 months and 12 months among 19 
participants. In 19 participants with active CD, median Ht SDS at time of diagnosis was 
0.04 (-3.1, 1.5) and it was not different from median MPH SDS -0.4 (1.5, -1.4) (p=0.55). 
Median Ht SDS dropped from -0.5 (-2.5, 0.9) at 12 months prior to starting anti-TNF-α to -
0.7 (-2.7, 1.7) at the time of starting anti-TNFα. (p=0.87). At baseline the median (range) 
Ht SDS was not different from zero (p=0.17) and there was no significant improvement in 
median Ht SDS (p=0.47) 12 months following anti-TNF-α. Among 19 participants, 3 
(16%) had Ht SDS <-2 at time of diagnosis, 2 (10%) had Ht SDS <-2 at time of baseline 
(both of them were male and their BA 16.9 and 11.5 years) and the Ht SDS of those two 
patients remained <-2 at 12 months. Median HV at baseline was 3.6 cm/year (0.0, 8.6) and 
dropped to 2.8 cm/year (0.0, 9.5) (p=0.37). There was no significant difference in median 
ΔHt SDS between baseline and 12 months after initiation of biologic 0.1 (-0.4, 0.5) 
(p=0.11). 
 
2.4.5 Body mass index, puberty and skeletal maturation  
Median BMI SDS at time of diagnosis was -1.1 (-3.6, 2.8); 3 (16%) was underweight (BMI 
SDS ≤-2) and one (5%) was overweight (BMI SDS ≥ 2). At baseline, median BMI SDS 
was not different from zero (p=0.136) and there was a trend toward an increase in median 
BMI SDS at 12 months (p=0.06); none of the participants were underweight and 2 (10%) 
were overweight at 12 months. Based on self-assessment, 2 (10%) participants were in pre-
puberty, 8 (42%) were early puberty and 9 (47%) were late-puberty (all of them were on 
tanner stage-4). By 12 months the majority of participants 14 (74%) were at late-puberty 





Table  2-5: Anthropometry, puberty at baseline and 12 months following anti-TNF-α. 
Data presented as median (range). CA, chronological age ; BA, bone age; Ht SDS, height SD score; HV, 
height velocity; ∆Ht SDS, change in height standard deviation scores; SH SDS; sitting height SD score SILL 
SDS, sub-ischial leg length SD score; BMI SDS, body mass index SD score. Values in bold indicate 




n, 19 Baseline 12 Months p-Value 













































Pubertal status  
 
  
Pre-pubertal 2(11%) 0(0) 0.15 
Early-pubertal 8(42%) 5(26%) 0.31 



































Figure  2-4: Individual change in anthropometric in 19 participants following 12 months of 
anti-TNF-α.  
HV, height velocity (cm/year); Ht SDS, height SD score; ΔHt SDS, change in height SD score; BMI SDS, 
body mass index SD score. Red solid lines represent the median values. Black dotted lines represent the 50th 
centile (0SDS), 3rd (-2SDS) and 97th (2SDS) centile. *indicate statistical significance (p<0.05).
Baseline 12 months 
Ht SDS 
Baseline 12 months 
Cm/year 
HV 
Baseline 12 months 
ΔHt SDS BMI SDS 





2.4.6 Impact of puberty on growth  
The cohort of participants was divided into two groups on whether they have potential to 
grow at the time of starting anti-TNF-α based on bone age (Table 2-6; Figure 2-5). At 
baseline, in group (A), the median Ht SDS was below zero (p=0.05). Participants grew at a 
sub-normal rate over 12 months prior to starting anti-TNF-α and experienced increase in 
growth rate during 12 months (p=0.008) following anti-TNF-α therapy. The increase in 
HV was associated with a trend toward increase in median (range) Ht SDS between 
baseline and 12 months (p=0.07). At 12 months, median Ht SDS stayed below zero 
(p=0.050). Their MPH SDS was -0.3 (-1.5, 1.1) (p=0.33, Ht SDS at baseline vs MPHSDS) 
and; p=0.53 (Ht SDS at 12months vs MPH SDS). After 12 months of TNF-α therapy this 
group experienced a significant increase in median ∆Ht SDS (p=0.015) with none of these 
participants having ∆Ht SDS >0.5 at 12 months. At baseline median SH SDS was -0.9 (-
2.2, 0.9) and SILL SDS was -1.1 (-3.7, 0.9) and at 12 months was -0.6 (-2.0, 0.9) (p=0.23 
vs. baseline) and -0.6 (-2.0, 0.9) (p=0.36 vs. baseline) respectively. 
At baseline no significant correlation was observed between Ht SDS in the group (A) with 
disease activity markers (including albumin, CRP, ESR, wPCDAI), disease duration and 
cytokines (IL-6, TNF-α). At 12 months a significant negative correlation was observed 
between Ht SDS and TNF-α (r=-0.81; p=0.02). ∆Ht SDS and HV at 12 months were not 
associated with 12 months change in disease biomarkers/cytokines. The majority of 
participants (6/9) in group (A) were on GC at baseline and stopped it by 6 months. Based 
on wPCDAI at 12 months, 6/9 participants in group (A) were in remission, thus 
categorising the participants based on GC use/wPCDAI was not practical for those 
participants. Multivariate analysis using linear regression was used to identify predictors of ΔHt 
SDS at 12 months in group (A)with average wPCDAI over 12 month as markers of disease 
activity, progress in puberty (∆BA/∆CA) and GC (Average dose on mg/kg/d over 12months) as 
independent variables (R
2
=50) showed no significant independent factor.  
In-group (B); at baseline the median Ht SDS was not different from zero (p=1.0). Median 
HV decreased from 3.7cm/year (0.0, 7.8) at baseline to 1.1cm/year (0.0, 2.8) (p=0.12) at 12 
months. Median Ht SDS and ∆Ht SDS remained static at 12 months. Their MPH SDS was 
-0.6 (-1.1, 1.4) [p=0.71(Ht SDS at baseline vs MPH SDS); p=0.77 (Ht SDS at 12 months 




Table  2-6: Change in growth following anti-TNF-α. Participants divided into two groups on 
whether they have potential to grow at time of starting anti-TNF-α based on bone age. 
Data presented as median (range).19 Participants, 9 (47%) had growth potential (BA<13.5yrs in girls and 
<14.5yrs in boys) (Group (A)); 10 (53%) participants had little/no growth potential (BA≥13.5yrs in girls and 
≥14.5yrs in boys) (Group (B)). CA, chronological age; BA, bone age; Ht SDS, height SD score; HV, height 
velocity; ∆Ht SDS, change in height standard deviation scores; BMI SDS, body mass index SD score; 
wPCDAI, weighted paediatric disease activity index; GC, glucocorticoid. Values in bold indicate statistical 
significance (p<0.05). 
 Baseline 12 Months p-value 
Age (year)    










Bone age (yr)    










Duration of Disease    
Group (A) 3.0 
(1.5, 5.5) 
  
Group (B) 3.6 
(0.2, 10.7) 
  
Height SDS    










HV (cm/year)    










∆Height SDS    










BMI SDS    










GC exposure    
Group (A) 6 (67) 0 (0) 0.001 
Group (B) 2 (20) 2 (20) 1.0 
wPCDAI    










Pre-pubertal    
Group (A) 2 (22) 0 (0) 0.11 
Group (B) 0 (0) 0 (0)  
Early-pubertal    
Group (A) 6 (66) 5 (55) 0.40 
Group (B) 2 (20) 0 (0) 0.14 
Late-pubertal    
Group (A) 1 (11) 4 (44) 0.11 



































Figure  2-5: Individual change in anthropometric following 12 months of anti-TNF-α. 
Participants divided into two groups on whether they have potential to grow at time of 
starting Anti-TNF-α based on bone age. 
19 Participants, 9(47%) had growth potential (BA<13.5yrs in girls and <14.5yrs in boys) (Group (A)); 10 
(53%) participants had little/no growth potential (BA≥13.5yrs in girls and ≥14.5yrs in boys) (Group (B)). 
HV, height velocity (cm/years); Ht SDS, height SD score; ΔHt SDS, change in height SD score; BMI SDS, 
body mass index SD score. Red solid lines represent the median values. Black dotted lines represent the 50th 
centile (0SDS), 3rd (-2SDS) and 97th (2SDS) centile. *indicate statistical significance (p<0.05).
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2.4.7 Growth biomarkers 
Table 2-7 summarises the median (ranges) changes of growth biomarkers and Figure 2-6 
shows individual data of growth biomarkers at baseline, 6 months and 12 months among 
19 participants. At baseline, the median IGF-1 SDS was not different compared to zero 
(p=0.80), median IGFBP-3 SDS was significantly higher compared to zero (p=0.002), the 
median ALS SDS at baseline was significantly lower compared to zero (p=0.00) and 
median IGFBP-2 SDS was significantly higher compared to zero (p=0.00). For IGF-1 SDS 
values did not change through the study interval. The percentage of participants with IGF-1 
SDS below minimum reference range (IGF-1 SDS <-2) decreased from 5 (26%) at baseline 
to 2 (10%) at 2 weeks, 1 (5%) at 6 weeks, 1 (5%) at 6 months and 0 (0%) at 12 months 
respectively. At 12 months the median IGFBP-3 SDS was not different to zero (p=0.09) 
with three participants with IGFBP-3 SDS >2 at baseline, and 2 with their values above 2 
SDS at 12 months. The median ALS SDS remained unchanged and stayed below zero 
(p=0.00); one participant had ALS SDS <-2 at baseline. There was a trend toward 
normalisation of median IGFBP-2 SDS by 12 months. 10 (53%) participants had their 
IGFBP-2 SDS >2 while for 6 (31%) participants their IGFBP-2 SDS remained >2. IGF-
1/IGFBP-3 ratio as a surrogate marker of bioavailable IGF-1 was below one and remained 
unchanged. When categorised by disease status (Table 2-8; Figure 2-7) or GC exposure, 
the growth biomarkers yielded the same results (Table 2-9). However, our results showed 
IGFBP-2 SDS at 12 months was lower in those who had remission compared to those who 






Table  2-7: Changes in growth biomarkers following anti-TNF-α.  
Data presented as median (range) and adjusted for bone age. IGF-1 SDS, serum insulin like growth factor-1SD score; IGFBP-3 SDS, serum insulin like growth factor binding protein-3 
SD score; ALS SDS acid-labile subunit; IGFBP-2 SDS, serum Insulin like growth factor binding protein-2. 
 



















0.36 0.29 0.83 0.35 
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Figure  2-6: Individual change in growth biomarkers following 12 month of anti-TNF-α. 
IGF-1 SDS, serum insulin like growth factor-1SD score; IGFBP-3 SDS, serum insulin like growth factor 
binding protein-3 SD score; ALS SDS, acid-labile subunit SD score; IGFBP-2 SDS, serum Insulin like 
growth factor binding protein-2 SD score. Red solid lines represent the median values. Black dotted lines 
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Table  2-8: Changes in growth biomarkers following anti-TNF-α. Participants divided according to wPCDAI at 12months. 
Data presented as median (range) and adjusted for bone age; IGF-1 SDS, serum insulin like growth factor-1SD score; IGFBP-3 SDS, serum insulin like growth factor binding protein-3 
SD score; ALS SDS acid-labile subunit SD score; IGFBP-2 SDS, serum insulin like growth factor binding protein-2 SD score. Values in bold indicate statistical significanc
n, 19 
 










at 12 months 
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0.68 0.68 0.41 0.34  
ALS SDS  























0.33 0.14 0.77 0.95  
IGFPB-2 SDS  























0.96 0.11 0.44 0.86  





































Figure  2-7: Individual change in growth biomarkers following 12 months of anti-TNF-α. 
Participants divided according to wPCDIA at 12 months (remission (left) and non-remission 
(right)). 
IGF-1 SDS, serum insulin like growth factor-1SD score; IGFBP-3 SDS, serum insulin like growth factor 
binding protein-3 SD score; ALS SDS, acid-labile subunit SD score; IGFBP-2 SDS, serum Insulin like 
growth factor binding protein-2 SD score; BL, baseline; 2wks, 2weeks; 6wks, 6week; 6m, 6 months; 12m, 
12months. Red solid lines represent the median values. Black dotted lines represent the 50th centile (0SDS), 














































































Table  2-9: Changes in growth biomarkers following Anti-TNF-α. Participants divided according to glucocorticoid use 
Data presented as median (range) and adjusted for bone age. IGF-1 SDS, serum insulin like growth factor-1SD score; IGFBP-3 SDS, serum insulin like growth factor binding protein-3 
SD score; ALS SDS, acid-labile subunit; IGFBP-2 SDS, serum Insulin like growth factor binding protein-2. GC, glucocorticoid; +/-, glucocorticoid at baseline and stopped by 6 
months; GC +/+, glucocorticoid throughout the study period. 
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0.96 0.17 0.44 0.44 0.24 
GC +/- (n, 7) 1.0 









0.13 0.87 0.25 0.61  
GC +/+ (ID-18) 1.7 1.5 1.4 0.03 0.7      
GC +/+ (ID-19) -3.8 -0.81 -1.7 -2.6 -1.9  
IGFPB-3 SDSD  










0.80 0.19 0.09 0.74 0.83 










0.74 0.87 0.35 0.87  
GC +/+ (ID-18) 0.50 0.35 0.2 -0.5 -0.1      
GC +/+ (ID-19) -2.9 -0.9 -0.5 0.6 -0.9  
ALS SDS  










0.65 0.17 0.37 0.44 0.53 










0.74 0.74 0.12 0.87  
GC +/+ (ID 18) 1.5 -1.9 0.6 -0.1 -0.2      
GC +/+ (ID19) -2.2 -1.4 -1.6 -1.5 -1.7  
IGFPB-2 SDSD  










0.51 0.33 0.07 0.14 0.83 










0.50 0.24 0.92 0.87  
GC +/+ (ID-18) 1.1 -0.6 0.7 2.3 -0.1      
GC +/+ (ID-19) 2.8 2.6 2.5 2.5 2.7  




2.4.7.1 Correlation between IGF-1 and disease biomarkers  
Figure 2-8 shows the correlation between IGF-1 SDS with wPCDAI and albumin; at each 
time point 19 CD received anti-TNF-α for 12 months. At baseline a significant negative 
correlation was observed between IGF-1 SDS and ESR (r=–0.48; p=0.037), CRP (r=–0.51; 
p=0.027), and a positive correlation with albumin (r=0.63; p=0.004). At 2 weeks a 
significant negative correlation was observed between IGF-1 SDS and CRP (r=–0.56; 
p=0.013) and wPCDAI (r=–0.52; p=0.023) and a positive correlation with albumin 
(r=0.50; p=0.031). At 6 weeks a significant negative correlation was observed between 
IGF-1 SDS and CRP (r=–0.69; p=0.001), and wPCDAI (r=–0.55; p=0.015), and a positive 
correlation with albumin (r=0.55; p=0.016). At 6 months, a significant negative correlation 
was observed between IGF-1 SDS and CRP (r=–0.81; p=0.00), and wPCDAI (r=–0.69; 
p=0.003) and a positive correlation with albumin (r=0.54; p=0.030). At 12 months a 
significant positive correlation was observed between IGF-1 SDS and albumin (r=0.70; 
p=0.001). 
 






















Figure  2-8: Correlation between IGF-1 SDS with wPCDAI (as indicator for disease activity) on the left and Albumin (as indicator for nutritional status) on 
the right. 
Baseline (filled black circle), 2 weeks (empty black circle), 6 weeks (filled grey circle), 6 months (empty grey circle) and 12 months (filled blue circle) in 19 CD received anti-TNF-α 



























r=-0.27; p =0.27 
r=-0.52; p=0.023 




6 months r=-0.69; p=0.003  
r=-0.45; p=0.065 12 months  




2.4.7.2 Correlation between IGFBP-3 and disease biomarkers 
Figure 2-9 shows the correlation between IGFBP-3 SDS with wPCDAI and albumin at 
each time point in 19 CD receiving anti-TNF-α for 12 months. At baseline a significant 
negative correlation was observed between IGFBP-3 SDS and wPCDAI (r=–0.57; 
p=0.014) and a positive correlation with albumin (r=0.69; p=0.001). At 2 weeks a 
significant negative correlation was observed between IGFBP-3 SDS and CRP (r=–0.60; 
p=0.007), and a positive correlation with albumin (r=0.64; p=0.003). At 6 weeks a 
significant negative correlation was observed between IGFBP-3 SDS and CRP (r=–0.61; 
p=0.006) and a positive correlation with albumin (r=0.53; p=0.02). At 6 months a 
significant negative correlation was observed between IGFBP-3 SDS with CRP (r=–0.73; 
p=0.001) and wPCDAI (r=–0.60; p=0.015). At 12 months no significant correlation was 
observed between IGF-1 SDS and disease biomarkers. 
 




























Figure  2-9: Correlation between IGFBP-3SDS with wPCDAI (as indicator for disease activity) on the left and Albumin (as indicator for nutritional status) on 
the right. 
Baseline (filled black circle), 2 weeks (empty black circle), 6 weeks (filled grey circle), 6 months (empty grey circle) and 12 months (filled blue circle) in 19 CD received anti-TNF-α 



















r=0.39; p=0.14  
r=0.22; p=0.38 




2.4.7.3 Correlation between ALS and disease biomarkers 
Figure 2-10 shows the correlation between ALS SDS with wPCDAI and albumin at each 
time point in 19 CD receiving anti-TNF-α for 12 months. At baseline a significant negative 
correlation was observed between ALS SDS with ESR (r=–0.48; p=0.040), CRP (r=–0.54; 
p=0.018), wPCDAI (r=–0.41; p=0.093) and a positive correlation with albumin (r=0.70; 
p=0.001). At 2 weeks no significant correlation was observed between ALS SDS and any 
of the disease biomarkers. At 6 weeks a significant negative correlation was observed 
between ALS SDS with CRP (r=–0.53; p=0.021) and a positive correlation with albumin 
(r=0.49; p=0.032). At 6 months a significant negative correlation was observed between 
ALS SDS with CRP (r=–0.57; p=0.023). At 12 months no significant correlation was 
observed between ALS SDS and any of the disease biomarkers. 
 





















Figure  2-10: Correlation between ALS SDS with wPCDAI (as indicator for disease activity) on the left and Albumin (as indicator for nutritional status) on 
the right. 
Baseline (filled black circle), 2 weeks (empty black circle), 6 weeks (filled grey circle), 6 months (empty grey circle) and 12 months (filled blue circle) in 19 CD received anti-TNF-α 
for 12 months. Large black circle indicates confidence limit, Values in bold indicate statistical significance (p<0.05).
r=-0.40; p=0.093 
r=-0.24; p=0.32 
















r =0.54; p=0.09  
r =0.44; p=0.07 




2.4.7.4 Correlation between IGFBP-2 and disease biomarkers 
Figure 2-11 shows the correlation between IGFBP-2 SDS with wPCDAI and albumin at 
each time point in 19 CD receiving anti-TNF-α for 12 months. At baseline a significant 
positive correlation was observed between IGFBP-2 SDS and ESR (r=0.48; p=0.036), CRP 
(r=0.54; p=0.017), and a negative correlation with albumin (r=-0.75; p=0.000). At 2 weeks 
a significant positive correlation was observed between IGFBP-2 SDS and wPCDAI 
(r=0.50; p=0.031) and a negative correlation with albumin (r=-0.59; p=0.008). At 6 weeks 
a positive correlation was observed between IGFBP-2 SDS and CRP (r=0.70; p=0.001) 
and wPCDAI (r=0.75; p=0.000) and a negative correlation with albumin (r=-0.66; 
p=0.002). At 6 months a significant positive correlation was observed between IGFBP-2 
SDS and CRP (r=0.56; p=0.024) and wPCDAI (r=0.71; p=0.002) and a negative 
correlation with albumin (r=-0.67; p=0.004). At 12 months a significant positive 
correlation was observed between IGFBP-2 SDS and wPCDAI (r=0.72; p=0.001) and a 
negative correlation with albumin (r=-0.89; p=0.000). At 12 months, no significant 
correlation was observed between IGFBP-2 SDS and any of the disease biomarkers. 




















Figure  2-11: The Correlation between IGFBP-2 SDS with wPCDAI (as indicator for disease activity) on the left and Albumin (as indicator for nutritional 
status) on the right. 
Baseline (filled black circle), 2 weeks (empty black circle), 6 weeks (filled grey circle), 6 months (empty grey circle) and 12 months (filled blue circle) in 19 CD received anti-TNF-α 









r=-0.67; p=0.004  
r=-0.89; p=0.000 








r=0.71; p=0.002  
r=0.72; p=0.001 




2.4.7.5 Correlation between IGF-1/IGFBP-3 and disease biomarkers 
At baseline, 2 weeks and 6 weeks no significant correlation was observed between IGF-
1/IGFBP-3 and any of the disease biomarkers. At 6 months a significant negative 
correlation was observed between IGF-1/IGFBP-3 with CRP (r=–0.61; p=0.009) and 
wPCDAI (r=–0.51; p=0.035). At 12 months a significant correlation was observed between 
IGF-1/IGFBP-3 with albumin (r=0.57; p=0.012). 
 
2.4.7.6 Correlation between growth biomarkers with cytokines and 
anthropometry 
No correlation was observed between growth biomarkers and inflammatory cytokines 
measured at baseline. At 6wks IGFBP-3 SDS was inversely associated with IL-6 (r=–0.52; 
p=0.029); however, taking out the outliers the results were not significant (r=-0.46; 
p=0.072). No association was observed between other growth biomarkers and 
inflammatory cytokines measured at other time points. At baseline, 12 months no 
significant correlation was observed between Ht SDS and growth biomarkers in children 
with growth potential. ∆Ht SDS and HV at 12 months in children with growth potential 
were not associated with a 12 month change in growth biomarkers. 
. 




2.4.7.7 Mixed model  
Table 2-10 displays the results of multivariate mixed-model regression analysis of the 
relationship of growth biomarkers SDS adjusted for gender and BA with albumin, 
wPCDAI, IL6 and GC exposure (yes/no) during the 12-month study interval. IGF-1 SDS 
and ALS SDS were significantly and positively associated with albumin independent of 
wPCDAI, IL6 and GC use. IGFBP-3 SDS was also significantly and positively associated 
with albumin and inversely associated with GC use independent of wPCDI and IL6. IGFB-
2 SDS was inversely and significantly associated with albumin and GC use. Similar results 
were observed by running the same model but with CRP/ESR. 




Table  2-10: Mixed model assessment of the effect of inflammation, nutrition and glucocorticoid use on growth biomarkers adjusted for bone age at each time 
points during 12 months study. 
IGF-1 SDS, serum insulin like growth factor-1SD score; IGFBP-3 SDS, serum insulin like growth factor binding protein-3 SD score; ALS SDS acid-labile subunit; IGFBP-2 SDS, 
serum Insulin like growth factor binding protein-2; wPCDAI, weighted paediatric disease activity index; IL-6, interleukin-6; GC, Glucocorticoid. Values in bold indicate statistical 
significance (p<0.05). *Natural log used to produce normality. 
Independent variables  Dependent variables  





















































































2.4.8  Bone biomarkers  
Table 2-11 summarises the median (ranges) changes of bone biomarkers and Figure 2-12 
shows individual data of bone biomarkers at baseline, 2 weeks, 6 weeks, 6 months and 12 
months among 19 participants. At baseline, BSAP SDS was lower than zero (p=0.00) and 
significantly increased over 6 weeks. Whereas β-CTX SDS was significantly below zero 
(p=0.00) at baseline and there was a trend toward an increase over 6 weeks. The median 
percentage change of BSAP from baseline to 2 weeks was 24.2% (-86.5, 379.4) (p=0.09), 
from baseline to 6 weeks was 43.6% (-31.2, 299.6) (p=0.001), from baseline to 6 months 
was 69.3% (-39.5, 844.9) (p=0.001) and from baseline to 12 months was 52.3% (-67.2, 
710.3) (p=0.01). The median percentage change of β-CTX from baseline to 2 weeks was 
0.7% (-67.1, 189.7) (p=0.95), from baseline to 6 weeks was 14.3% (-51.9, 187.5) (p=0.16), 
from baseline to 6 months was 24.9% (-59.4, 1359.6) (p=0.03) and from baseline to 12 
months was -0.3% (-53, 823.7) (p=0.34). The 12 month magnitude of increases in BSAP 
SDS levels was higher in participants who were in remission compared with those who did 
not enter remission (p=0.042) (Table 2-12, Figure 2-13). The magnitude of increases in 
bone biomarker levels was comparable in participants who were not treated with 
glucocorticoids throughout induction, compared with those in whom glucocorticoids were 
discontinued during the induction period (Table 2-13). At baseline, median (range) of 
serum 25(OH) vitamin D levels was 40.0 nmol/l with 6 (32%) participants having their 
level below 25 nmol/l and remaining unchanged at 12 months. All 6 participants with 
serum 25(OH) vitamin D levels below 25 nmol/l were fair skinned and measurements 
taken between December and January.  




Table  2-11:.Changes in bone biomarkers following anti-TNF-α therapy. 
Data presented as median (range) and adjusted for bone age; BSAP SDS, bone-specific alkaline phosphatase SD score; β-CTX SDS, C-telopeptide of collagen cross-link SD score. 
Values in bold indicate statistical significance (p<0.05).









BSAP SDS -1.7 (-3.6, -1.0) -1.5 (-3.6, -0.4) -1.2 (-3.6, -0.5) -0.5 (-2.4, 1.1) -1.1 (-2.3, 2.3) 0.40 0.013 0.00 0.004 
β-CTX SDS -1.1 (-2.6, 0.4) -1.1 (-2.7, 0.4) -1.0 (-2.3, 0.5) -0.6 (-2.1, 0.4) -0.5(-1.9, 0.4) 0.69 0.30 0.17 0.31 
25(OH)D (nmol/l) 
<25 nmol/l, n (%) 
40.0 (13.0, 91.0) 
6 (32) 
   37.0 (8.0, 81.0) 
6 (32) 
   0.73 



































Figure10. Showed the Individual Change in Bone Biomarkers Following 12 Month of Anti- 
 
Figure  2-12: Individual change in bone biomarkers following 12 months of anti-TNF-α. 
BSAP SDS, bone-specific alkaline phosphatase SD score; Β-CTX SDS, C-telopeptide of collagen cross-link 
SD score. Red solid lines represent the median values. Black dotted lines represent the 50th centile (0SDS), 
3rd (-2SDS) and 97th (2SDS) centile. *indicate statistical significance (p<0.05).
* 
Baseline 2 weeks 6 weeks 6 months  12 months 
SDS 
β-CTX 










Table  2-12: Changes in bone biomarkers following anti-TNF-α. Participants divided ccording to wPCDAI at 12months. 
Data presented as median (range) and adjusted for bone age; BSAP SDS, bone-specific alkaline phosphatase SD score; Β-CTX SDS, C-telopeptide of collagen cross-link. Values in 
bold indicate statistical significance (p<0.05).









between groups  
at 12 months 
BSAP SDS   










0.17 0.14 0.048 0.06 0.042 



















β-CTX SDS  










0.20 0.37 0.26 0.68 0.54 










0.09 0.51 0.28 0.31  




























Figure  2-13: Individual change in bone biomarkers following 12 months of anti-TNF-α. 
Participants divided according to wPCDAI at 12 months (remission (left) and non-remission 
(right)). 
BSAP SDS, bone-specific alkaline phosphatase SD score; Β-CTX SDS, C-telopeptide of collagen cross-link 
SD score. BL, baseline; 2wks, 2weeks; 6wks, 6week; 6m, 6 months; 12m, 12months. Red solid lines 
represent the median values. Black dotted lines represent the 50th centile (0SDS), 3rd (-2SDS) and 97th 












































Table  2-13:.Change in bone biomarkers following anti-TNF-α. Participants divided according to glucocorticoid use.  
Data presented as median (range) and adjusted for bone age; BSAP SDS, bone-specific alkaline phosphatase SD score; β-CTX SDS, C-telopeptide of collagen cross-link SD score. GC, 
glucocorticoid; +/-, glucocorticoid at baseline and stopped by 6 months; +/+, glucocorticoid throughout the study period. Values in bold indicate statistical significance (p<0.05). 
 











between groups  
at 12 months  
BSAP SDS  










0.66 0.028 0.04 0.20 0.59 










1.0 0.09 0.11 0.07  
GC +/+ (ID-18) -1.4 -1.7 -1.7 1.1 -1.3      
GC +/+ (ID-19) -1.3 -0.5 -1.0 -1.2 -1.1 
β-CTX SDS  










0.39 0.72 0.37 0.95 1.00 










0.61 0.13 0.18 0.11  










     
GC +/+ (ID-18) 0.2 0.4 0.5 -0.4 -0.8      




2.4.8.1 Correlation between bone biomarkers with disease biomarkers and 
anthropometric 
At baseline, 2 weeks, and 6 weeks no significant correlation was observed between BSAP 
SDS and β-CTX SDS with any of the disease biomarkers (ESR, CRP, wPCDAI, albumin) 
or cytokines. At 6 weeks, a significant negative correlation was observed between β-CTX 
SDS and IL-6 (r=-0.55; p =0.019); however, taking out the outliers the results were not 
significant (r=-0.44; p=0.090). At 6 months a significant negative correlation was observed 
between BSAP SDS and CRP (r=-0.50; p=0.048) and a positive correlation with albumin 
(r=0.65; p=0.007). At 12 months, a significant negative correlation was observed between 
BSAP SDS and wPCDAI (r=-0.67; p=0.002). The 12 month changes in bone biomarkers 
were not correlated with 12 month changes in disease biomarkers or 12 months changes in 
cytokines. 
At baseline, 12 months no significant correlation was observed between Ht SDS and bone 
biomarkers in children with growth potential. ∆Ht SDS and HV at 12 months were not 








2.5  Discussion  
In this chapter we have comprehensively evaluated linear growth, the IGF-1 axis and 
biomarkers of bone turnover following initiation of anti-TNF-α therapy in children and 
adolescents with CD. Anti-TNF therapy was associated with rapid improvements in 
disease activity, improvement in IGF-1 axis for those with low levels and increases in 
BSAP. The declines in wPCDAI scores and increases in bone formation biomarker levels 
were associated with subsequent improvements in height in those with growth potential, 
although no benefit was seen in more mature patients over 12 months follow up. 
The rates of growth failure at time of diagnosis seen in our cohort are similar to what has 
already been published (84;88;89). In our cohort anti-TNF-α maintenance therapy for 12 
months was associated with significant improvement in growth velocity and ∆Ht SDS, in 
those who had potential to grow at time of anti-TNF-α induction, although no benefit was 
seen in more mature patients. These observations are consistent with previous data 
showing that anti-TNF-α therapy is associated with linear growth improvement in children 
with chronically active CD in early puberty (88;240). The available data propose that there 
is a window of opportunity for improvement in growth for those with potential to grow. 
However, inflammatory bowel disease tends to present in late childhood and adolescence 
(12) giving a narrow window for growth failure to be diagnosed and treated. In accordance 
with previous observation (88;240), our study’s anti-TNF-α therapy was not associated 
with significant improvement in Ht SDS and may suggest that controlling the inflammation 
improves growth velocity, which is not sufficient to improve overall height but prevent 
further deterioration in height. This finding may suggest that if the anti-TNF-α therapy is 
given to patients with CD who still had potential to grow, attained height may still be sub-
optimal as would be expected in a healthy population. The restoration of normal height 
distribution in childhood onset patients with CD has been only published recently in one 
study which showed that among tanner stage 1-2, the earlier initiation of anti-TNF-α 
( disease duration <18 months after diagnosis) was associated with restoration of normal 
height distribution by 3 years, whereas tanner stage 1-2 with duration of disease >18 
months at initiation of infliximab remain shorter than healthy counterparts (248). The 
patients in our cohort had longer disease duration compared to the previous study; this may 
explain our finding. 
The sub-optimal first year growth response is defined as minimal increase in height SDS of 
<0.3 or <0.5 compared with healthy children (283). In our study the net increase in Ht SDS 
in those with growth potential was 0.1. This observation is consistent with previous data 




showing that anti-TNF-α therapy associated with net gain Ht SDS in children with CD 
ranged from 0.1 to 0.3 SDS with duration of follow up between 6 to 12 months 
(203;235;239;240;245;249) with one study reporting net increase in height of 2SDS after 1 
year; however, the number of patients involved is not clear (238). It obvious from our 
finding and other previous evidence, net height gain, albeit statistically significant, was 
clinically modest and if growth is the concern then adjuvant therapy with other forms of 
growth promoting therapy may also need to be considered. 
The intact GH-IGF1 pathway is a critical regulator of linear growth (284). Systemic GH-
IGF-1 axis is frequently disturbed in children with CD and it was realised that the 
depressed concentration was a direct consequence of pro-inflammatory cytokines 
(112;114) and not merely the result of undernutrition. Thus, the best strategy to restore 
IGF-1 axis and therefore to improve growth and also improve bone impairment is the 
resolution of inflammation. 
At the time of anti-TNFα induction, we found that patients with CD have a IGF-1 SDS 
within the average, and IGFBP-3 SDS relatively higher than average. Our finding of an 
alteration in the IGF-1:IGFBP3 ratio, normal IGF-1 and relatively high IGFBP3 in 
adolescents with CD suggests that the disease may have a disproportionate effect on these 
two GH-responsive proteins in favour of reduced IGF-1 bioavailability and is similar to 
that previously understood for patients with CD (98;115). Furthermore, there was a sub-
group in the present study with low IGF-1 SDS which normalised by 12 months. The 
ability of TNF-α blockade to restore liver GH signalling was shown by DiFedele in a 
murine colitis model (250); however, a study by Vespasiani et al. (251) failed to 
demonstrate normalization of IGF-1 levels during maintenance therapy with infliximab. 
IGF-1 levels did increase during induction though they returned to low baseline levels 
during maintenance. The short-term effect of anti-TNF therapy on IGF-1 was supported by 
Eivindson et al. (252). 
This is the first report in paediatrics to show low level of ALS SDS in patients with CD 
which remained low throughout the study period even though those with very low values 
normalised by 12 months. The finding of low ALS in CD patients is consistent with 
previous reports of an association of IL-1β with low plasma concentrations of ALS 
(285;286). 
The finding of high IGFBP-2 SDS levels has previously been described in patients with 
CD diseases and may be caused by catabolic status induced by inflammation itself 
(117;252;287). Despite controlling disease status in the present study, there was partial 
normalisation of IGFBP-2 SDS by 12 months; this finding is consistent with adult data 




(252). Furthermore, decrease in IGFBP-2 SDS level was more pronounced in subgroups of 
children who achieved remission compared to those who still had mild to moderate 
disease. 
Multiple correlations have been reported between IGF-1 and IGFBP-3 and inflammatory 
markers in CD (117;251;252), as in our study univariate analysis demonstrated that IGF-1 
SDS and IGFBP3 SDS, ALS SDS were lower in patients with greater disease activity at 
baseline as depicted by a significant negative correlation of IGF-1SDS, ALS SDS and 
IGFBP3 SDS with different markers of disease activities; this correlation disappeared by 
12 months as disease status improved. However, this is not proof of causality. When these 
parameters were adjusted for a variety of confounders in a multivariate regression model, 
albumin was associated with IGF-1, with ALS independent of GC use, inflammatory 
markers and cytokines. The relative role of nutrition status on GH/IGF-1 axis is established 
(112). Based on the level of albumin and BMI SDS our study population seems to have a 
satisfactory nutritional status; this may explain the relatively normal IGF-1 level seen in 
this cohort. The multivariate regression model showed that albumin and GC use are 
associated with IGFBP-3 axis independent of inflammatory markers and cytokines. Forty 
seven percent of our cohort were on GC during the first six weeks of anti-TNF-α therapy 
and these drugs may also be associated with an alteration in the GH/IGF-1 axis (124). The 
growth biomarkers based on GC exposure were not different in those who did versus those 
who did not use GC during the study interval. Nevertheless, it is impossible to isolate the 
effect of GC therapy on GH-IGF-1 axis weighing its anti-inflammatory properties against 
its described impact on the GH-IGF-1 axis.  
Our data is the first study to explore the improvement in growth in CD following anti-
TNF-α in relation to IGF-1 axis. We did not find a relationship between systemic markers 
of growth and height in those with growth potential. However, the liver is not the only 
source of IGF-1 as IGF-1 is produced locally in the growth plate. In the mouse, the 
targeted disruption of IGF-1 synthesis in the liver results in relatively normal-sized mice 
with a 75% reduction in circulating IGF-1 levels, suggesting that local IGF-1 may be more 
important for body growth than liver IGF-1 (69) and may in part explain the relatively 
modest improvement in growth that we see in our cohort.  
At the time of starting anti-TNF-α, indirect markers of bone cell function, including BSAP 
for osteoblasts and β-CTX for osteoclasts reduced suggest that participants have decreased 
bone turnover and in turn reduced both bone modelling and remodelling at different sites. 
This state of low bone turnover closely mirrors previously reported results (149;150;178). 
Comparable to the previous evidence, the current study demonstrates marked increases in 




bone formation biomarkers and moderate increases in bone resorption markers following 
biological therapy (237;243). As cited before, CTX is subjected to diurnal variation and a 
fasting sample is required (58;60).  In the current study blood was taken coincident with 
time of anti-TNF-α; we did not use fasting blood samples. However, the sample was 
collected at the same time of day to minimise diurnal variability. In contrast to previous 
evidence, the biomarkers of bone formation and resorption were not associated with height 
(205;237). 
 
2.6 Limitations and strengths of study  
This study had numerous limitations. First, the number of patients included was small; 
therefore, meaningful analyses of various subgroups were restricted. However, we increase 
the obtained association through the application of mixed model regression analysis. A 
second limitation is the large number of studies outcomes and repeated measures increase 
the potential for type 1 error; however, we adjust for multiple comparisons by using 
Bonferroni correction. An additional limitation is we did not have a comparable control 
group to examine the protective role of anti-TNF-α; however, it was not ethically possible 
to enrol CD patients with comparable disease severity for untreated control as anti-TNF-α 
is a standard therapy for children and adolescents with moderate to severe disease. 
Moreover, we relied on a validated survey of child self-assessment of puberty instead of 
investigator examination, potentially leading to misclassification of pubertal stage. 
However, we overcome this issue by adjusting for bone age and subdividing the group 
according to bone age. Notwithstanding these limitations, this study has important 
strengths. To our knowledge this is the first study to have examined the effect of anti-TNF-
α on IGF-1 and binding protein in the context of chronic inflammation in paediatrics even 
if these must be regarded as preliminary data owing to the small number of patients 
enrolled in the study.  
 
2.7 Conclusion  
In summary, there is a modest increase in growth in those children who have the potential 
to grow; there is some evidence of increased bone formation. Our data suggest that 
targeted therapy with either recombinant human GH or, perhaps, in combination with 











 Persistence of Musculoskeletal Deficits in Paediatric 








3.1 Abstract  
Background: CD is associated with deficits in bone mineral density (BMD) and bone 
structure that are potentially related to tumour necrosis factor α. 
Aims: (1) To assess change in bone density and structure in a cohort of children and 
adolescents with CD at time and 12 month after initiation of treatment with anti-TNF-α. (2) 
To explore association of IGF-1 axis, cytokines and muscle with bone density in children 
with CD. 
Design and participants: Prospective longitudinal study of 16 (11 male) participants with 
CD, aged 11.2, 17.2 (median 15.1) years, completing a 12 months study. 
Main outcomes: Assessment of areal bone mineral density (aBMD) by DXA (total body 
(TB), lumbar spine (LS) and volumetric BMD and geometry at tibia and radius were 
performed using pQCT and obtained at baseline, 6 months and 12 months. DXA bone 
outcomes expressed as sex, race, bone age or height age specific standard deviation scores 
(SDS) and compared to reference data. pQCT bone outcomes were expressed as sex, race 
and age specific standard deviation scores (SDS) and compared to reference data. Muscle 
measurement by DXA and pQCT and pQCT parameters for thickness were adjusted for 
sex and height. Maximal isometric grip force (MIGF) of the non-dominant hand was 
determined by an adjustable-handle Jamar Dynamometer and transformed to sex and 
height-dependent SDS. 
Results: wPCDAI decreased significantly during 2 weeks of induction (p=0.006) with 
subsequent gains in bone specific alkaline phosphatase level from -1.5 (-3.1, -1.0) at 
baseline to -0.5 (-2.4, 1.1) at 6 months (p=0.002) and to -1 (-2.0, 2.3) at 12 months 
(p=0.008). At baseline, DXA BMD SDS (TB-BMD SDS and LS-BMD SDS), radius and 
tibia pQCT (trabecular BMD SDS and cortical thickness SDS) and muscle mass and 
function were in substantial deficit and remained unchanged over 12 months. Mixed model 
regression analysis of tibia pQCT bone outcomes showed that ALS SDS (p=0.007) and 
muscle area (p=0.003) were positively associated with trabecular BMD; muscle area 
(p<0.0001) and IGFBP3 SDS (p=0.004) were associated with cortical thickness positively 
and negatively respectively. 
Conclusion: Musculoskeletal health as assessed by imaging in children starting anti-TNF-
α therapy for CD showed a deficit in bone and muscle mass at baseline as well as 12 
months. Thus, although anti-TNF-α therapy was associated in an improvement in bone 











3.2 Introduction  
CD is a chronic inflammatory condition that is characterized by impaired bone density and 
alteration in bone geometry in children (149;150;153;155;165;199;288). The clinical 
relevance of CD related bone disease can be immediate and results in increased fracture 
risk (159) or delayed with suboptimal peak bone mass accrual by end of adolescence (165) 
and therefore may cause significant increase in fracture risk in adulthood. Although the 
underlying pathogenesis for this poor bone health may be multifactorial (289), the 
inflammatory process mediated by pro-inflammatory cytokines such a TNF-α and 
interleukins (IL) may play an important role (150;178;179). The monoclonal anti TNF-α 
antibody induces and maintains remission in moderate to severe disease and is first line 
medication in refractory CD (227;249). However, the effect of anti TNF-α therapy on bone 
health in paediatrics has not yet been established (186;237;241;243). DXA is advised by 
The International Society for Clinical Densitometry (ISCD) (161) to monitor of BMD in 
children with CD. However, areal BMD (g/cm2) does not separate bone compartments 
(cortical/ trabecular) and is confounded by differences in body size (146;290). 
Furthermore, monitoring areal BMD in young individuals with CD may not entirely 
account for all the bone abnormalities of a CD related bone disease. Investigating other 
parameters of bone (volumetric trabecular/cortical BMD, bone geometry such as cortical 
thickness) and muscle, which is possible pQCT, may provide additional relevant 
information for skeletal health (146). 
The current prospective study was, therefore, performed to evaluate bone health and 
muscle function using both DXA and pQCT in a cohort of children and adolescents with 
CD at the time and after initiation of treatment with anti-TNF-α and to explore the 






3.3 Methods  
3.3.1 Study population 
Of 19 participants who were diagnosed with CD and who participated in prospective study 
of effect of anti-TNF-α on linear growth (Chapter-2), 16 had their bone imaging and 19 
had muscle function were included for the purpose of current study. These participants 
were either newly diagnosed or patients with long-lasting disease in clinical relapse who 
failed to reach inactive disease despite conventional therapy. Participants were excluded 
for prior anti-TNF-α therapy in the previous 6 months; pregnancy; and medical illnesses or 
therapies unrelated to CD that could potentially affect bone , nutrition, or growth such as 
kidney disease, seizure disorder, diabetes, or liver disease. Disease phenotype was 
classified using the Montreal criteria (5). None of the participants were on growth or 
puberty promoting treatments during the period of study. The diagnosis reached in each 
participant was according to standard criteria after small bowel imaging, endoscopy and 
colonoscopy with multiple biopsies, and other investigations, as indicated(3). 
The study protocol was approved by the local research ethics committee (LREC) 
Reference Number: 09/S0703/58 and the research and development office. Informed 
consent was obtained from patients and the parents or guardians. 
 
3.3.2 Concomitant medication, anthropometry and biochemical markers  
Detailed of concomitant medication, anthropometry data collection and biochemical 
markers of inflammation, biochemical markers of growth and bone turnover were 
described in chapter 2. Cut-off points for categorised the participants according to disease 
status, GC exposure or growth potential were detailed in chapter 2 and adapted in this 
chapter to categorise DXA and pQCT and muscle function outcomes. 
 
3.3.3 DXA 
DXA scans were performed in 15 participants at the baseline, 6 and 12 months and 
performed with a narrow fan beam Lunar Prodigy densitometer (GE Medical Systems, 
Waukesha, Wisconsin, U.S.A) and phantoms analysed using the Encore software (Version 
8.80.001). The measurements were performed at total body (TB) and anteroposterior 
lumbar spine (LS) (L2-L4) with standard positioning techniques were analysed to generate 
estimates of BMD (g/cm
2
) and TB lean mass (TB-LM, kg) and TB fat mass (TB-FM, kg). 




Each scan took approximately 10 min to complete. All these scans were acquired by Dr 
Sheila Shepherd at RHC, Glasgow. To minimise the size effect, we applied height age (Ht-
age) adjustment for TB and LS using GE Lunar paediatric reference data of over 2000 US 
children (5-19 years). To adjust for skeletal maturation, we employed bone age (BA) for 
TB and LS using GE Lunar paediatric reference data of over 2000 US children (5-19 
years). Body composition was adjusted for sex and height using our local reference data of 
201(140 male) children aged between 5-19 years. The LS and TB phantom scan was 
performed daily in our hospital and the coefficient of variation (CV) was 1.315% for spine-
BMD for children; precision data for TB measurements are not available for children. 
 
3.3.4 pQCT 
Bone measures for density and geometry in non-dominant radius (n,16) and tibia (n,15) 
were performed by pQCT (XCT-2000scanner; Stratec, Pforzheim, Germany) with voxel 
size of 0.4 mm and slice thickness of 2 mm. Image acquisition, processing and the 
calculation of numerical values were performed using the manufacturer's software package 
(XCT 5.50). The phantom was scanned weekly and no precision data is available in our 
centre.  
All scans were performed and analysed by Dr Sheila Shepherd at RHC, Glasgow to ensure 
consistency of reference line placement. The pQCT scans were performed at similar time 
points to DXA. Radius limb length was defined as the distance between the ulnar styloid 
process and the olecranon. The reference line was placed at the distal part of the horizontal 
part of the radius end plate. Tibia length was defined as the distance between the medial 
malleolus and the superior margin of the medial condyle. Limb length was measured 
manually using a non-stretch retractable anthropometric tape. The reference line was 
placed through the middle of the horizontal part of the tibia endplate. The measurement 
sites for the radius were located proximal to a reference line by a distance corresponding to 
4% (distal radius, metaphysis) and 66% (diaphyseal radius) of the forearm length. The 
measurement sites for the tibia were located proximal to a reference line by a distance 
corresponding to 4% (distal tibia, metaphysis) and 38% (diaphyseal tibia) of the tibia 
length. For the upper limb the muscle and subcutaneous fat were measured at 66% of the 
length of the radius. At the 4% site of the radius and tibia trabecular volumetric BMD were 
evaluated. At the 66% site of the radius and 38% site of the tibia cortical volumetric BMD 
and cortical thickness were measured. As growth retardation is common in children with 
CD, the bone size-dependent parameters (muscle and fat cross sectional area and cortical 
thickness) were corrected for height. Radius reference data were software derived (n, 478) 




(291;292) and published data were used to adjust tibia parameters (n, 432) (293). Four 
participants were excluded from analysis of radius cortical thickness due to movement and 
poor scan.  
 
3.3.5 Maximal isometric grip force (MIGF) 
Maximal isometric grip force (MIGF) of the non-dominant (ND) hand was determined in 
19 participants by an adjustable-handle Jamar Dynamometer (Preston, Jackson, Mich., 
USA). The test was performed in a sitting position with elbow flexed at 90° and the 
children asked to squeeze as hard as possible. MIGF measured in triplicate with 1 min rest 
between each test and the highest value was recorded; the result for each participant 
transformed to height-dependent standard deviation scores (SDS) based on published 
reference data (n, 315 (148 mal)) (294). 
 
3.3.6 Statistics  
Analyses were performed using SPSS software version 22 (New York, USA). Non-
parametric data were presented with medians and ranges. Changes between parameters 
were assessed at different time points and analysed using repeated measures with 
Wilcoxon signed-rank tests and subsequently adjusted for multiple comparison using a 
Bonferroni correction and p<0.05 considered as statistically significant. Mann Whitney U 
test was used for continuous and Chi-square test for categorical variable to assess inter-
group differences divided according to disease, GC exposure or growth potential. The 
univariate correlation between variables was assessed using the Spearman’s correlation. 
Mixed-model regression analysis was used to assess the independence of the relationship 
of bone mass with IGF-1 axis (SDS adjusted for gender and BA), wPCDAI/IL-6, GC 
exposure and muscle over 3 study visits. The statistical analysis was only done for those 
who had complete data. All graphs were prepared by GraphPad Prism software version 7 
(San Diego California, USA) and XSTAT software version 2016.02.27970 (Addinsoft, 
New York, USA). 
 





3.4 Results  
3.4.1 Participant characteristics  
Table 3-1 summarises the characteristics of the 16 CD participants at the time of starting 
anti-TNF-α. The median (range) age at diagnosis of CD and age at anti-TNF-α initiation 
was 12.0 years (5.5, 15.5) and 15.1 years (11.2-17.2) with median interval since diagnosis 
of 3.1 years (0.2, 10.7); only 3 participants had the disease duration less than 18 months. 
 











Table  3-1: Participant characteristics at time of starting anti-TNF-α. 
Data presented as number, n; percentage, %, median (range). CA, chronological age; BA, bone age; Ht SDS, 
height SDS score; BMI SDS, body mass index SDS score. 
 
  CD (n, 16) 
Male, n (%) 11 (69%) 
CA at Diagnosis (year) 12.0 (5.5, 15.5) 
CA at starting anti-TNF-α (year) 15.1 (11.2, 17.2) 
Duration of disease 3.1 (0.20, 10.7) 
BA at starting  anti-TNF-α (year) 14.4 (9.3, 16.9) 
BA delay (year) 0.5 (-0.8, 2.3) 
Tanner stage, n (%)  
Pre-puberty (tanner stage-1) 1 (6) 
Mid-puberty (tanner stage 2-3) 7 (44) 
Late puberty (tanner stage 4-5) 8 (50) 
Ht SDS at starting anti-TNF-α -0.7 (-2.7, 1.7) 
BMI SDS at starting anti-TNF-α -0.4 (-2.7,3 .2) 
Disease location, n (%)  
Ileal (L1) 1 (6) 
Colonic (L2) 8 (50) 
Ileocolonic (L3) 7 (44) 
Isolated upper disease(L4) 4 (25) 
Behaviour (non-stricturing, non-penetrating) 
16 (100) 
Perianal  4 (25) 





3.4.2 Disease, laboratory, treatment characteristics and anthropometry 
Table 3-2 summarises disease, laboratory and treatment characteristic in 16 CD 
participants at each visit. At baseline, 8 (50%) participants had moderate to severe disease 
activity based on wPCDAI with marked improvement to two (12%) at 6 weeks and three 
(19%) at 12 months. Serum level of growth biomarkers and 25(OH) vitamin D levels did 
not change during 12 months. 5/16 (31%) participants have their 25(OH) vitamin D level 
below 25 nmol/l and remained unchanged at 12 months. At baseline, BSAP SDS was 
lower than zero (p=0.00) and significantly increased over 6 months and this increase was 
sustained at 12 months. Whereas β-CTX SDS was significantly below zero (p=0.00) at 
baseline with a trend toward an increase at 6 months. 8/16 (50%) participants were treated 
with GC at baseline and corresponding data were 8/16 (50%) at 2 weeks, 8/16 (50%) at 6 
weeks, 2/16 (12%) at 6 months and 2/16 (12%) at 12 months respectively. None of the 








Table  3-2: Changes in disease activity, laboratory results, and treatment over the study interval. 
Data presented as number, n; percentage, %, median (range). wPCDAI, weighted paediatric disease activity index; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; IL-6, 
interleukin-6; TNF-α, tumour necrosis factor-α; IGF-1 SDS, serum insulin like growth factor-1SD score; IGFBP-3 SDS, serum Insulin like growth factor binding protein-3 SD score; 
ALS SDS acid-labile Subunit SD score; IGFBP-2 SDS, serum insulin like growth factor binding protein-2 SD score; BSAP SDS, bone-specific alkaline phosphatase SD score; β-CTX 
SDS, C-telopeptide of collagen cross-link SD score; HtS DS, height SDS score; BMI SDS, body mass index SDS score. Values in bold indicate statistical significance (p<0.05). 









wPCDAI 45.0 (0.0, 95.0) 17.5 (0.0, 70.0) 3.7 (0.0, 67.0) 10.0 (0.0, 42.0) 10.0 (0.0, 47.0) 0.006 0.012 0.008 0.002 
wPCDAI, n (%)          
Not active (<12.5) 2 (12) 7 (44) 10 (58) 10 (63) 9 (56)     
Mild (12.5-40) 6 (38) 8 (50) 4 (25) 4 (25) 4 (25)     
Moderate-sever (>40) 8 (50) 1 (6) 2 (12) 1 (6) 3 (19) 0.006 0.022 0.006 0.06 
Albumin (g/l)  33.0 (17.0, 41.0) 35.0 (17.0, 42.0) 36.0 (25.0, 42.0) 37.0 (20.0, 44.0) 36.0 (23.0, 42.0) 0.12 0.06 0.036 0.044 
ESR (mm/hr)  28.0 (5.0, 70.0) 12.0 (4.0, 70.0) 13.0 (3.0, 86.0) 13.0 (4.0, 56.0) 12.0 (2.0, 48.0) 0.004 0.11 0.092 0.12 
CRP (mg/l)  11.0 (3.0, 95.0) 7.0 (3.0, 98.0) 7.0 (3.0, 51.0) 3.0 (3.0, 39.0) 4.0 (3.0, 23.0) 0.19 0.07 0.11 0.11 
Il-6 (pg/ml)  53.0 (4.0, 153.0) - 59.3 (23.8, 155.5) 54.0 (21.0, 151.5) 43.3 (26, 116.0) - 0.61 0.73 0.022 
TNF-α (pg/ml)  14.0 (10.0, 48.5) - 17.5 (9.0, 52.5) 18.8 (8.8, 118.5) 14.5 (9.5, 91.8) - 0.13 0.09 0.33 
IGF-1 SDS 0.2 (-3.8, 2.1) -0.6 (-3.1, 1.7) -0.3 (-4.8, 1.8) -0.8 (-2.6, 1.9) -0.1 (-1.9, 2.0) 0.82 0.72 0.57 0.68 
IGFBP-3 SDS 0.9 (-2.9, 3.0) 0.3 (-1.1, 2.9) 0.3 (-1.7, 2.9) 0.4 (-1.2, 2.4) 0.2 (-1.0, 2.9) 0.49 0.22 0.11 0.72 
ALS SDS -0.9 (-2.2, 1.5) -0.9 (-1.9, 0.3) -0.7 (-2.3, 0.6) -1.0 (-2.0, 0.2) -0.9 (-1.7, 0.2) 0.96 0.88 0.39 0.76 
IGFBP-2 SDS 2.2 (-1.2, 4.1) 2.4 (-1.5, 3.9) 1.7 (-0.6, 3.0) 1.8 (-1.3, 3.7) 1.3 (-0.9, 4.1) 0.57 0.18 0.13 0.25 
25(OH) vitamin D 38.0 (13.0, 91.0) - - - 38.0 (8.0, 81.0) - - - 1.00 
BALP SDS -1.5 (-3.1, -1.0) -1.5 (-3.5, -0.4) -1.2 (-2.8, -0.5) -0.5 (-2.4, 1.1) -1 (-2.0, 2.3) 0.79 .052 0.002 0.008 
β-CTX SDS -0.9 (-2.6, 0.4) -1.1 (-2.7, 0.4) -0.8 (-2.3, 0.5) -0.4 (-2.1, 0.4) -0.6 (-1.8, 0.2) 0.30 0.61 0.19 0.76 
Medication, n (%)          
Glucocorticoid 8 (50) 8 (50) 8 (50) 2 (12) 2 (12)    0.022 
Aminosalicylate 8 (50) 7 (44) 8 (50) 7 (44) 4 (25)    0.14 
Methotrexate  10 (63) 10 (63) 10 (63) 10 (63) 10 (63)    1.0 
Mercaptopurine/Azathioprine  3 (19) 4 (25) 4 (25) 5 (31) 5 (31)    0.41 
Exclusive enteral nutrition  5 (31) 4 (25) 3 (19) 2 (12) 2 (12)    0.20 
Anthropometry          
Ht SDS -0.7 (-2.7, 1.7) - - -0.5 (-3.0, 1.7) -0.4 (-3.1, 1.8) - - 0.72 0.84 
BMI SDS -0.4 (-2.7, 3.3)   -0.2 (-2.7, 2.9) 0.2 (-2.7, 2.7) - - 0.10 0.28 






3.4.3 DXA bone outcomes 
Table 3-3 summarise the median (ranges) changes of the DXA bone outcomes and Figure 
3-1 shows individual data at baseline, 6 months and 12 months among 15 participants with 
results at each visit limited to those with a 12 month visit to facilitate comparisons across 
the visits. At baseline, overall TB-BMD SDS Ht-age (p=0.004), TB-BMD SDS BA (p=0.011), 
LS-BMD SDS Ht-age (p=0.00) and LS-BMD SDS BA (p=0.00) were below zero. The values 
remained unchanged over the study interval. The categorised DXA bone parameters based 
on disease status, or GC exposure or growth potential yield the same results (Table 3-4 and 














Table  3-3: DXA bone outcomes at baseline, 6 months and 12 months following anti-TNF-α.  





  Baseline 6 Months 12 Months p-values 
Baseline vs. 6 months Baseline vs. 12 months 
DXA (n, 15) (n, 14) (n, 15)   
TB-BMD SDS Ht-age -0.9 (-2.3, 0.5) -0.7 (-1.6, 1.1) -0.9 (-2.1, 1.1) 0.56 0.90 
TB-BMD SDS BA -1.2 (-3.0, 0.6) -1.4 (-2.9, 0.1) -1.3 (-3.0, 0.2) 0.21 0.12 
LS-BMD SDS Ht-age -1.1 (-2.9, 0.4) -1.1 (-3.5, 0.4) -1.0 (-3.2, 0.8) 0.22 0.27 
LS-BMD SDS BA -1.5 (-3.4, 0.6) -1.7 (-2.9, -0.1) -0.8 (-3.0, -0.2) 0.10 0.18 
























Figure  3-1: Individual changes in DXA bone outcomes at baseline, 6 months and 12 months 
following anti-TNF-α. 
TB, total body; BMD, areal bone mineral density; SDS Ht-age, adjusted for height age and sex; SDS BA, 
adjusted for bone age and sex; LS, lumbar spine. Red solid lines represent the median values. Black dotted 
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Table  3-4: DXA bone outcomes at baseline, 6 months and 12 months following anti-TNF-α. 
Participants divided according to wPCDAI at 12 months. 
Data presented as median (range). TB, total body; BMD, areal bone mineral density; SDS Ht-age, adjusted for 
height age and sex; SDS BA, adjusted for bone age and sex; LS, lumbar spine. Values in bold indicate 
statistical significance (p<0.05)
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Figure  3-2: Individual changes in DXA bone outcomes at baseline, 6 months and 12 months following anti-TNF-α. Participants divided according to wPCDAI 
at 12 months (remission (left) and non-remission (right)). 
TB, total body; BMD, areal bone mineral density; SDS Ht-age, adjusted for height age and sex; SDS BA, adjusted for bone age and sex; LS, lumbar spine. Red solid lines represent the 
median values. Black dotted lines represent the 50th centile (0SDS), 3rd (-2SDS) and 97th (2SDS) centile. 
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SDS LS-BMD SDS Ht-age 
Baseline 6 months  12 months Baseline 6 months  12 months 
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Data presented as median (range).TB, total body; BMD, areal bone mineral density; SDS Ht-age, adjusted for height age and sex; SDS BA, adjusted for bone age and sex; LS, 
lumbarspine; GC, glucocorticoid; +/-, glucocorticoid at baseline and stopped by 6 months; GC+/+, glucocorticoid throughout the study period. Values in bold indicate statistical 
significance (p<0.05).
n, 15 Baseline 6 Months 12 Months p-values 




GC naïve (n, 7) -0.7 





0.67 0.67 0.25 






0.28 0.41  
GC+/+ (ID-18) 0.5 0.1 0.0    
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0.69 0.22  
GC+/+ (ID-18) 0.6 -0.1 -0.2    
GC+/+ (ID-19) -3.4 -2.9 -2.8    




Table  3-6: DXA bone outcomes at baseline, 6 months and 12 months following anti-TNF-α. Participants divided into two groups on whether they have 
potential to grow at time of starting anti-TNF-α based on bone age.  
Data presented as median (range). 15 participants; 7 (47%) had growth potential (BA<13.5yrs in girls and <14.5yrs in boys) (Group (A)); 8 (53%) patients had little/no growth potential 
(BA≥13.5yrs in girls and ≥14.5yrs in boys) (Group (B)). TB, total body; BMD, areal bone mineral density; SDS Ht-age, adjusted for height age and sex; SDS BA, adjusted for bone age 
and sex; LS, lumbar spine. Values in bold indicate statistical significance (p<0.05). 
 n, 15  Baseline (n, 15)  6 Months (n, 14)  12 Months (n, 15) p-Value  
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Figure  3-3: Individual changes in DXA bone outcomes at baseline, 6 months and 12 months 
following anti-TNF-α. Participants divided into two groups on whether they have potential to 
grow at time of starting anti-TNF-α based on bone age. 
Growth potential on the left and had little/no growth potential on the right. TB, total body; BMD, areal bone 
mineral density; SDS Ht-age, adjusted for height age and sex; SDS BA, adjusted for bone age and sex; LS, 
lumbar spine. Red solid lines represent the median values. Black dotted lines represent the 50th centile 
(0SDS), 3rd (-2SDS) and 97th (2SDS) centile.
SDS TB-BMD SDS Ht-age 
Group B 
Baseline 6 months  12 months Baseline 6 months  12 months 
SDS 
LS-BMD SDS Ht-age 
Group A 
Baseline 6 months  12 months Baseline 6 months  12 months 





3.4.3.1 Correlation of DXA bone outcomes with disease and anthropometry 
At baseline a significant negative correlation was observed between TB-BMD SDS Ht-age 
and disease duration (r=-0.71, p=0.003) (Figure 3-4) but not with age, disease biomarkers 
(wPCDAI, CRP, ESR) or cytokines. A significant negative correlation was observed 
between TB-BMD SDS BA with disease duration (r=-0.73, p=0.002) but not with age 
disease biomarkers (wPCDAI, CRP, ESR) or cytokines. At baseline LS-BMD SDS Ht-age 
and LS-BMD SDS BA were not associated with disease duration or age disease biomarkers 
(wPCDAI, CRP, ESR) or cytokines. At 6 months, no significant correlation was observed 
between any of the DXA bone outcomes and disease biomarkers or cytokines. At 12 
months a significant negative correlation was observed between TB-BMD SDS Ht-age and 
CRP (r=-0.53, p=0.040). 
At baseline a significant positive correlation was observed between TB-BMD SDS BA with 
height SDS (r=0.53, p=0.04). At 6 months no significant correlation was observed between 
any of the DXA bone outcomes and Ht SDS. At 12 months no significant correlation was 
observed between any of the DXA bone outcomes and Ht SDS. Repeated analysis for sub-
group with growth potential showed no correlation with any of the DXA bone outcomes 




























Figure  3-4: Correlation between TB-BMD SDS Ht-age at baseline with disease duration in 15 
CD received anti-TNF-α for 12 months. Large black circle indicates confidence limit



























3.4.3.2 Correlation of DXA bone outcomes with biomarkers of growth and 
bone turnover 
Figure 3-5 shows a correlation between TB-BMD SDS Ht-age with growth biomarkers at 
each time point in 15 CD receiving anti-TNF-α for 12 months. At baseline a significant 
positive correlation was observed between TB-BMD SDS BA and IGF-1 SDS (r=0.56, 
p=0.024), IGFBP-3 SDS (r=0.51, p=0.052), ALS SDS (r=0.65, p=0.009) and a negative 
correlation with IGFBP-2 SDS (r=-0.55, p=0.036). At 6 months a significant positive 
correlation was observed between TB-BMD SDS Ht-age and IGF-1 SDS (r=0.59, p=0.034). 
At 6 months no significant correlation was observed between DXA bone outcomes and 
growth biomarkers. At 12, a significant positive correlation was observed between TB-
BMD SDS Ht-age and IGF-1 SDS (r=0.56, p=0.030) and a negative correlation with IGFBP-
2 SDS (r=-0.60, p=0.019). At 12, a significant positive correlation was observed between 
TB-BMD SDS BA and IGF-1 SDS (r=0.55, p=0.034) and a significant negative correlation 
was observed between LS-BMD SDS BA and IGFBP-2 SDS (r=-0.56, p=0.032). At 
baseline, 6 months and 12 months no correlation was observed between LS-BMD SDS Ht-
age and growth biomarkers. 
At baseline, 6 months and 12 months no significant correlation was observed between 
DXA bone outcomes with bone biomarkers or 25(OH) vitamins D. No association was 






























Figure  3-5: Correlation between TB-BMD SDS Ht-age with growth biomarkers. 
Baseline (filled black circle), 6 months (empty black circle) and 12 months (filled grey circle) in 15 CD received anti-TNF-α for 12 months. IGF-1 SDS, serum insulin like growth 
factor-1SD score; IGFBP-3 SDS, serum insulin like growth factor binding protein-3 SD score; ALS SDS, acid-labile subunit SD score. Large black circle indicates confidence limit, 
Values in bold indicate statistical significance (p<0.05). 
r = 0.39; p = 0.15 
r=0.59; p = 0.034 







r = 0.43; p = 0.11 
r=0.34; p = 0.25 







r = 0.39; p = 0.15 
r=0.43; p = 0.14 









3.4.4 pQCT bone outcomes 
Table 3-7 summarise radius (n, 16) and tibia (n, 15) pQCT outcomes and Figures 3-6 
shows individual data at each visit limited to those with a 12 month visit to facilitate 
comparisons across the visits. 
 
3.4.4.1 Trabecular BMD 
At baseline, both median radius (p=0.001) and tibia (p=0.000) trabecular BMD SDS were 
significantly below zero and significant deficits remained between 6 and 12 months. 
Similar observations were seen by stratifying the participants according to the disease 
conditions or GC exposure or growth potential (Table 3-8 and Figure 3-7; Table 3-9; Table 
3-10 and Figure 3-8). 
 
3.4.4.2 Cortical BMD 
At baseline, radius cortical BMD SDS was not different from zero (p=0.56) and stayed 
unchanged over the study period. In contrast at baseline, the tibia cortical BMD was above 
zero (p=0.004) and there was a trend towards a decline over the study period but it stayed 
above zero (p=0.029). Consistent with trabecular BMD SDS, no difference in results was 
seen by stratifying the participants according to the disease conditions or GC exposure or 
growth potential (Table 3-8 and Figure 3-7; Table 3-9; Table 3-10 and Figure 3-8). 
However, when dividing the group according to growth potential, those with growth 
potential had a lower radius cortical BMD SDS at 12 months compared with those who 
completed their growth and there was a trend towards declined tibia cortical BMD in both 
groups, even though it was more pronounced in those who still had potential to grow. 
 
3.4.4.3 Cortical Dimension  
At baseline the median radius cortical thickness SDS was below zero (p=0.00) in the 
participants and deficiency persisted at 12 months. At the tibia, cortical thickness SDS was 
not different from zero (p=0.13) and did not change over the study period or when analysed 
according to disease status or GC use or growth potential (Table 3-8 and Figure 3-7; Table 
3-9; Table 3-10 and Figure 3-8). 




Table  3-7: pQCT Bone outcomes at baseline, 6 months and 12 months following Anti-TNF-α.  
Data presented as median (range). BMD, volumetric bone mineral density. 
  Baseline 6 Months  12 Months  p-values 
Baseline vs. 6 months Baseline vs. 12 months 
Radius pQCT (n, 16) (n, 14) (n, 16)   
Trabecular BMD SDS -1.8 (3.5, 3.5) -1.8 (-3.5, 1.0) -1.8 (-3.0, 2.0) 0.78 0.83 
Cortical BMD SDS -0.2 (-3.3, 2.3) 0.1 (-2.2, 2.5) -0.4 (-4.8, 2.0) 0.43 0.29 
Cortical Thickness SDS (n, 12) -1.8 (-3.7, 0.8) -1.8 (-3.3, -1.1) -1.9 (-2.6, 0.46) 0.72 0.64 
Tibia pQCT (n, 15) (n, 12) (n, 15)   
Trabecular BMD SDS -1.6 (-3.2, 1.1)  -0.9 (-2.1, 0.7)  -1.3 (-2.6, 1.2)  0.12 0.73 
Cortical BMD SDS 1.2 (-0.6, 2.8) 0.9 (-1.2, 2.6) 0.5 (-2.5, 2.1) 0.18 0.05 
Cortical Thickness SDS -0.1 (-2.1, 1.0) -0.3 (-1.9, 0.3) -0.3 (-2.0, 0.7) 0.43 0.53 




































Figure  3-6: Individual changes in pQCT (Radius& Tibia) bone outcomes at baseline, 6 
months and 12 months following anti-TNF-α. 
BMD, volumetric bone mineral density. Red solid lines represent the median values. Black dotted lines 
represent the 50th centile (0SDS), 3rd (-2SDS) and 97th (2SDS) centile. 
Baseline 6 months  12 months 
Radius  
SDS 
Baseline 6 months  12 months 
SDS 
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Table  3-8: pQCT bone outcomes at baseline, 6 months and 12 months following anti-TNF-α. 
Participants divided according to wPCDAI at 12months. 
Data presented as median (range). BMD, volumetric bone mineral density. 






at 12 months 
Radius pQCT (n, 16) (n, 14) (n, 16) 
   
Trabecular BMD SDS 






0.40 0.53  0.79  






0.27 0.67   
Cortical BMD SDS 






0.51 0.32  0.53 






0.68 0.93   
Cortical Thickness SDS (n, 12) 





(-2.3, -0. 3) 
0.92 0.60 0.94  






0.72 0.92   
Tibia pQCT (n, 15) (n, 12) (n, 15)    
Trabecular BMD SDS 






0.40 0.53  






0.27 0.67 0.18 
Cortical BMD SDS 






0.50 0.07 0.22 






0.23 0.11  
Cortical thickness SDS 






0.40 0.67 0.33 






0.89 0.74  
















































Figure  3-7: Individual changes in pQCT (Radius& Tibia) bone outcomes at baseline, 6 
months and 12 months following anti-TNF-α. Participants divided according to wPCDAI at 
12 months (remission (left) and non-remission (right)). 
BMD, volumetric bone mineral density. Red solid lines represent the median values. Black dotted lines 
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Baseline 6 months  12 months Baseline 6 months  
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Baseline 6 months  12 months Baseline 6 months  12 months 
Baseline  6 months  12 months Baseline 6 months  12 months 
Baseline 6 months  12 months Baseline 6 months  12 months 
Baseline 6 months  12 months Baseline 6 months  12 months 
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Table  3-9: pQCT bone outcomes at baseline, 6 months and 12 month following anti-TNF-α. 
Participants divided according to glucocorticoid use. 
Data presented as median (range). BMD, volumetric bone mineral density; GC, glucocorticoid; +/-, 













at 12 months 
Radius pQCT (n, 16) (n, 14) (n, 16)    
Trabecular BMD SDS 








1.00 0.92 1.0 








0.35 0.75  
GC +/+ (ID-18) 
 
-1.5 -1.6 -1.5   
 
GC +/+ (ID-19) -3.0 -3.5 -2.8    


















1.00 0.25  
GC+/+ (ID-18) 2.0 2.5 2   
 
GC+/+ (ID-19) -3.3 -0.1 -0.5    
Cortical thickness SDS(n, 12) 








0.69 0.61 0.17 






1.00 0.29  
GC+/+ (ID-18) -0.8 -1.1 -0.5   
 
GC+/+ (ID-19) -1.7  -1.2 -1.6    
Tibia pQCT (n, 15) (n, 12) (n, 15)    
Trabecular BMD SDS 








0.47 1.00 0.83 








0.16 0.25  
GC+/+ (ID-18) 0.8 0.7 0.7    
GC+/+ (ID-19) -1.6 -1.9 -2.1    
Cortical BMD SDS  








0.46 0.13 0.72 








0.16 0.06  
GC+/+ (ID-18) -0.2 0.2 0.1    
GC+/+(ID-19) -0.03 0.1 0.1    
Cortical thickness SDS 






0.47 0.13 1.00 






0.60 0.09  
GC+/+ (ID-18) 0.2 -0.4 -0.3    
GC+/+( ID-19) -0.1 -0.3 -0.3  





Table  3-10: pQCT Bone outcomes at baseline, 6 months and 12 months following anti-TNF-α. 
Participants divided into two groups on whether they have potential to grow at time of 
starting anti-TNF-α based on bone age.  









Between groups at 
12 months 
Radius pQCT (n, 16) (n, 14) (n, 16)    
Trabecular BMD SDS 






0.60 0.41 0.67 






1.00 0.25  
Cortical BMD SDS 






0.55 0.41 0.026 






0.61 0.53  
Cortical thickness SDS (n, 12) 






1.00 0.29  






0.61 0.95 0.46 
 
Tibia pQCT (n, 15) (n, 12) (n, 15)    
Trabecular BMD SDS 






0.09 0.51 0.69 






0.75 1.0  
Cortical BMD SDS 









0.04 0.09 0.52 






0.17 0.16  
Cortical thickness SDS 






0.35 0.31` 0.27 






0.92 0.16  










































Figure  3-8: Individual changes in pQCT (Radius & Tibia) bone outcomes at baseline, 6 
months and 12 months following anti-TNF-α. Participants divided into two groups on 
whether they have potential to grow at time of starting anti-TNF-α based on bone age.  
Growth potential on the left and had little/no growth potential on the right. BMD, volumetric bone mineral 
density. Red solid lines represent the median values. Black dotted lines represent the 50th centile (0SDS), 3rd 
(-2SDS) and 97th (2SDS) centile.
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3.4.4.4 Correlation of pQCT bone with disease and anthropometry 
At baseline, 6 months and 12 months no significant correlation observed between pQCT 
bone outcomes (at radius /tibia) with disease duration, age, disease biomarkers (wPCDAI, 
CRP, ESR), cytokines (IL-6, TNF-α). At baseline, 6 months and 12 months no significant 
correlation was observed between pQCT bone outcomes (at radius /tibia) with Ht SDS. 
Repeating the analysis for sub-group with growth potential; at 6 months, a significant 
negative correlation was observed between cortical BMD SDS (Radius) and Ht SDS (r=-
0.79, p=0.036). No correlation was observed with other pQCT bone outcomes and Ht SDS 
at each time point. 
 
3.4.4.5 Correlation of pQCT bone with biomarkers of growth and bone 
turnover 
Figure 3-9; Figure 3-10; Figure 3-11 show correlation between tibia pQCT bone outcomes 
with growth biomarkers at each time point. At baseline and 6 months no significant 
correlation was observed between pQCT bone outcomes (at radius /tibia) with growth 
biomarkers. At 12 months, a significant negative correlation was observed between tibia 
cortical BMD SDS with IGFBP-3 SDS (r=-0.55, p=0.033). 
At baseline, no significant correlation was observed between pQCT bone outcomes (at 
radius /tibia) with bone biomarkers. At 6 months, a significant positive correlation was 
observed between radius cortical BMD SDS and BSAP SDS (r=0.69, p=0.01). At 12 
months no significant correlation was observed between pQCT bone outcomes (at radius 
/tibia) with bone biomarkers. Twelve month change in tibia cortical BMD SDS was 
significantly and negatively correlated with 12 months change in BSAP SDS (r=-0.63, 
p=0.011). At baseline, 6 months and 12 months no significant correlation was observed 
between pQCT bone outcomes (radius /tibia) with 25(OH) vitamin D. 























Figure  3-9: Correlation between tibia trabecular BMD SDS with growth biomarkers. 
Baseline (filled black circle), 6 months (empty black circle) and 12 months (filled grey circle) in 16 CD received anti-TNF-α for 12 month. IGF-1 SDS, serum insulin like growth 
factor-1SD score; IGFBP-3 SDS, serum insulin like growth factor binding protein-3 SD score; ALS SDS, acid-labile subunit SD score. Large black circle indicates confidence limit, 
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Figure  3-10: Correlation between tibia cortical BMD SDS with growth biomarkers. 
Baseline (filled black circle), 6 months (empty black circle) and 12 months (filled grey circle) in 16 CD received anti-TNF-α for 12 month. IGF-1 SDS, serum insulin like growth 
factor-1SD score; IGFBP-3 SDS, serum insulin like growth factor binding protein-3 SD score; ALS SDS, acid-labile subunit SD score. Large black circle indicates confidence limit, 
Values in bold indicate statistical significance (p<0.05). 
























Figure  3-11: Correlation between tibia cortical thickness SDS with growth biomarkers. 
Baseline (filled black circle), 6months (empty black circle) and 12 months (filled grey circle) in 16 CD received anti-TNF-α for 12 month. IGF-1 SDS, serum insulin like growth factor-
1SD score; IGFBP-3 SDS, serum insulin like growth factor binding protein-3 SD score; ALS SDS, acid-labile subunit SD score. Large black circle indicates confidence limit, Values in 







































































































3.4.5 Change in body composition and ND-MIGF  
Table 3-11 summarises DXA (n, 15) and radius pQCT (n, 16) body composition outcomes 
and MIGF in CD participants at each visit, limited to those with a 12 months visit to 








Table  3-11: Change in body composition by DXA, radius pQCT and MIGF at baseline, 6 months and 12 months following anti-TNF-α.  
Data presented as median (range). LM SDS, lean mass adjusted for height and sex. FM, fat mass adjusted for height and gender; Muscle CSA, muscle cross sectional area adjusted 
for height and sex; Fat CSA, Fat cross sectional area adjusted for height and sex; ND-hand MIGF, non-dominant hand maximal isometric grip force adjusted for height and sex. 
 
  Baseline 6 Months 12 Months p-values 
Baseline vs. 6 months Baseline vs. 12 months 
DXA (n, 15) (n, 14) (n, 15)   
TB-LM SDS -1.3 (-3.1, 0.1) -1.0 (-2.8, 1.8) -1.4 (-3.7, 0.1) 0.07 0.139 
TB-FM SDS -0.2 (-0.6, 4.3) -0.1 (-0.7, 3.5) 0.1 (-0.8, 3.0) 0.57 0.38 
Radia pQCT (n, 16) (n, 14) (n, 16)   
Muscle CSA SDS -2.4 (-4.3, -0.3) -2.0 (-3.5, -0.5) -2.0 (-4.3,0.2) 0.12 0.21 
Fat CSA SDS -0.4 (-1.5, 4.3) -0.2 (-1.0, 4.2) -0.2 (-0.9, 3.6) 0.53 0.73 
Grip strength  (n, 19) (n, 19) (n, 19)   
ND-hand MIGF SDS -1.5 (-4.5, 0.5) -0.6 (-5.3, 1.1) -1.2 (-5.8, 0.5) 0.33 0.57 




3.4.6 Whole body composition outcomes by DXA 
At baseline, participants had TB-LM SDS significantly lower than zero (p=0.00) and this 
persisted over the 12 months study. At baseline, median TB-FM SDS was not different 
from zero (p=0.78) and stayed unchanged (Figure 3-12). Categorising the participants 
according to disease status or GC exposure or growth potential did not show any 
significant results (Table 3-12). 
 
























Figure  3-12: Individual changes in body composition by DXA at baseline, 6 months and 12 
months following anti-TNF-α. 
TB-LM SDS, total body lean mass adjusted for height and sex. TB-FM SDS, total body fat mass adjusted for 
height and sex. Red solid lines represent the median values. Black dotted lines represent the 50th centile 
(0SDS), 3rd (-2SDS) and 97th (2SDS) centile.
Baseline 6 months  12 months 
SDS 
TB-LM SDS  
Baseline 6 months  12 months 
TB-FM SDS 
SDS 




Table  3-12: Change in body composition in 15 CD participants by DXA at baseline, 6 months 
and 12 months following anti-TNF-α. Participants divided according to disease status, GC 
use and growth potential. 
Data presented as median (range); TB; total body; LM SDS, lean mass adjusted for height and sex; FM, fat 
mass adjusted for height and sex. 






at 12 months 
TB-LM SDS  






0.016 0.17 0.26 






0.89 0.60  






0.46 0.75 0.17 






0.06 0.12  
GC+/+ (ID-18) -1.8 -1.5 -1.6    
GC+/+ (ID-19) 
-3.1 -2.8 -2.0    






0.09 1.00 0.86 






0.18 0.26  
TB-FM SDS  






0.59 0.52 0.61 






0.89 0.46  






0.75 0.74 0.43 






0.60 0.75  
GC+/+ (ID-18) -0.6 -0.1 0.3    
GC+/+ (ID-19) 
0.6 -0.2 0.04    






0.89 0.40 0.27 






0.40 0.67  





3.4.6.1 Correlation of whole body composition outcomes by DXA with 
disease and bone outcomes by DXA 
At baseline, 6 months and 12 months, no significant correlation was observed between TB-
LM SDS and disease biomarkers (wPCDAI, ESR, CRP, albumin), cytokines (TNF, IL-6) 
or duration of disease. At baseline, 6 months and 12 months, no significant correlation was 
observed between TB-FM SDS and disease biomarkers (wPCDAI, ESR, CRP, albumin), 
cytokines (TNF, IL-6) or duration of disease. At baseline, 6 months and 12 months, no 
significant correlation observed between TB-LM SDS and bone parameters by DXA. 
 




3.4.7 Body composition outcomes by radius pQCT 
At baseline, participants had muscle CSA SDS significantly lower than zero (p=0.00) and 
this persisted over the 12 months study. At baseline, median fat CSA SDS was not 
different from zero (p=0.24) and stayed unchanged (Figure 3-13). Categorising the 
participants according to disease status or GC exposure or growth potential did not show 







































Figure  3-13: Individual changes in body composition by radius pQCT at baseline, 6 months 
and 12 months following anti-TNF-α. 
Muscle CSA, muscle cross sectional area adjusted for height and sex; Fat CSA, Fat cross sectional area 
adjusted for height and sex. Red solid lines represent the median values. Black dotted lines represent the 50th 
centile (0SDS), 3rd (-2SDS) and 97th (2SDS) centile. 
 
 
Baseline 6 months  12 months 
SDS Muscle CSA SDS 
Baseline 6 months  12 months 
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Table  3-13: Change in body composition in 16 CD participants by radius pQCT at baseline, 6 
months and 12 months following anti-TNF-α. Participants divided according to disease 
status, GC use and growth potential. 
Data presented as median (range). Muscle CSA, muscle cross sectional area adjusted for height and sex; Fat 
CSA, Fat cross sectional area adjusted for height and sex. Participants divided according to disease status, 
GC use and growth potential. Values in bold indicate statistical significance (p<0.05). 
 






at 12 months 
Muscle CSA SDS  






0.022 0.07 0.92 






0.14 0.46  






0.50 0.87 1.0 






0.21 0.46  
GC+/+ (ID-18) -4.3 -3.2 -2.8    
GC+/+ (ID-19) -2.4 -2.2 -1.9    






0.29 0.87 0.34 






0.13 0.10  
Fat CSA SDS  






0.57 0.95 0.63 






0.71 0.59  






0.46 0.57 0.02 






0.85 0.69  
GC+/+ (ID-18) -0.50 1.0 2.0    
GC+/+ (ID-19) 0.20 -1.0 -0.9    






0.46 0.74 0.09 






0.92 0.78  





3.4.7.1 Correlation of body composition outcomes by pQCT with disease 
and bone outcomes by pQCT 
At baseline, 6 months and 12 months, no significant correlation was observed between 
muscle CSA SDS or fat CSA SDS and disease biomarkers (wPCDAI, ESR, CRP, 
albumin), or duration of disease. At baseline, 6 months and 12 months, no significant 
correlation was observed between muscle CSA SDS and cytokines (TNF, IL-6). At 
baseline and 6 months, no significant correlation was observed between fat CSA SDS and 
cytokines (TNF, IL-6). At 12 months, a significant negative correlation was observed 
between fat CSA SDS with TNF-α (r=-0.66, p=0.007). 
Figure 3-14 and Figure 3-15 show correlation between pQCT (radius& tibia) bone 
outcomes and muscle CSA SDS at each time point. At baseline, a significant positive 
correlation was observed between muscle CSA SDS with radius trabecular BMD SDS 
(r=0.52, p=0.041), tibia trabecular BMD SDS (r=0.53, p=0.042) and tibia cortical thickness 
SDS (r=0.53, p=0.041). At 6 months, no correlation was observed between muscles CSA 
SDS with radius or tibia pQCT bone outcomes. At 12 months, a significant positive 
correlation was observed between muscle CSA SDS and tibia cortical BMD SDS (r=0.67, 
p=0.006). 





























Figure  3-14: Correlation between radius trabecular BMD SDS with radius muscle CSA SDS. 
Baseline (filled black circle), 6 months (empty black circle) and 12 months (filled grey circle) in 16 CD 
received anti-TNF-α for 12 month. Large black circle indicates confidence limit, Values in bold indicate 
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Figure  3-15: Correlation between tibia pQCT bone outcomes with radius muscle CSA SDS 
Baseline (filled black circle), 6 months (empty black circle) and 12 months (filled grey circle) in 16 CD 
received anti-TNF-α for 12 months. Large black circle indicates confidence limit, Values in bold indicate 




































































































ND-MIGF SDS was reduced at baseline (p=0.00 vs zero) with no improvement noticed 
during the study interval (Figures 3-16). The result was not different when the participants 
were categorised according to disease condition or GC exposure or growth potential (Table 
3-14).






















Figure  3-16: Individual changes in MIGF at baseline, 6 months and 12 months following anti-
TNF-α. 
MIGF, maximum isometric grip force adjusted for height and sex. Red solid lines represent the median 
values. Black dotted lines represent the 50th centile (0SDS), 3rd (-2SDS) and 97th (2SDS) centile. 
MIGF 
SDS 
Baseline 6 months  12 months 










Table  3-14: Change in ND-MIGF at baseline, 6 months and 12 months following anti-TNF-α. 
Participants divided according to disease status, GC use or growth potential. 
Data presented as median (range); ND-hand MIGF SDS, non-dominant hand maximal isometric grip force 
adjusted for height and sex.  
ND-MIGF SDS 
(n, 19) 






at 12 months 



















0.39 0.80  









0.047 0.17 1.00 









1.00 0.31  
GC+/+ (ID-18) -1.4 1.09 -0.94    
GC+/+ (ID-19) 
 
-1.9 -2.2 -2.2    









0.31 0.77 0.71 






0.09 0.58  





3.4.8.1 Correlation of ND-MIGF and disease  
At baseline and 6 months, no significant correlation was observed between ND-MIGF SDS 
with disease biomarkers (wPCDAI, ESR, CRP, albumin), duration of disease, cytokines 
(TNF, IL-6). At 12 months, a significant negative correlation was observed between ND-
MIGF SDS with wPCDAI (r=-0.47, p=0.41). At baseline, 6 months and 12 months no 
significant correlation was observed between ND-MIGF SDS with cytokines (TNF, IL-6). 
 
3.4.8.2 Correlation of MIGF and muscle  
Figure 3-17 shows the correlation between muscle CSA SDS and ND-MIGF SDS at each 
time point. At baseline, a significant positive correlation was observed between ND-MIGF 
SDS with radius muscle CSA SDS (r=0.57, p=0.020). At 6 months, a significant positive 
correlation was observed between ND-MIGF SDS with radius muscle CSA SDS (r=0.65, 



























Figure  3-17: Correlation between muscle CSA SDS and ND-MIGF SDS. 
Baseline (filled black circle), 6 months (empty black circle) and 12 months (filled grey circle) in 16 CD 



























12 months  





3.4.8.3 Correlation of MIGF and bone 
At baseline, a significant positive correlation was observed between ND-MIGF SDS with 
radius trabecular BMD SDS (r=0.69, p=0.003) (figure 3-18), tibia trabecular BMD SDS 
(r=0.54, p=0.037) and tibia cortical thickness SDS (r=0.53, p=0.041) (figure 3-19). At 6 
months and 12 months no significant correlation was observed between ND-MIGF SDS 
and pQCT bone parameters (radius/tibia). No correlation was observed between ND-MIGF 
SDS and bone outcome by DXA. 
 


































Figure  3-18: Correlation between radius trabecular BMD SDS and ND-MIGF SDS. 
Baseline (filled black circle), 6 months (empty black circle) and 12 months (filled grey circle) in 16 CD 
received anti-TNF-α for 12 months. Large black circle indicates confidence limit, Values in bold indicate 

































12 months  




















Figure  3-19: Correlation between Tibia trabecular BMD SDS (on the left), tibia cortical thickness SDS (on the right) and ND-MIGF SDS 
Baseline (filled black circle), 6 months (empty black circle) and 12 months (filled grey circle) in 16 CD received anti-TNF-α for 12 month. Large black circle indicates confidence limit, 






































































3.4.9 Multivariate mixed-model regression analysis for DXA bone 
outcomes 
Table 3-15 displays the results of multivariate mixed-model regression analysis of the 
relationship of DXA bone outcomes with IL6, GC (Yes/No) growth biomarkers SDS and 
TB-LM SDS during the 12-months study interval. TB-BMD SDS BA and LS-BMD SDS 
BA, were significantly and positively associated with IGF-1 SDS independent of IL6, GC 
use, other growth biomarkers and TB-LM SDS. Similar results were observed by running 
the same model but using wPCDAI. 




Table  3-15: Mixed model assessment of the effect of inflammation, glucocorticoid use, and growth biomarkers adjusted for bone age on DXA bone outcomes 
 at each time points during 12 months study. 
TB, total body; BMD, areal bone mineral density; SDS Ht-age, adjusted for height age and sex; SDS BA, adjusted for bone age and sex; AP, anteroposterior; LS, lumbar spine; LM, lean 
mass; IGF-1 SDS, serum insulin like growth factor-1SD score; IGFBP-3 SDS, serum insulin like growth factor binding protein-3 SD score; ALS SDS acid-labile subunit; IL-6, 
interleukin-6; GC, glucocorticoid. Values in bold indicate statistical significance (p<0.05). *Natural log used to produce normality. 
 
Independent variables  Dependent Variables  





















































































































3.4.10 Multivariate mixed-model regression analysis for radius pQCT 
bone outcomes 
Table 3-16 displays the results of multivariate mixed-model regression analysis of the 
relationship of radius trabecular BMD SDS (We have excluded cortical BMD and cortical 
thickness as the measurement seems to be influenced by partial volume effect compared to 
tibia) with, IL6, GC (yes/no), growth biomarkers SDS and radius muscle CSA SDS during 
the 12-months study interval. Results of mixed model regression analysis showed that IL-6 
(p=0.005) was negatively and muscle CSA (p=0.035) positively and independently 
associated with trabecular BMD. Repeating the same model using wPCDAI instead of IL-
6, only muscle CSA (p=0.005) was positively and independently associated with trabecular 
BMD SDS.






Table  3-16: Mixed-model assessment of the effect of inflammation, glucocorticoid use, growth 
biomarkers adjusted for bone age on radius trabecular BMD SDS at each time points during 
12 months study. 
BMD , volumetric bone mineral density; SDS, adjusted for age and sex; muscle CSA SDS, muscle cross 
sectional area adjusted for sex and height; IGF-1 SDS, serum insulin like growth factor-1SD score; IGFBP-3 
SDS, serum insulin like growth factor binding protein-3 SD score; ALS SDS acid-labile subunit; IL-6, 
interleukin-6; GC, glucocorticoid. Values in bold indicate statistical significance (p<0.05). *Natural log used 
to produce normality.
Independent variables  Dependent Variables 


































3.4.11 Multivariate mixed-model regression analysis for tibia pQCT bone 
outcomes 
Table 3-17 displays the results of multivariate mixed-model regression analysis of the 
relationship of tibia pQCT bone outcomes with, IL6, GC (yes/no), growth biomarkers SDS 
and radius muscle CSA SDS during the 12-months study interval. Results of mixed model 
regression analysis showed that ALS SDS (p=0.024) and muscle CSA (p=0.015) were 
positively and independently associated with trabecular BMD; muscle CSA was 
independently associated with cortical BMD SDS (p=0.049). Muscle CSA (p=0.003) and 
IGFBP3 SDS (p=0.024) were independently associated with cortical thickness positively 
and negatively respectively. Similar results were observed by running the same model but 
using wPCDAI.











Table  3-17: Mixed-model assessment of the effect of inflammation, glucocorticoid use, growth 
biomarkers adjusted for bone age on tibia pQCT bone outcomes at each time points during 
12 months study. 
BMD , volumetric bone mineral density; SDS, adjusted for age and sex; muscle CSA SDS, muscle cross 
sectional area adjusted for sex and height; IGF-1 SDS, serum insulin like growth factor-1SD score; IGFBP-3 
SDS, serum insulin like growth factor binding protein-3 SD score; ALS SDS acid-labile subunit; IL-6, 
interleukin-6; GC, glucocorticoid. Values in bold indicate statistical significance (p<0.05). *Natural log used 
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3.4.12 Correlations between DXA and radius pQCT outcomes 
At baseline, a positive correlation was observed between radius pQCT trabecular 
volumetric BMD and DXA LS-BMD SDS Ht-age (r=0.60, p=0.017) and with LS-BMD 
SDSBA (r=0.800, p=0.00). At 6 months, a positive correlation was observed between radius 
pQCT trabecular volumetric BMD and DXA LS-BMD Ht-age (r=0.61, p=0.035) and with 
LS-BMD SDSBA (r=0.77, p=0.000). At 12, a positive correlation was observed between 
radius pQCT trabecular volumetric BMD and DXA LS-BMD SDS BA (r=0.54, p=0.037) 
and no correlation was observed between radius pQCT trabecular volumetric BMD and 
DXA LS-BMD SDS Ht-age (figure 3-20). No correlation was observed between radius 
pQCT cortical volumetric BMD and DXA TB-BMD SDS. 
 




















Figure  3-20: Correlation between radius trabecular BMD SDS and LS-BMD SDS 
Ht-age
 (on the left) and LS-BMD SDS
BA
(on the right). 
Baseline (filled black circle), 6months (empty black circle) and 12 months (filled grey circle) in 16 CD received anti-TNF-α for 12 month. Large black circle indicates confidence limit, 
























3.4.13 Correlations between DXA and tibia pQCT outcomes 
At baseline, a positive was correlation observed between tibia pQCT trabecular volumetric 
BMD and DXA LS-BMD SDS Ht-age (r=0.61, p=0.025) and with LS-BMD SDSBA (r=0.61, 
p=0.021). At 6 months, a positive correlation was observed between tibia pQCT trabecular 
volumetric BMD and DXA LS-BMD SDS Ht-age (r=0.62, p=0.031) and with LS-BMD 
SDSBA (r=0.64, p=0.026) (figure 3-21). At 12 months, no correlation was observed 
between radius pQCT trabecular volumetric BMD and DXA LS-BMD SDS. No 
correlation was observed between tibia pQCT cortical volumetric BMD and DXA TB-




























Figure  3-21: Correlation between tibia trabecular BMD SDS and LS-BMD SDS Ht-age (on the left) and LS-BMD SDS BA(on the right). 
Baseline (filled black circle), 6 months (empty black circle) and 12 months (filled grey circle) in 16 CD received anti-TNF-α for 12 month. Large black circle indicates confidence limit, 























3.5 Discussion  
The current study was primarily aimed at assessing the extent of change that may occur in 
bone health (by DXA and pQCT), bone geometry and muscle mass and function following 
initiation of anti-TNF-α therapy in children and adolescents with CD. In addition, this 
study aimed to study the association of IGF-1 axis, cytokines and muscle with bone 
density. 
Anti-TNF-α therapy was associated with rapid improvements in disease activity and 
increases in BSAP. However, this improvement in markers of disease and bone turnover 
was not translated into meaningful improvements in bone mineral density or geometry. It is 
possible that this lack of improvement may have been related to poor muscle mass and 
function which tended to remain persistently low despite an improvement in disease status. 
Our cohort showed a high proportion of vitamin D deficiency according to the National 
Osteoporosis Society guidelines (295). However, in keeping with other reports in healthy 
children (171) as well as children with IBD (147-149;172;173), vitamin D in our cohort 
was not associated with any of the bone parameters. Our finding of no changes in vitamin 
D level following anti-TNF-α is consistent with recent studies (241;247).  
This prospective study involved assessment of bone health at axial and appendicular 
skeleton by using DXA (TB, LS) and bone parameters at both weight- and non-weight 
bearing limbs by pQCT with evaluation of muscle health by DXA and pQCT and muscle 
function by grip strength. At baseline, both bone parameters and muscle mass were 
impaired and persist despite marked improvements in disease, bone biomarkers and 
reduction in corticosteroid use 12 months following anti-TNF-α therapy. Our data confirm 
the previous evidence that CD was associated with significant deficits in trabecular 
volumetric BMD and cortical thickness (150;154;155;199). Previous data suggest that 
younger age and concurrent growth provide a window of opportunity for skeletal recovery 
(153;156;237); we failed to confirm this finding as we did not find any improvement in 
bone or muscle health by categorised group according to their growth potential. However, 
the high percentage younger group were on GC at the time of starting anti-TNF-α and may 
have a more severe form of the disease. 
Detrimental effect of glucocorticoids on bone health is well established (296) also there is 
some evidence showing that less glucocorticoid exposure was associated with greater 
recovery of the cortical area, especially in the setting of linear growth in children with CD 
(153). In our study 50% of the participants were on glucocorticoids during the first 6 weeks 




of therapy and they had potential to grow and musculoskeletal deficiency did not differ in 
those who did versus did not use GC over the study interval.  
At baseline, we found tibia cortical BMD above average in our patients. Assimilating all 
available data, we postulated that bone impairment in children with CD may include 
impairment of intracortical bone remodelling (154;155;199). Similar to the data of Griffin 
et al (237), we found a drop in cortical BMD at the tibia. This decline in cortical bone 
density may be transient and could be explained by the fact that bone mass accrual lags 
behind increase in linear growth by approximately 6 to 12 months in both boys and girls 
(297). The current study found a discrepancy between cortical BMD and cortical geometry 
measured at radius and tibia with the one measured at radius being significantly reduced. 
Our finding in line with the recommendation that tibia is the preferred site for measuring 
cortical BMD and thickness as it is less subjected to underestimation of cortical 
measurement (298). However, lack of reference data for tibia hamper it is use in paediatric 
(146;290). Indeed, there was no available reference data for muscle and fat measured at the 
tibia matched for our cohort; for that reason we have not included these parameters in our 
results. 
CD children who participated in this study had reduced muscle mass measured by both 
DXA and radius pQCT. Reduced muscle mass has already been reported in CD children 
(115;153-155;199;200). Our cohort showed persistent muscle deficiency following anti-
TNF-α regardless of disease status and GC use. Chronic diseases may be associated with 
lower muscle strength relative to muscle mass that is not captured by DXA or pQCT. 
Accordingly, direct measures of muscle force may more fully explain bone deficits in 
chronic disease (201). Our present data showed that the reduced muscle mass was reflected 
in the significant reduction in muscle strength in the non-dominant hand measured by grip 
strength and persisted at 12 months despite improvement of the disease status.  
To gain insights into the possible underlying mechanisms that may lead to abnormality of 
skeletal development in our CD cohort, multivariate mixed-model regression analysis was 
used. The possible reason for the abnormality in trabecular bone mineral density and 
cortical geometry in this cohort of children with CD could be partially related to persistent 
deficiency in muscle mass and function. The relationship between muscle or lean mass 
deficits and bone mass or structure deficits has been documented in cross-sectional (199) 
and longitudinal studies in children with IBD (155;205;237). Our study emphasizes the 
importance of muscle mass on bone mass. We found a strong independent positive 
association between muscle and bone density and geometry. In accordance with the 
concept of bone muscle unit (muscle strength strongly modulates bone strength) (299), the 




persistent muscle deficits and reduced muscle force may give a plausible explanation to 
persistent bone deficiency seen in our group despite improvement of disease and 
biomarkers of bone metabolism; this finding may lead to speculation on the beneficial role 
of physical activity after controlling the inflammation. 
It is evident that systemic IGF-1 maintains cortical bone structure and geometry, whereas 
locally produced IGF-1 serves to maintain trabecular bone structure (76-79). The inability 
to form ternary complex, with the marked reduction in circulating IGF-1, and the reduction 
in trabecular BMD and cortical bone volume were present in ALS-Knock mice 
(77;77;300). The association between ALS SDS and trabecular BMD SDS and negative 
correlation between IGFBP-3 and tibia cortical thickness SDS raise the possibility that the 
IGF axis may contribute to trabecular and cortical geometry impairment seen in those 
groups of children. The finding in the current study of the positive association between 
ALS SDS and trabecular BMD SDS in agreement with recent reports from our group 
showed a significant negative relationship between ALS and trabecular bone separation in 
women with childhood onset type 1 diabetes mellitus (301). Taking our group finding 
together suggests that ALS could play a role in the regulation of trabecular bone, and this 
might be exerted via IGF-1 independent mechanisms. However, more in depth preclinical 
studies are needed to improve our understanding about the role of IGF ternary complex, 
not only on bone density, but also on the architectural structure of both trabecular and 
cortical bone in children with CD.  
Even though the wPCDAI,or IL-6 was not independently associated with bone parameter 
in the regression model, persistent trabecular deficiency over 12 months after anti-TNF-α 
even in sub-groups with complete remission could be partly explained by persisting low-
grade mucosal inflammation, even in clinical remission, similar to Sylvester et al (149) 
already described.  
Another possibility is that improvement in bone mass may lag behind the improvement in 
inflammation and a 12 month study was insufficient; a longer period of follow up may be 
required(302). Our finding also could be explained by the fact that our cohort had longer 
(3.1 years) compared to 2.1 years reported by Griffin et al (237); also we found a negative 
relationship between disease duration and TB-BMD measured by DXA. Disease duration 
in our study was similar to two previous studies in paediatrics which showed a negative 
result (241;254). Available evidence about growth recovery and normalisation of height 
has been linked to duration of cytokines exposure and duration of disease (120;248). 
Integrating our finding with previous studies, we may speculate that there is a certain 
window of reversible recovery similar to the growth, after which the detrimental effect of 




inflammation on bone may be irreversible. However, this needs to be further explored 
before a final conclusion can be made. 
Finally, the Griffin group (237) showed that in the younger age group, greater decline in 
PCDAI was independently associated with greater increase in trabecular BMD. Our cohort 
may miss the narrow window of opportunity for intervention to improve bone health. It is 
clear that there is no possible individual mechanism for lack of musculoskeletal recovery 
in our cohort and most likely it is a combination of them all.  
Irrespective of method adjustment of LS-BMD SDS, trabecular BMD measured at tibia 
and radius showed a significant association. This finding highlighted that reductions in 
aBMD, specifically at the LS regions of interest, may suggest reductions in trabecular 
BMD based on the understanding of the higher amount of trabecular bone located in LS 
(31;32). However, such results may still not be synonymous with true trabecular BMD at 
spine. The overlaid cortical bone may have obscured trabecular deficits in the DXA scans. 
The observation that the decreases in pQCT trabecular BMD SDS were significantly 
greater than the declines in LS BMD SDS in this study is consistent with this concept. 
This study provides a broad view of skeletal health at different sites of the body by the use 
of DXA and pQCT. Furthermore, this is the first study that charts the effect of anti-TNF-α 
therapy on changes in upper limb muscle function in paediatric patients with CD. Finally, 
this study provides insight that may enable future clinical and research strategies to 
optimise bone health in children with CD. However, a number of important limitations 
need to be considered. The most important limitation lies in the fact that our study group 
was relatively small and therefore conclusions must be drawn with some caution. An 
additional limitation is by using DXA and pQCT we examine only the BMD and bone 
geometry, insufficient to characterise the microarchitecture of trabecular and cortical bone 
which are crucial components of bone strength; thus future studies need to use other 
techniques such as measuring trabecular bone score by DXA, high resolution pQCT and 
micro MRI for accurate measurement of bone microstructure. Lack of data on sex steroids 
and their relation with change in bone density is an additional limitation. pQCT geometry 
was adjusted only for height without taking age into consideration so it may yield in 
comparing the same height with different age and pubertal maturation, ignoring the 
influence of sexual hormones on bone and muscle development.  
 
3.6 Conclusion  
In summary, there is some evidence of bone formation but this is not translated into an 
improvement in bone mass or density over a period of one year of anti-TNF-α and this is 




probably due to two factors. Firstly, there is probably a lag between growth and bone 
formation and secondly these patients have poor muscle mass and function and a sustained 
deficit in these may hinder skeletal acquisition. Given that our results suggest that 
inflammation, the insult to the skeleton is not completely removed even with anti TNF 
therapy, the role of adjuvant therapy to improve musculoskeletal development in children 
with CD such as nutritional, exercise or manipulation of the GH-IGF axis requires further 
exploration. Our result also highlighted that there may be perhaps limited window of 
intervention which may be augmented by improved nutritional status to improve muscle 












 The Sustained Effects of Recombinant Human 
Growth Hormone Therapy on Linear Growth in 






4.1 Abstract  
Background: It is unclear whether the beneficial effect of rhGH on short-term growth in 
children with CD is sustained over a longer period 
Aims: To investigate the effects of prolonged rhGH therapy on linear growth and insulin 
sensitivity in children with CD. 
Design and participants: Fourteen cases of CD (9 male) who received rhGH 
(67mcg/kg/day) for 24 months were compared to another 14 children with CD matched for 
age, gender and duration of disease. Study time points included baseline, 12 months and 24 
months of follow-up. Results were reported as median (range). 
Results: Median change in Ht SDS was -0.3 (-0.7, -0.3) at baseline, 0.6 (0.2, 1.0) at 12 
months (p=0.003 vs. baseline,) and 0.5 (-0.05, 0.9) at 24 months (p=0.003 vs. baseline) in 
the rhGH group, whereas in the control group it was 0.01 (-0.2, 0.7), 0.05 (-0.5,0.9) 
(p=0.88 vs. baseline) and -0.01 (-0.6, 0.5) (p=0.69 vs. baseline ), respectively. In the rhGH 
group, median plasma IGF-1SDS adjusted for bone age increased from -2.9 (-6.0, +2.0) at 
baseline to 0.6 (-3.9, 3.0) (p=0.008 vs. baseline) at 12 months and -0.4 (-3.9, 2.0) (p=0.2 
vs. baseline) at 24 months. HOMA-IR increased from 0.8 (0.4, 4.6) at baseline to 1.5 (0.6, 
3.5) at 12 months (p=0.045 vs. baseline) and 1.7 (0.5, 6.1) at 24 months (p=0.03 vs. 
baseline). One patient developed impaired glucose tolerance at 12 months but normalised 
at 24 months with no reduction in rhGH dose. 
Conclusion: This report showed that improved growth with rhGH therapy in children with 
CD is sustained over a two year period. However, the use of rhGH needs careful 












4.2 Introduction  
Despite improvements in the management of CD, growth retardation is still commonly 
encountered (84) with significant reduction in final adult height in approximately 20% 
treated with contemporary treatment regimens (91). Poorly growing children with CD may 
exhibit combined abnormalities of functional GH insufficiency as well as GH resistance 
(101). There may, therefore, be a rationale for considering treatment with high dose rhGH 
in children with CD and ongoing growth retardation. Therapy with rhGH in children with 
inflammatory diseases such as JIA and cystic fibrosis lead to short term catch up growth 
(256;267;303;304). Current studies of short term treatment with rhGH over 6-12 months in 
children with CD have reported significant improvement in linear growth (259;260;262) 
but it is unclear if longer term therapy is associated with continued catch up growth. 
Chronic inflammation maybe associated with a degree of insulin resistance (305) and this 
is evident in children with CD (262). Treatment with rhGH in such children may be 
therefore lead to deterioration in insulin sensitivity and this may be more notable in those 
who are on concomitant GC (259;264). The impact of longer term rhGH treatment in CD 
and insulin sensitivity is currently unknown.  
The goal of this study is therefore to assess linear growth over 2 years of rhGH treatment 
in children with CD and a comparison of this growth to that in a contemporary group of 
children with CD who were matched for age, gender and duration of disease but who did 







4.3 Methods  
4.3.1 Study population 
Fourteen children with CD who received rhGH (NorditropinSimplexx®; NovoNordisk, 
Crawley, UK), 67 mcg/kg/day as part of a six-month RCT (262) and who subsequently 
continued rhGH for 24 months as part of the study protocol were compared to a 
contemporary group of 14 CD children (84)who did not receive rhGH but were matched 
for gender (5female rhGH; 5female control), disease duration: median 3.3 years (0.6, 12.4) 
and 3.0 years (0.6, 7.3) and age 14.5 years (9.0, 16.4) and 13.0 years (8.6, 15.8) for rhGH 
and control group, respectively. The two groups also turned out comparable for their MPH 
SDS. rhGH dose was adjusted for weight at each visit. 
Of the 22 children included in the initial RCT (262), rhGH was discontinued due to 
completion of linear growth (n, 2), poor compliance (n, 2), lost to follow-up (n, 2), needle 
phobia (n, 1) and post-colectomy in a child with UC (n, 1). Disease phenotype was 
classified using the Montreal classification (5). Data on therapeutic interventions including 
EEN, CD medication and surgery were collected for both groups at baseline, 12 months 
and 24 months. Figure 4-1 summarise the available study data for two groups.  
The original clinical trial was approved by the UK multicentre research ethics committee, 
and its conduct was approved by the Health Boards. Written informed consent was 
obtained from all parents and patients as appropriate for those patients on rhGH. Data from 














Figure  4-1: Flow chart of available data at each study visit for rhGH group and the control 
n, number; Ht SDS, height SD score; ΔHt SDS, change in height SD score; HV, height velocity ;ESR, 
erythrocyte sedimentation rate; CRP, c-reactive protein. 
rhGH group
(n, 14 CD)
baseline 12 months 24 months
Ht SDS (n, 14)
ΔHt SDS (n, 12)
HV (n, 12)
BA (n, 14)





Pubertal data (n, 14)
Ht SDS (n, 14)
ΔHt SDS (n, 14)
HV (n, 14)
BA (n, 13)
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4.3.2 Study parameters 
For the study participants, Ht was measured with a Harpenden stadiometer and used to 
calculate annual HV. Ht, Wt, and BMI at 12 months before baseline, at starting rhGH, at 
12 months and at 24 months after starting rhGH. In the rhGH group, SH was measured and 
SILL was calculated from Ht and SH. SH and SILL were converted to SDS using the 1978 
Tanner-White-house standards (275). The Ht, Wt and BMI were converted into SDS for 
chronological age using 1990 UK standards (273;274).  
Pubertal status in rhGH group was systemically assessed clinically by a member of the 
research team and were available at baseline, 12months and 24 months, whereas in the 
control group (historical controls), pubertal data had been collected as part of clinical 
assessment by the clinical team and were available in 12 participants at baseline, 12months 
and 11 participants at 24 months. The participants were categorised as pre-pubertal 
(Tanner stage1), mid-pubertal (Tanner stages 2-3) and late pubertal (Tanner stages 4-5). 
Data for bone age (BA) were available for rhGH group at baseline, 12 months and 24 
months. BA was determined using the Tanner (TW2) RUS method (277).  
 
4.3.3 Biochemical assays 
All laboratory parameters were taken at 9 am after overnight fasting. Systemic markers of 
disease activity including ESR‚ CRP, and serum albumins were evaluated at the study time 
points in both groups. Fasting glucose, glycosylated haemoglobin (HbA1c), insulin and C-
peptide, triglycerides, cholesterol, were obtained at baseline, 12 and 24 months in the 
rhGH group. Glucose was measured in both centres using Abbott Architect c8000 (Abbott 
Laboratories Ltd, Maidenhead, UK) and between batch coefficient of variation (CV) was 
<3.9%. In 11 of the 14 children, an oral glucose tolerance test (OGTT) (n,11 children who 
were on treatment group during first 6 months on original trial) was also performed at 
baseline, 12 months and 24 months with plasma glucose levels before and 120 min after an 
oral glucose load (1·75g/kg up to maximum 75g). Impaired glucose tolerance and diabetes 
mellitus were defined according to the International Society for Paediatric and Adolescent 
Diabetes Clinical Consensus Guidelines 2014 ( impaired glucose intolerance defined as 
fasting glucose level 5.6-6.9 mmol/l, 2 hour post load glucose level 7.8-<11.1 mmol/l) 
(306).  




In Glasgow, insulin was measured using the Abbott Architect Analyser (Abbott 
Laboratories Ltd); with inter- and intra-assay CVs of <4.7% and <8%, respectively. In 
Liverpool, insulin was measured using Immunolite 2000 Analyzer (Siemens UK Ltd, 
Camberley, Surrey); with inter- and intra-assay CVs of <3.3% and <7.3%, respectively 
with standard. Fasting hyperinsulinemia was defined as fasting insulin (mU/l) ≥15 in 
tanner stage 1-2, ≥30 tanner stage 3-4 and ≥20 in tanner stage 5 (307) and this cut off point 
was used to categorised the participants at 24 months. As surrogate estimate of insulin 
resistance, the homeostatic model assessment (HOMA-IR) index was calculated as (fasting 
insulin (mU/I) × fasting glucose (mmol/l) / 22.5) (insulin resistance in children and 
adolescence defined as HOMA-IR, ≥4.5) (307).  
C-peptide was measured in both centres using Immunolite 2000 Analyzer (Siemens UK 
Ltd); with inter- and intra-assay CVs of <3.3% and >6.3%, respectively (local reference 
range: 0.36-1.12 nmol/l). HbA1c measured using high performance liquid chromatography 
(local reference range: 4.8-6.6%).  
Cholesterol and triglycerides were measured using the Abbott Architect c8000 (Abbott 
Laboratories Ltd); with inter- and intra-assay CVs of 0.8% and 0.4%, (local reference 
range: cholesterol, 0.36-1.12 mmol/l and triglyceride 0.4-1.5 mmol/l). IGF-1 was assayed 
in in both centres using a two-site chemiluminescent immunoassay (Nichols Advantage; 
Quest Nichols, Institute Diagnostic, Chantilly, VA, USA); with inter- and intra-assay CVs 
of <4% and <7.8%, respectively. To account for delayed puberty, IGF-1 was converted to 
SDS by adjusting for gender and BA (308).  





4.3.4 Statistics  
Analyses were performed using SPSS software version 22 (Newyork, USA). Non-
parametric data presented with medians and ranges. Comparison between the groups was 
analysed using the Mann–Whitney test for continuous variables and Chi-square test for 
categorical variable. Changes between parameters were assessed at different time points 
analysed using repeated measure with Wilcoxon signed-rank tests and subsequently 
adjusted for multiple comparison using a Bonferroni correction. The association between 
variables was assessed using the Spearman’s correlation coefficient. p<0.05 was 
considered as statistically significant. All graphs performed by GraphPad Prism software 
version 7(San Diego California, USA). 





4.4 Results  
4.4.1 Disease and laboratory characteristics  
Disease location was L1 in 2/14 (14%) of the rhGH group and 1/14 (7%) of the control 
group (rhGH vs controls, p=0.54). L2 involvement was present in 5/14 (36%) of the rhGH 
group and 10/14 (71%) of the control group (rhGH vs controls, p=0.06). and L3 disease 
was present in 7/14 (50%) in the rhGH group and 3/14 (21%) in the control group (rhGH 
vs controls, p=0.11). L4 involvement was present in 6/14 (36%) of the rhGH group and 
4/14 (42%) of the control group (rhGH vs controls, p=0.43). Perianal disease was present 
in 6/14 (42%) of rhGH and 3/14 (21%) in the control group (rhGH vs controls, p= 0.22). 
At baseline, indices of disease biomarkers were similar in both groups and did not show 
any significant change at 12 months and 24 months (Table 4-1).  
 
4.4.2 Treatment characteristics  
Table 4-1 summarises the treatment characteristics of both groups. At baseline, all children 
in both groups were on concomitant immunomodulator therapy. There were no significant 
differences in the use of 5-aminosalicylate, methotrexate, anti-TNF-α therapy, 
prednisolone or number of children undergoing surgical resection of bowel between 
groups’ at all three time points. At baseline, the proportion of azathioprine use was 








Table  4-1: Disease and treatment factors 
Data presented as number, n; percentage, %, median (range). ESR, erythrocyte sedimentation rate; CRP, C - reactive protein; EEN, exclusive enteral nutrition. 
a 
p value<0.05 (rhGH 
group vs. control).
 rhGH Control 
 Baseline 12 Months 24 Months Baseline 12 Months 24 Months 












n (%) >20 mm/hr 7 (50)  4 (29) 6 (50)  3 (23) 












n (%) >7 mg/l 6 (50)  8 (57) 5 (36)  6 (46) 












n (%) <35 g/l 3 (21)  2 (14) 1 (7)  3 (21) 
Medication n (%)       
5-aminosalicylate  6/14 (42) 4/14 (28) 4/14 (28) 10/14 (71) 10/14 (71) 9/14 (64) 
Azathioprine  9/14 (64)
a 
8/14 (57) 8/14 (57) 3/14 (21) 3/14 (21) 4/14 (29) 
Methotrexate  4/14 (28) 3/14 (21) 4/14 (28) 8/14 (57) 8/14 (57) 8/14 (57) 
Anti-TNF-α 2/14 (14) 4/14 (28) 4/14 (28) 2/14 (14) 1/14 (7 5/14 (36) 
Glucocorticoids 3/14 (21) 2/14 (14) 1/14 (7) 2/14 (7) 3/14 (21) 3/14 (21) 
EEN  0/14 (0) 0/14 (0) 0/14 (0) 2/14 (14) 1/14 (7) 1/14 (7) 
Surgery n (%) 2/14 (14) 2/14 (14) 0/14 (0) 2/14 (14) 1/14 (0) 1/14 (0) 





4.4.3 Anthropometric characteristics  
Table 4-2 summarises median (ranges) changes of anthropometric and pubertal outcomes 
in rhGH compared to control group at each time point of study interval and figure 3-2 
show individual data. At baseline, Ht SDS in rhGH group was significantly below zero 
(p=0.000), below their MPH SDS (p=0.00) and below control group (0.001). All children 
in the rhGH group grew at subnormal rate prior to starting rhGH therapy and showed 
significant improvement in HV; at 12 months representing a median percentage increase of 
143.0% (32.0, 587.0). At baseline, Ht SDS in control was significantly below zero 
(p=0.000), below their MPH SDS (p=0.01) and there was a trend toward decrease HV at 
24 months (p=0.13 vs. baseline). The median percentage of HV in control group at 12 
months was 0.6% (-70.0, 85.0) (p=0.72). 
In the rhGH group there was a signficant fall in median Ht SDS from -2.5 (-3.9, -1.0) at 12 
months prior starting rhGH therapy to to -2.8 (-3.8, -1.4) at baseline (basline vs. 12 months 
prior to satring rhGH, p=0.03), median Ht SDS increased signficantly at 12months (12 
months vs. baseline, p=0.002) and at 24 months (24 months vs. baseline, p=0.002). The 
increase in Ht SDS in the rhGH group was associated with an increase in SH SDS from -
2.2 (-4.1, -1.2) at baseline to -1.8 (-3.8, -1.2) (12 months vs. baseline, p=0.012) at 12 
months and to -1.8 (-2.8, -0.7) (24 months vs. baseline, p=0.012) at 24 months. 
Corresponding increase in SILL SDS which was -2.1 (-4.2, -0.8) at baseline, -1.4 (-3.7, -
0.02) at 12 months (12 months vs. baseline, p=0.004) and -1.3 (-3.4, 1.2) at 24 month (24 
months vs. baseline, p=0.004). In the control group, median Ht SDS remained unchanged 
at baseline, 12 and 24 months respectively. Although at baseline, Ht SDS of the rhGH 
group was significantly lower than the control group [vs. controls, p=0.66], by 24 months 
there was no significant difference between the two groups [vs. controls, p=0.66].  
In rhGH group, median ΔHt SDS increased signficantly at 12 months (12 months vs. 
baseline, p=0.004) and at 24 months (24 months vs. baseline, p=0.004). In the control 
group, ΔHt SDS remained unchanged during study interval. 
 





4.4.4 Body mass index, puberty & skeletal maturation 
At baseline, median BMI SDS in the rhGH was significantly lower than the control group 
(rhGH vs. controls, p=0.04) and remained unchanged in both groups. Of the 14 children in 
the rhGH group, 8 (57%) showed pubertal progression at 24 months whereas 2 out of the 
11 (18.1%) who had puberty assessed showed pubertal progression in the control group 
(Table 4-2). Median (range) BA at baseline, 12 and 24 months was 13.2 years (8.0, 14.4), 
13.8 years (8.0, 15.2) and 14.8 years (10.1, 16.7) respectively. At baseline, median (range) 
of BA in rhGH group was not different from chronological age of control (rhGH vs. 
controls, p=0.51). Similarly, 24 months values was not different (rhGH vs. controls, 
p=0.41). Median BA delay in rhGH group at baseline, 12 and 24 months was 1.5 years 
(0.4, 3.9), 2.2 years (0.1, 4.2) (12 months vs. baseline, p=0.06) and 1.8 years (-0.3, 3.9) (24 
months vs. baseline, p=0.14), respectively. 




Table  4-2: Change in anthropometric measurements, body mass index and puberty over 24 months 
Data presented as number; median (range). MPH SDS, mid-parental height SD score; Ht SDS, height SD score; ΔHt SDS, change in height SD score; HV, height velocity; BMI SDS, 
body mass index SDS.
 a 
pvalue<0.05 (rhGH group vs. control), 
b
 p value<0.05 (baseline vs. 12 months), 
c 
p value <0.05 (baseline vs. 24months)  
 
  rhGH  Control 
 Baseline 12 Months 24 Months  Baseline 12 Months 24 Months 
MPH SDS -0.5 
(-1.2, 0.1) 
   -0.6 
(-2.1, 1.4) 
  


































































Pre-pubertal  3/14 3/14 2/14  4/12 4/12 4/11 
Mid-pubertal 10/14 5/14 3/14  5/12 4/12 3/11 
Late pubertal 1/14 6/14 9/14
d




























Figure  4-2: Individual change in anthropometric in rhGH (left) and the control (right) group. 
HV, height velocity (cm/years); Ht SDS, height SD score; ΔHtSDS, change in height SD score. Red solid 
lines represent the median values. Black dotted lines represent the 50th centile (0SDS), 3rd (-2SDS) and 97th 









Baseline 12 months 24 months Baseline 12 months 24 months 













Figure 4-3 individual data of plasma IGF-1 SDS. Median plasma IGF-1 SDS adjusted for 
BA increased from -2.7 (-3.7, 2.9) at baseline to 0.3 (-2.1, 2.4) (12 months vs. baseline, 
p=0.014) at 12 months and to -0.6 (-3.1, 3.1) (24 months vs. baseline p=0.12) at 24 
months. The proportion of IGF-1 SDS <-2 was 8 /11 at baseline decreased to 1/11 at 12 
months (12 months vs. baseline, p=0.004) and 2/11 at 24 months (24 months vs. baseline 
p=0.02) respectively. At baseline, 12 and 24 months, no correlation observed between 
IGF-1 SDS with disease biomarkers (ESR, CRP, and albumin) or with Ht SDS. Similarly, 
no association observed between 12 months change in IGF-1 SDS with HV or Δ Ht SDS at 
12 months. To be noted three participants had their IGF-1 value at baseline and 12 months 
and no 24 months data were available [(IGF-1 SDS: ID-1 baseline (-2.8), 12 months (1.5); 






























Figure  4-3: Individual changes in serum insulin like growth factor-1 SD score in rhGH 
following therapy with rhGH therapy. 
Red solid lines represent the median values. Black dotted lines represent the 50th centile (0SDS), 3rd (-
2SDS) and 97th (2SDS) centile. *indicate statistical significance (p<0.05). 
 
 








4.4.6 Metabolic status 
Table 4-3 summarises median (ranges) changes of glucose homeostasis and lipid status in 
rhGH at each time point of study interval and figure 4-4, shows individual data of fasting 
insulin, HOMA-IR and figure 4-5, shows individual data of OGTT. Median glucose, 
HbA1c, cholesterol and triglycerides remained unchanged over the 24 months. Despite an 
increase in median fasting insulin, C-peptide and HOMA-IR, median values remained 
within the normal reference range. No significant results observed in parameters of glucose 
homeostasis by sorting the participants according to ESR. 
 One participant, a 14.9-year-old boy who had a fasting insulin level (19 mU/l), within the 
reference range at baseline (Tanner stage-2; BMI SDS, 0.3; ESR, 26.0), who had not 
received GC throughout the study period developed hyperinsulinemia (24 mU/l) at 24 
months (tanner stage-5; BMISDS, 1.5; ESR, 21.0) with normal OGTT (Fasting glucose 5.6 
mmol/l, 2 hour 7.3 mmol/l and HbA1C (5.2%)). This participant was followed up 5 years 
after stopping rhGH therapy and he did not develop diabetes.  
None of the 11 rhGH treated children who had an OGTT at 24 month was found to have 
asymptomatic diabetes mellitus. One participant, a 14.7-year-old girl at baseline (B3; BMI 
SDS, -1.1), who had not received GC throughout the study period and who had a normal 
OGTT at baseline (fasting glucose 5.1 mmol/l; 2-hr glucose 6.5 mmol/l; fasting insulin 11 
mU/L) developed impaired glucose tolerance (fasting glucose 4.7 mmol/L; 2-hr glucose 9 
mmol/L; fasting insulin 11.3 mU/L) at 12 months (B5; BMI SDS, -1.2; ESR, 9.0). By 24 
months, her OGTT normalised (fasting glucose 4.6 mmol/l; 2-hr glucose 3.5 mmol/l; 
fasting insulin 9.1 mU/L) with no change in rhGH dose. At baseline, 12 and 24 months no 








Table  4-3: Glucose homeostasis and lipid status following therapy with rhGH 
Data presented as median (range); n, number. HbA1C (%), glycosylated haemoglobin; HOMA-IR, the 
homeostatic model assessment. Values in bold indicate statistical significance (p <0.05). 
 
Baseline 12 Months 24 Months 
p-values 
Baseline vs.  
12 months  
Baseline vs 
24months 
























































HOMA-IR ≥4.5(n) 1 0 1   














Oral Glucose Tolerance Test  
(n, 11) 
    
Fasting Glucose (mmol/l) 



















































Figure  4-4: Individual change in fasting insulin (left), HOMA-IR (right). 
HOMA-IR, the homeostatic model assessment following therapy with rhGH therapy. Red solid lines 
represent the median values. Blue filled circles represent fasting insulin data for participants who stayed at 
tanner stage 1-2 at 24 months, grey filled circles represent fasting insulin data for participants who were at 
tanner stage 3-4 at 24 months and black filled circles represent fasting insulin data for participants who were 
at tanner stage 5 at 24 months. Black dotted lines represent the cut-off point of fasting insulin and HOMA-IR 
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Figure  4-5: Individual change in fasting glucose (left), 2 hour glucose (right) after oral glucose 
tolerance test following therapy with rhGH therapy. 
Red solid lines represent the median values. Black dotted lines represent the cut-off point of definition of 
impaired glucose tolerance to the International Society for Paediatric and Adolescent Diabetes Clinical 
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4.5 Discussion  
To date, several short-term studies of rhGH up to 12 months, suggest that rhGH therapy 
can promote short term growth in children with CD (258-263). The extended period of 
study in this current report clearly shows that in these children, rhGH therapy for 24 
months at a dose of 67 mcg/kg/day leads to a sustained improvement in growth.  
Increasingly, an adequate growth response to growth promoting therapy is defined as ∆Ht 
SDS of greater than +0.3 or +0.5 over the first 12 months of the intervention (283). In the 
current study, the median ∆Ht SDS at 12 and 24 months was +0.6SDS and +0.5SDS, 
respectively. These data are comparable to a previous open label non-randomised study in 
7 children with IBD using rhGH, 50mcg/kg/day, for 12 months (261). In another study that 
administered rhGH at 75 mcg/kg/day, ∆Ht SDS was +0.7SDS for the subgroup of 18 
children with CD who continued on rhGH for 12 months (259). The observed response 
was also comparable to other groups of children with chronic disease who has received 
rhGH for similar lengths of period (256;267;309). However, the key question does this 
translate into an increase in final height? Still remain unanswered. 
Pubertal status is a potential confounder in this study. The treatment group had regular 
assessment of puberty and although puberty did progress in this group, over the two-year 
period of this study, the extent of bone age delay remained unchanged and, the increase in 
height was associated with an a proportionate increase in subischial leg length and sitting 
height suggesting that the improvement in height was not solely due to progression in 
puberty. In the historical control group, puberty was only examined in those where there 
were concerns about pubertal development thus explaining the lower percentage of 
pubertal progression in the control group. A greater proportion of controls were 
prepubertal at baseline and throughout the study. These factors could have contributed to a 
greater growth response in the rhGH-treated groups compared to controls. This 
heterogeneity in assessment makes the comparison between pubertal status weak and the 
complementary role of puberty on growth in this cohort cannot be overlooked. 
Although there were some differences between the two groups with respect to the use of 
immunomodulator therapy with azathioprine use higher in the rhGH group compared to the 
control group, it is unlikely that these differences would have influenced the different 
growth response. Whilst the use of azathioprine may lead to maintenance of remission, it is 
unclear if its use or timing of introduction in CD has a positive impact on linear growth 
(127). 
Although the two groups were matched for age, sex and duration of disease, the control 
group was not matched for Ht SDS as very short children around this period were all 




recruited into the rhGH therapy trial. Whilst there is a possibility that the more marked 
short stature of the rhGH group provided them with a greater potential for catch up growth, 
we believe that this does not fully explain the improvement in growth that was observed in 
the treatment group especially as the disease status was similar throughout the two year 
period. 
Besides a growth promoting effect, rhGH therapy has been reported to be associated with 
an improvement in disease status (268;269). In the current study, inflammatory markers 
were similar between both groups and remained unchanged over 24 months. The 
possibility that an improvement in disease secondary to rhGH therapy, itself, could be a 
contributing mechanism for improvement in linear growth is intriguing and would require 
a more detailed assessment of disease activity in future studies.  
Patients with chronic inflammation are known to display insulin resistance (305) and this 
has also been observed previously in those with CD who received rhGH therapy (262). 
Therapy with even higher doses of rhGH at 75mcg/kg/day for one year in children with 
CD was associated with a rise in fasting insulin level without impairment in glucose 
tolerance (259). Whilst HOMA-IR rose with rhGH treatment in our cohort, this was not 
deemed clinically significant based on current consensus guidelines (307). The increase in 
HOM-IR was not associated with impaired glucose tolerance and was not as marked as 
observed in children with JIA at the same dose of rhGH (264). Nevertheless, we believe 
close monitoring of glucose homeostasis is required. 
Finally, our results suggest that rhGH therapy might be associated with sustained 
improvement in linear growth in short pubertal children with mild or inactive CD. 
However, the current study was limited to a relatively small group of cases and historical 
controls hamper drawing firm conclusion. Thus, the results will be important to confirm in 
a larger group of subjects. 
 
4.6 Conclusion  
In conclusion, the results of our study indicate that the growth promoting effect of rhGH in 
children with CD that we previously observed over a period of 6 months is sustained over a 
longer period and this finding needs to be confirmed in a randomised clinical trial. In the 
meantime, the use of rhGH in children with CD and growth retardation needs to be 
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5.1 Abstract  
Background: Data on bone mineral density (BMD) in children and adolescents with CD 
during rhGH treatment are not available. 
Aims: To determine the effects of prolonged rhGH therapy on BMD by DXA of total body 
and lumbar spine.  
Study design and subjects: Prospective study of eight children with CD (six male), aged 
9 - 16.4 (median 14.8) years who were in puberty and received rhGH (67 mcg/kg/day) for 
24 months. 
Main outcomes: BMD by DXA (TB and LS) were measured at baseline, 6 months, 12 
months and 24 months following rhGH therapy. DXA bone outcomes are expressed as sex, 
race, bone-age or height-age specific standard deviation scores (SDS) and compared with 
reference data. TB-lean mass and fat mass were measured by DXA and adjusted for sex 
and height. A biomarker of bone formation, P1NP, was measured in fasting blood and 
adjusted for sex and bone age. A biomarker of bone resorption, CTX, was measured in 
urine and reported as absolute values.  
Results: At baseline, CD participants were short and had low TB-BMD, LS-BMD, LS-
BMAD and TB-LM SDS. Based on wPCDAI: at baseline, 4/8 were in remission and 3/8 
had mild disease; by 6 months, 5/8 were in remission and 3/8 had mild disease, and at 24 
months, 4/8 were in remission and 4/8 had mild disease. Three out of eight participants 
were on GC at baseline, 2/8 were on GC at 6 months, and 1/8 at 24 months. At 6 months, 
P1NP levels increased a median of 24% (0.0, 1048.0) (p=0.02) and urinary CTX a median 
of 37% (9.0, 450.0) (p=0.04). Twenty-four months following rhGH therapy, participants 
showed significant improvement in height and 6/8 completed their pubertal growth. TB-
BMD, LS BMD and LS BMAD remained unchanged at 24 months. 
Conclusion: These data demonstrate persistent musculoskeletal deficits in children with 






5.2 Introduction  
Bone mass deficits are well described in children with CD (289). The intact GH-IGF1 
pathway is a critical regulator of linear growth, osteoblast function, bone homeostasis and 
ultimately bone mass (73-75;284). In children with CD, systemic markers of the GH-IGF-1 
axis are altered, suggesting that many may exhibit a range of functional GH insufficiency 
and resistance (101). In accordance with an anabolic effect of GH, previous studies on 
rhGH therapy in children with chronic inflammation such as JIA showed that, in addition 
to an increase in height, GH also has a positive effect on bone health and body composition 
(265;266;310). RhGH therapy may help to reduce detrimental effects of CD on bone health 
and muscle. However, the effect of rhGH on bone health in CD has scarcely been studied 
(260;261). Furthermore, there are no data on the long-term consequences of GH treatment 
on bone and body composition in paediatric CD. As an initial test of the hypothesis that 
GH treatment may increase BMD in children with CD, we carried out a small, preliminary 
pilot study to assess the changes in biomarkers of bone metabolism and bone mineral 
density in children with CD and growth retardation who received rhGH treatment for two 
years. 





5.3 Methods  
5.3.1 Study population 
Eight out of thirteen children with CD (6male), who received rhGH at a dose of 67 
mcg/kg/day as part of a six-month RCT at the Royal Hospital for Sick Children Glasgow 
(262) were studied for bone biomarkers and bone health by DXA. The participants at the 
Liverpool site were not included for the bone health assessment study as it was not feasible 
to conduct DXA scans at that location. Of the 13 children, rhGH was discontinued due to 
completion of linear growth (n=2), lost to follow-up (n=1), needle phobia (n=1) and post-
colectomy in a child with UC (n=1). rhGH dose was adjusted for weight at each visit. 
Disease phenotype was classified using the Montreal criteria (5). 
The original clinical trial was approved by the UK Multicentre Research Ethics 
Committee, and its conduct was approved by the Health Boards. Written informed consent 
was obtained from all parents and patients as appropriate for those patients on rhGH.  
 
5.3.2 Study parameters and biochemical markers of disease and growth 
Data on therapeutic interventions, anthropometry, puberty and disease biomarkers were 
collected and reported at baseline, 6 months, 12 months and 24 months as described 
previously in Chapter 4. Disease activity was assessed by wPCDAI as previously described 
in Chapter 2. Cut-off points for categorising the participants according to disease status, or 
GC exposure were defined as detailed in Chapter 2 and adapted in this chapter to 
categories DXA outcomes. To investigate the impact of pubertal progress on BMD and 
LM the participants were categorised based on pubertal status at 24 months as follows: 
stayed pre-pubertal (Tanner stage 1; n=1); progressed from pre-pubertal to early puberty 
(Tanner stage 2-3; n=1); completed their pubertal growth (Tanner stage 5; n=6). 
 
5.3.3 DXA outcomes 
DXA data were available for eight participants at baseline, 6 months, 12 months and 24 
months. DXA scans acquisitions and analyses were described previously in Chapter 3. We 
adjusted for size using Ht-age and adjusted for skeletal maturation using BA for TB and 
LS using GE Lunar paediatric reference data of over 2000 US children (5-19 years). Body 
composition was adjusted for height using our local reference data of 201 (140 male) 




children aged between 5-19 years. Bone mineral apparent density (BMAD) was calculated 
for LS and was adjusted to bone age (311). 
 
5.3.4 Bone biomarkers  
Biomarkers of bone turnover were measured at baseline and 6 months. A biomarker of 
bone formation, serum P1NP, was analysed in fasting blood with a radioimmunoassay kit 
(Intact P1NP; Orion Diagnostica, Finland) with inter- and intra-assay CVs of 7.8% and 
8.3%, respectively. Gender and pubertal variation were adjusted for using published 
reference data (312). A biomarker of bone resorption, CTX-1, was measured in first 
morning voided urine with an enzyme immunesorbent assay (Immunodiagnostic Systems, 
UK) with inter- and intra-assay CVs of 4.3% and 6.9%, respectively. No reference data 
were available for urinary CTX-1. 
 
5.3.5 Statistics  
Analyses were performed using SPSS software version 22 (New york, USA). Non-
parametric data presented with medians and ranges. Changes between parameters were 
assessed at different time points analysed using repeated measure with Wilcoxon signed-
rank tests and subsequently adjusted for multiple comparison using a Bonferroni 
correction. Spearman
’
s correlation coefficient was used to assess univariate relationship 
between continuous variables. SPSS mixed modelling was employed to explore the 
confounding effects of independent variables (IGF-1 SDS, wPCDAI, GC exposure, and 
TB-LM SDS) on TB-BMD and LS-BMD over the 24 months period. p<0.05 was 
considered as statistically significant. All graphs performed by GraphPad Prism software 
version 7(San Diego California, USA). 
 





5.4 Results  
5.4.1 Participant characteristics  
Table 5-1 summarises the characteristics of the eight CD participants at the time of starting 
rhGH. The median (range) age at diagnosis of CD and age at rhGH initiation was 10.1 
years (6.0, 13.8) and 14.8 years (9.0, 16.4) with median interval since diagnosis of 3.3 








Table  5-1: Participant characteristics at time of starting rhGH therapy 
Data presented as number, n; percentage, %, median (range). CA, chronological age; BA, bone age; Ht SDS, 
height SDS score; BMI SDS, body mass index SDS score. 
  CD (n, 8) 
Male, n (%) 6 (75%) 
CA at Diagnosis (year) 10.1 (6.0, 13.8) 
CA at starting rhGH (year) 14.8 (9.0, 16.4) 
Duration of disease 3.3 (0.6, 10.1) 
BA at starting  rhGH (year) 13.3 (8.0, 14.4) 
BA delay (year) 1.3 (-0.4, 2.2) 
Tanner stage, n (%)  
Pre-puberty (tanner stage-1) 2 (25) 
Mid-puberty (tanner stage 2-3) 5 (63) 
Late puberty (tanner stage 4-5) 1 (12) 
Ht SDS at starting rhGH -2.4 (-3.3, 1.4) 
BMI SDS at starting rhGH -0.5 (-1.5, 0.3) 
Disease location, n (%)  
Ileal (L1) 2 (25) 
Colonic (L2) 4 (50) 
Ileocolonic (L3) 2 (25) 
Isolated upper disease(L4) 2 (25) 
Behaviour (non-stricturing, non-penetrating) 
8 (100) 
Perianal  4 (50) 





5.4.2 Disease, treatment characteristics and anthropometry 
Table 5-2 summarises disease, treatment characteristics and anthropometry in eight CD 
participants at each visit. At baseline, based on wPCDAI, 4/8 (50%) participants were in 
remission, 3/8 (38%) had mild CD, 1/8 (12%) had moderate CD and none (0%) had severe 
CD. At 6 months and 24 months, all participants had quiescent disease (remission: n=4; 
mild disease: n=4). Three out of eight (38%) participants were on GC at baseline, 2/8 
(25%) at 6 months and 1/8 (12%) at 24 months.  
The percentage of participants with Ht SDS below the minimum reference range (Ht SDS 
≤ -2) decreased from 6 (75%) at baseline to 3 (38%) at 12 months and 3 (38%) at 24 
months. At baseline, 6/8 participants had entered puberty and 5/6 of participants were in 
mid-puberty. At 6 months, only one participant showed pubertal progress, from G2 to G4. 
However, 6/8 participants were in the late pubertal stage at 24 months. At baseline, the 
median (range) BA was 13.3 years (8.0, 14.4) (BA vs. CA, p=0.16), 14.1 years at 6 
months, 14.5 years (8.0, 15.2) at 12 months and 15.3 years (10.1, 16.7) (BA vs. CA, 
p=0.23) at 24 months. Interestingly, we found that the bone age of those who were in late 
puberty at 24 months was ≥ 14.5 years for males and ≥ 13.5 years for one female. The BA 
of one male in early puberty was 10.1 and that of one female in pre-puberty was 11.2. 
 




Table  5-2: Changes in disease activity, laboratory results, and treatment over the study interval 
Data presented as number, n; median (range). wPCDAI, weighted paediatric disease activity index; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; Ht SDS, height SD 
score; BMI SDS, body mass index SD score. Values in bold indicate statistical significance (p<0.05). 
 n, 8 Baseline 6 Months  12 Months 24 Months p-values 
Baseline vs.  




24 months  
wPCDAI 17.5 (0.0, 53.0) 7.5 (0.0, 35.0) 7.5 (0.0, 20.0) 13.7 (0.0, 25.0) 0.18 0.11 0.25 
Remission  4/8 5/8 6/8 4/8       
Mild disease  3/8 3/8 2/8 4/8       
Moderate 1/8 0 0 0       
ESR (mm/hr) 24.0 (7.0, 53.0) 24.0 (4.0, 41.0) 21.5 (3.0, 30.0) 16.5 (5.0, 48.0) 0.49 0.14 0.78 
CRP (mg/l) 8.0 (7.0, 42.0) 7.0 (7.0, 25.0) 7.0 (7.0, 20.0) 9.0 (3.0, 35.0) 0.50 0.56 0.23 
Albumin (g/l) 35.0 (20.0, 44.0) 35.0 (25.0, 39.0) 37.0 (19.0, 41.0) 37.0 (30.0, 39.0) 0.83 0.91 0.23 
Medication 
Glucocorticoids 3/8 2/8 1/8 1/8     
Aminosalicylates 2/8 2/8 2/8 2/8      
Mercaptopurine/Azathioprine 4/8 5/8 5/8 4/8    
Methotrexate 4/8 2/8 2/8 3/8      
Anti-TNF-α  2/8 3/8 1/8    
Exclusive enteral nutrition 0 1/8 0- 0      
Anthropometry 
Ht SDS -2.4 (-3.3, -1.4) -1.9 (-3.0, -1.2) -1.4 (-2.9, -0.81) -0.9 (-2.4, -0.2) 0.05 0.035 0.035 
HV (cm/year) 3.4 (0.6,8.4) 9.1 (6.1, 11.6) 7.8 (5.9, 9.7) 6.9 (2.0, 11.3) 0.036 0.036 0.21 
BMI SDS -0.5 (-1.5, 0.3) -0.6 (-1.45, 0.31) -0.3 (-2.3, 0.73) -0.8 (-1.7, 1.5) 0.89 0.48 0.87 
Pre-puberty  2/8 2/8 1/8 1/8    
Early-puberty 5/8 4/8 2/8 1/8    
Late- puberty 1/8 2/8 5/8 6/8    




5.4.3 DXA bone outcomes  
Table 5-3 summarises the DXA bone outcomes at baseline, 6months, 12 months and 24 
months among eight participants and Figure 5-2, shows individual data. At baseline, 
overall TB-BMD SDS Ht-age (p=1.00) was not different from zero while, TB-BMD SDS BA 
(p=0.010), LS-BMD SDS Ht-age (p=0.01), LS-BMD SDS BA (p=0.00) and LS-BMAD SDS 
BA (p=0.010) were below zero. No significant improvement was found in BMD at any of 
the measurement sites during follow-up. In a sub-analysis of disease status, GC exposure 
or pubertal progress, no significant results were found (Tables 5-4, 5-6 and 5-7).





Table  5-3: DXA bone outcomes at baseline, 6 months, 12 month and 24 month following rhGH therapy 
Data presented as median (range). TB, total body; BMD, areal bone mineral density; BMAD, bone mineral apparent density; SDS Ht-age, adjusted for 
height age and sex; SDS BA, adjusted for bone age and sex; LS, Lumbar spine.  







DXA (n, 8) (n, 8) (n, 8) (n, 8)    
TB-BMD SDS Ht-
age 
0.1 (-2.3, 0.7) -0.4 (-1.9, 0.3) -0.7 (-2.2, 0.4) -0.7 (-2.2, 0.1) 0.19 0.06 0.16 
TB-BMD SDS BA -1.0 (-1.9, 0.1) -1.1 (-2.0, -0.2) -1.0 (-2.4, 0.0) -1.2 (-1.7, -0.3) 0.12 0.21 0.57 
LS-BMD SDS Ht-age -1.1 (-2.9, 0.6) -1.4 (-2.0, 0.4) -1.3 (-2.2, 0.7) -0.8 (-2.9, 0.6) 0.94 0.73 1.00 
LS-BMD SDS BA -1.7 (-3.0, -0.2) -1.8 (-2.2, -0.2) -1.6 (-2.8, 0.2) -1.9 (-2.4, 0.1) 0.42 0.18 0.73 
LS-BMAD SDS BA -1.1(-3.6, 0.8) -0.9 (-2.1, 0.9) -0.7 (-2.3, 1.5) -0.9 (-1.6, 0.5) 0.89 0.15 0.49 












































Figure  5-1: Individual changes in DXA bone outcomes at baseline, 6 months 12months and 
24months following rhGH therapy 
TB, total body; BMD, areal bone mineral density; BMAD, bone mineral apparent density; SDS Ht-age, adjusted 
for height age and sex; SDS BA, adjusted for bone age and sex; LS, lumbar spine. Black solid circle represents 
participants who had mild disease (based on wPCDAI) and progressed in puberty at 24 months, red solid 
circle represents participants who had remission and progressed in puberty whereas red sold triangle had 
remission and stayed at tanner stage 1 at 24 months. Red solid lines represent the median values. Black 
dotted lines represent the 50th centile (0SDS), 3rd (-2SDS) and 97th (2SDS) centile. *indicate statistical 
significance (p<0.05). 
Mild disease (pubertal progression)  
Remission (pubertal progression)  
Remission (no pubertal progression)  
Baseline 6months 24 months 12 months 
SDS 
LS-BMD SDS BA 
Baseline 6months 24 months 12 months 
LS-BMD SDS Ht-age 
SDS 
SDS 
Baseline 6months 24 months 12 months 
LS-BMAD SDS BA 
Baseline 6months 24 months 12 months 
TB-BMD SDS BA 
SDS 
Baseline 6months 24 months 12 months 
SDS 
TB-BMD SDS Ht-age 




Table  5-4: DXA bone outcomes at baseline, 6 months, 12 months and 24 months following rhGH. Participants divided according to wPCDAI at 24 months. 
Data presented as median (range). TB, total body; BMD, areal bone mineral density; BMAD, bone mineral apparent density; SDS Ht-age, adjusted for height age and sex; SDS BA, 
adjusted for bone age and sex; LS, lumbar spine.  


















0.58 0.20 1.0 




















0.71 1.00 0.41 




















1.00 0.47 0.59 




















0.18 0.18 0.29 








1.0 0.28 0.71 
LS-BMAD SDS BA 








0.47 0.20 0.29 








0.71 0.27 1.00 




Table  5-5: DXA bone outcomes at baseline, 6 months, 12 months and 24 months following rhGH. Participants divided according to glucocorticoid use. 
Data presented as median (range).TB, total body; BMD, areal bone mineral density; BMAD, bone mineral apparent density; SDS Ht-age, adjusted for height age and sex; SDS BA, 
adjusted for bone age and sex; LS, lumbar spine; GC, glucocorticoid; +/- ID-1, glucocorticoid at baseline and stopped before 6 months; +/- ID-2, glucocorticoid at baseline and stopped 
after 6 months; GC+/+, glucocorticoid throughout the study period.  
n, 8 Baseline 6 Months 12 Months 24 Months p-values 




GC naïve (n, 5) 0.4 (-2.3, 0.5) -0.2 (-1.9, 0.3) -0.8 (-2.2, 0.4) -0.5 (-1.6, 0.1) 0.28 0.10 0.50 
GC +/- (ID-1) -0.2 -0.6 -0.5 0.1    
GC+/- (ID-2) -0.9 -1.0 -1.6 -2.2    




GC naïve (n, 5) -1.0 (-1.9, 0.1) -0.6 (-2.0, -0.2) -0.6 (-2.4, 0. 0) -1.1 (-1.5, -0.3) 0.50 0.50 0.85 
GC +/- (ID-1) -1.1 -1.5 -1.2 -1.2    
GC+/- (ID-2) -1.0 -1.4 -1.5 -1.7    




GC naïve (n, 5) -1.0 (-2.9, 0.6) -1.5 (-1.6, 0.4) -1.6 (-2.2, 0.7) -0.7 (-2.3, 0.6) 0.68 0.89 1.0 
GC +/- (ID-1) -1.4 -1.2 -1.0 -0.9    
GC+/- (ID-2) -1.5 -2.0 -02.0 -2.9    




GC naïve (n, 5) -1.7 (-3.0, -0.2) -1.5 (-2.2, -0.2) -1.5 (-2.8, 0.2) -1.5 (-2.2, 0.1) 0.41 0.19 0.72 
GC +/- (ID-1) -2.2 -2.2 -1.7 -2.4    
GC+/- (ID-2) -1.6 -2.0 -1.9 -2.3    




GC naïve (n, 5) -0.8 (-3.6, 0.8) -0.7 (-2.1, 0.9) -0.6 (-2.3, 1.5) -0.7 (-1.6, 0.5) 0.89 0.23 0.14 
GC +/- (ID-1) -1.5 -1.6 -1.1 -1.5    
GC+/- (ID-2) -0.9 -1.1 -0.8 -1.2    
GC+/+ (ID-3) -1.5 -0.6 -0.6 0.03    




Table  5-6: DXA bone outcomes at baseline, 6 months, 12 months and 24 months following rhGH. Participants divided into two groups based on pubertal 
status at 24 months 
Data presented as median (range). TB, total body; BMD, areal bone mineral density; BMAD, bone mineral apparent density; SDS Ht-age, adjusted for height age and sex; SDS BA, 
adjusted for bone age and sex; LS, lumbar spine.
n, 8 Baseline 6 Months 12 Months 24 Months p-values 
Baseline vs. 
 6 months 
Baseline vs. 
 12 months 
Baseline vs. 












0.08 0.08 0.12 
Early-puberty (ID-3) 0.7 -0.1 -0.2 -0.8    









(-2.0, 0. 0) 
-1.2 
(-1.7, -0.3) 
0.24 0.46 0.34 
Early-puberty (ID-3) -0.4 -0.7 -0.7 -1.3    












0.14 0.34 0.23 
Early-puberty (ID-3) -1.1 -0.3 -0.5 -0.2    












0.41 0.14 0.53 
Early-puberty (ID-3) -1.7 -0.7 -0.8 -0.7    
Pre-pubertal (ID-7) -3.0 -2.0 -2.8     
                                LS-BMAD SDS 
BA
  








0.17 0.17 0.12 
Early-puberty (ID-3) -1.5 -0.6 -0.6 0.03    
Pre-pubertal (ID-7) -3.6 -2.1 -2.3 -    





5.4.3.1 Correlation of DXA bone outcomes with disease and anthropometry 
At baseline, 6 months, 12 months and 24 months no significant correlation was observed 
between BMD at different sites by using different methods of adjustment and disease 
biomarkers (ESR, CRP) or disease duration. At 6 months, significant negative correlation 
was observed between wPCDAI with LS-BMD SDS Ht-age (r=-0.77, p=0.044) and LS-BMD 
SDS BA (r=-0.91, p=0.006). At 24 months, significant negative correlation was observed 
between wPCDAI and TB-BMD SDS BA (r=-0.84, p=0.018).  
At baseline, 6 months, 12 months and 24 months no significant correlation was observed 
between BMD at different sites by using different way of adjustment and Ht SDS. 
Similarly, no significant correlation was observed 24 months change in BMD at different 
site by using different way of adjustment and 24 months change in Ht SDS. 
 





5.4.4 Whole body composition outcomes by DXA  
Table 5-6 summarises the DXA body composition outcomes at baseline, 6 months, 12 
months and 24 months among of eight participants with result of each visit limited to those 
with a 24 months visit to facilitate comparisons across the visits. Figure 5-8 shows 
individual data. At baseline, participants had low TB-LM SDS but were not significantly 
different from zero (p=0.11) and remained unchanged during the study. The median TB-
FM SDS was also not significantly different from zero (p=1.0) and remained unchanged. 
At baseline, 6 months, 12 months and 24 months no significant correlation was observed 
between TB-LM SDS  and disease biomarkers (wPCDAI, ESR, CRP, albumin) or duration 
of disease. At baseline, significant positive correlation was observed between TB-FM SDS 
and CRP (r=-0.87, p=0.012) but no significant correlation was observed between TB-FM 
SDS and other disease biomarkers or disease duration. At 6 months, 12 months and 24 
months no significant correlation was observed between TB-FM SDS and disease 
biomarkers (wPCDAI, ESR, CRP, albumin). 
At baseline and 6 months no significant correlation was observed between TB-LM SDS 
and bone parameters measured by DXA. At 12 months, significant positive correlation was 
observed between TB-LM SDS with TB-BMD SDS Ht-age (r=0.83, p=0.010) and LS-BMD 
SDS Ht-age (r=0.74, p=0.035). At 24 months, significant positive correlation was observed 












Table  5-7: Change in body composition by DXA, at baseline, 6 months, 12 months and 24 months following rhGH therapy 




  Baseline 6 Months  12 Months 24 Months                              p-values  
Baseline vs.  
6 months 
Baseline vs. 
 12 months 
Baseline vs. 
 24 months 
DXA (n, 8) (n, 8) (n, 8) (n, 8)    
TB-LM SDS -0.8 (-2.4, 3.0) -0.4 (-1.2, 0.1) -0.6 (-2.3, 0.5) -1.0 (-2.0, 0.1) 0.41 0.89 0.21 
TB-FM SDS 0.04 (-0.6, 1.8) -0.5 (-0.7, 0.8) -0.6 (-0.9, 0.3) -0.2 (-0.8, 1.4) 0.13 0.16 0.78 
















Figure  5-2: Individual changes in body composition by DXA at baseline, 6 months, 12 months and 24 months following rhGH therapy 
TB, total body; LM SDS, lean mass adjusted for height and sex. FM, fat mass adjusted for height and sex. Black solid circle represents participants who had mild disease (based on 
wPCDAI) and progress in puberty at 24 months, red solid circle represents participants who had remission progress in puberty whereas red sold triangle had remission and stayed at 
tanner stage 1 at 24 months. Red solid lines represent the median values. Black dotted lines represent the 50th centile (0SDS), 3rd (-2SDS) and 97th (2SDS) centile.  
Baseline 6months 24 months 12 months 
SDS TB-FM SDS 
Mild disease (pubertal progression)  
Remission (pubertal progression)  
Remission (no pubertal progression)  
Baseline 6months 24 months 12 months 
TB-LM SDS SDS 




5.4.5 Bone biomarkers  
There was a significant median percentage change of P1NP from baseline to 6 months of 
24% (0, 1048) (p=0.02), and of CTX from baseline to 6 months of 37% (9, 450) (p=0.04). 
At baseline, P1NP SDS was -3.6 (-7.9, -0.9) and it increased significantly to -2.4 (-3.7, 0.4) 
at 6 months (p=0.012). At 6 months, P1NP SDS improved in six participants, while 
participants 4 and 6 remained unchanged (Figure 5-1). The median (range) of urinary CTX 
significantly increased from 6625 μg/l (1800, 8780) at baseline to 9800 μg/l (6620, 9900) 
at 6 months (p=0.028). The median IGF-1 SDS was -2.7 (-3.7, 2.9) at baseline and to -2.8 
(-3.7, 4.1) at 6 months (p=0.78), and to 1.5 (-2.5, 2.4) at 12 months (12 months vs. 
baseline, p=0.10) and -1.4 (-2.2, 3.1) at 24 months (24 months vs. baseline, p=0.40). Apart 
from participants 3 and 5, IGF-1 SDS remained unchnaged (Figure 5-1) 
 



















Figure  5-3: Individual changes in P1NP SDS (right) and IGF-1 SDS (left)  
Baseline (black columns) and 6 months (grey columns) following therapy with rhGH therapy. P1NP, 
procollagen type 1 N-terminal propeptide; IGF-1 SDS, insulin like growth factor-1; SDS, SD score adjusted 
for sex and bone age; G1or B1, tanner stage 1; G2, tanner stage 2; G3or B3, tanner stage 3; G4, tanner stage 
4; G5, tanner stage 5. Participants who had remission at 6 months (based on wPCDAI) are indicated by 
arrows and the rest had mild disease at 6 months.  
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5.4.5.1 Correlation of bone biomarkers with disease, anthropometry and 
DXA bone outcomes  
At baseline and at 6 months, no significant correlation was observed between bone 
biomarkers and disease biomarkers. Similarly, no significant correlation was observed 
between bone biomarkers and height at baseline and at 6 months. No correaltion obseved 
bewtween 6 months changes in P1NP ,CTX with HV at 6 months. 
 
5.4.5.2 Correlation of bone biomarkers with DXA bone outcomes  
At baseline, significant positive correlation was observed between P1NP SDS and LS-
BMD SDS Ht-age (r=0.81, p=0.014). At 6 months no significant association was observed 
between P1NP and BMD measured by DXA. The 6 month change in P1NP SDS was not 
correlated with BMD measured by DXA at 24 months. At 6 months, a significant positive 
correlation was observed between IGF-1 SDS and LS-BMD SDS Ht-age (r=0.85, p=0.007) 
and at other time points, no significant correlation was observed between IGF-1 SDS and 
BMD by DXA.





5.4.6 Multivariate mixed-model regression analysis for DXA bone 
outcomes 
Table 5-8 displays the results of multivariate mixed-model regression analysis of the 
relationship of DXA bone outcomes with wPCDAI, GC (Yes/No), IGF-1 SDS and TB-LM 
SDS during the 24-months study interval. TB-BMD SDSHt-age was significantly positively 
associated with TB-LM SDS independent of wPCDAI, GC use and IGF-1 SDS. LS BMD 
SDS Ht-age was positively and negatively associated with IGF-1 SDS and GC exposure 
respectively. LS BMD SDS BA was positively associated with IGF-1 SDS independent of 
other confounders.  
 





Table  5-8: Mixed model assessment of the effect of inflammation, glucocorticoid use, growth biomarkers adjusted for bone age and lean mass on DXA bone 
outcomes at each time points during 24 months study 
TB, total body; BMD, areal bone mineral density; BMAD, bone mineral apparent density; BMAD, bone mineral apparent density;SDS Ht-age, adjusted for height age and sex; SDS BA, 
adjusted for bone age and sex; AP, anteroposterior; LS, lumbar spine; LM, lean mass; IGF-1 SDS, serum insulin like growth factor-1SD score; GC, glucocorticoid. Values in bold 







Dependent Variables  









































































































5.5 Discussion  
This chapter reports the results of a two-year longitudinal study of rhGH therapy on bone 
health and lean mass measured by DXA in CD children with short stature. Our data for 
first time showed that rhGH increased height, biomarkers of bone formation and resorption 
at 6 months, and persistent bone mineral density deficiency of total body and lumbar spine, 
adjusted for size and skeletal maturation. 
It is evident that inflammation has a detrimental effect on bone health in CD, and 
controlling inflammation may lead to improvement in trabecular bone, cortical structure 
and muscle mass (156;237). The disease was clinically inactive in most of our participants 
at 24 months. Participants were further categorized according to their disease status to 
examine whether rhGH therapy has a beneficial effect on those who entered remission 
compared with those who had a mild case of the disease and we found that patients with 
inactive disease still had impaired bone health. This finding confirms our initial 
observation (Chapter 3) and further emphasizes that patients with inactive CD still 
manifest impaired bone mass and muscle. It is also crucial to highlight that the disease 
duration in this small cohort was long. However, there is currently no consensus on the 
relative importance of disease duration and bone recovery and further research is needed to 
shed light on this issue. 
Apart from disease, other confounder that may influence the bone health in our cohort was 
GC exposure. The inverse association that was observed between LS BMD and GC 
exposure would be consistent with GC resulting in sustained reductions in bone formation 
due to decreased osteoblast differentiation, function, and life span and increases in bone 
resorption by osteoclasts (191;192). Although 5/8 of our small cohort of CD patients were 
not on GC during the study interval, they did not demonstrate improvement in BMD 
scores, contrary to previous reports on recovery of density with less GC exposure (153). 
However, it is challenging to identify the independent effect of GC therapy in CD. Muscle 
is another potential factor that influences bone health (299). We observed a significant 
positive association between lean muscle mass and bone in this cohort. The persistent low 
BMD observed in our participants may be related, in part, at least, to the fact that they have 
low lean mass. Thus, it seems that increased LM (for example through nutrition and 
physical activity) in combination with GH treatment would be worth further 
exploration. 
Linear growth is a major driver of periosteal apposition by which bones can increase in 
length and width leading to greater bone strength (31). Bone mass attainment, on the other 
hand, is also closely related to pubertal growth (50). Evidence from JIA data speculated on 




the beneficial effect of rhGH therapy during puberty (266;310). In our study, there was 
significant improvement in height and most of the participants (6/8) completed their 
pubertal growth during the 24-months study follow up; however, when we examined the 
sub-group who completed their puberty, no parallel improvement was observed in bone or 
muscle mass. Concurring with evidence of the change in BMD lagging behind the pubertal 
growth spurt by 0.6-0.7 years (50), we may not assume that the duration of follow-up in 
our study was insufficient to see favorable effects of rhGH on bone. 
Some available data from GH-deficient mice demonstrated that rhGH therapy commencing 
during puberty rescued the quantity of trabecular bone but not the structure (313;314). In 
addition, data from JIA children showed that rhGH therapy is associated with improvement 
in bone geometry (266). Although we have addressed the confounding effect of growth and 
skeletal maturation on BMD, our study was limited by using DXA which does not take 
into account parameters of bone strength other than bone mass. Thus, our final conclusion 
on the benefit of GH therapy on bone health in CD children cannot be definitively drawn in 
the absence of detailed study of bone microarchitecture and geometry. 
Serum IGF-1 levels is a biochemical response to rhGH and usually rises during treatment 
with rhGH (283). However, CD patients can be GH resistant (101). In fact, the observed 
persistent low systemic IGF-1 SDS despite supra-physiological doses of rhGH in those 
children suggests the possibility of partial rescue of GH resistance following rhGH 
therapy. Normalisation of IGF-1 through rhIGF-1 therapy may perhaps result in 
improvement of bone deficits and future research is needed to evaluate this. 
The current study is limited by a small sample size, lack of control, and the fact that other 
determinants of bone strength were not investigated in our cohort. Therefore, our results 
may be insufficient to make a final conclusion. Nevertheless, the current pilot study is 
important as first the study that extensively explored the long term effect of rhGH on 
biomarkers of bone turnover and BMD and body composition in this particular population. 
Thus we can only postulate that future larger studies are needed using high resolution bone 
imaging to evaluate the effect of rhGH alone and in combination with rhIGF-1 or in 
combination with exercise on bone and body composition in CD. 
 
5.6  Conclusion  
This long term study depicts that bone and muscle deficiencies persist in chronic CD 
children over 24 months of rhGH therapy. Although the biomarkers of bone turnover 
increased and most children completed pubertal growth, bone mineral density did not 
increase and this may be due to partial recovery of the GH-IGF-1 axis and/or decreased 




muscle mass. Further studies are needed to explore the effect of rhGH, targeting those with 











 Assessing the Feasibility of Injectable Growth-







Background: Despite optimal therapy, many children with CD experience growth 
retardation.  
Objectives: To assess the feasibility of performing RCT of injectable forms of growth 
promoting therapy; and to survey the attitudes of children with CD and their parents to it.  
Methods: A face to face questionnaire surveyed willingness to consent to future 
participation in the RCT. Eligibility to the survey was any young person (with their 
parent/guardian) with CD whose Ht SDS was ≤1.0. Of 118 questionnaires, 94 (80%) were 
returned (48 by young people and 46 by parents). 
Results: The median age of the patients in the survey was 14.3 years (range 7.0 to 17.7) 
and 35 (73%) were male. Median Ht SDS was -1.2 (-3.0, 0.2) and significantly lower than 
the median mid-parental Ht SDS was -0.6 (-3.1, 1.4) (p=0.003). Overall, 21 (44%) young 
people and 22 (48%) parents were willing to take part in the proposed RCT. Common 
reasons for not taking part in the RCT were either fear of injections (44%) or not 
concerned about their height (44%).  
Conclusion: Around 40% of young people and parents surveyed would take part in an 








Around one quarter of cases of CD are diagnosed in children under 18, with the incidence 
in childhood increasing (315). Growth failure is a common manifestation and may be the 
first presentation of disease (20). Despite advances in CD treatments, around 20% of 
affected children may continue to grow slowly (84) and remain short on reaching their 
final adult height (90;91). 
The cause of growth failure is multi-factorial, and includes poor nutrition, inflammation 
and corticosteroid treatment. The mechanisms involve a disturbance of GH-IGF-1 at 
peripheral and central levels (99). Although the exact mechanisms of disturbance of the 
GH-IGF-1 axis in CD are still not fully elucidated, the abnormalities may range from 
functional GH deficiency to GH resistance with low circulating IGF-1 (81;99-101). 
Current treatment is to improve growth using steroid-sparing anti-inflammatory medication 
(212). 
Preliminary evidence from the use of rhGH therapy in CD children indicates potential 
efficacy despite the expected insensitivity to GH (259;260;262). However, there are no 
RCT that investigate rhIGF-1 alone or in combination with rhGH on growth of children 
with CD. 
There are concerns with regards to the acceptability of conducting such a trial to both 
patients with CD and their families. It is important to establish whether it is feasible to 
conduct a trial of this nature. We therefore undertook a feasibility study to survey attitudes 







6.3  Methods 
A British study group collaborating with the Medicines for Children Clinical Trials Unit 
(MC- CTU) examined the feasibility of a trial of injectable growth promoting drugs with a 
view to establish an RCT. 
Two questionnaire surveys were developed for two groups; potential participants for the 
trial and their parents. These questionnaires were developed by the trial management group 
and their format was based on a successful earlier questionnaire survey by the MC-CTU 
(316). As the questionnaire was a survey on patients’ willingness to consent to a future 
trial, it did not require research ethics committee approval, which was confirmed by the 
Barts Health NHS Trust R&D office. Information sheets were written for the clinical 
teams, which included a description of the four proposed arms of the RCT: (1) treatment to 
combat inflammation; (2) added injections of rhGH; (3) added injections of rhIGF; and (4) 
added rhGH and rhIGF-1. 
Content validity was assessed through questionnaires piloted on five patients and their 
parents. They were amended based on feedback and then sent to a wider group. The 
questions (Appendix-1 and Appendix-2) included demographic data: age, height on the day 
of attending clinic and parental height. Specific questions included their degree of concern 
regarding their height, attitudes to injections to improve growth, willingness to join an 
RCT, and any previous growth promoting drugs. All questionnaires were anonymous and 
no patient identifiable data were collected. Parents and patients in the same family were 
given a single study number to enable comparison of responses. 
 
6.3.1 Subjects  
Questionnaires were distributed in two paediatric IBD clinics (Barts Health (London) and 
Royal Hospital for Sick Children (Glasgow)) to consecutive participants between 1st 
March and 31st July 2014. The target recruitment at each of the centres was at least 30 
patient questionnaires and 30 parent questionnaires. The child questionnaire was 
completed by a patient with CD who fulfilled the eligibility criteria (Ht SDS was ≤ 1.0). 
One of the child’s parents completed the parental questionnaire. A healthcare worker was 
available to explain the meaning of any questions that a child did not understand, but was 
not involved in recording the answers. 
Completed questionnaires were sent back to the MC CTU for initial result collation. For 
the study participants, Ht was measured with a Harpenden stadiometer and converted into 




standard deviation scores (SDS) for chronological age using 1990 UK standards (274). 
MPH and MPH SDS were calculated from reported parent heights. 
 
6.3.2 Statistics 
Data were analysed using Minitab software version 17. Descriptive analyses were used for 
all variables. Comparison between the patients and their parents and between subgroups 
was analysed using the Mann–Whitney test. Non-parametric data are presented with 
medians and ranges. For categorical variables percentages were calculated. The degree of 
agreement between responses of children and their parents was represented using the kappa 
statistic with 95% confidence interval and I would like to thank Professor Thomas Jaki for 
performing this analysis. Missing responses were not included in the descriptive analyses. 
p<0.05 was considered as statistically significant. All graphs were prepared by GraphPad 








6.4.1 Demographic characteristics  
The overall response rate was 48 (80%) out of 60 questionnaires were completed by 
patients and 46 (77%) out of 60 were completed by parents. Patient’s demographics, 
anthropometric and clinical information are presented in Table 6-1. Median Ht SDS at time 
of approach was -1.2 (-3.0, 0.9) and median MPH SDS was -0.6 (-3.2, 2.4) [Ht SDS vs. 
MPH SDS, p=0.004). 4 (9 %) of young people had been specifically treated with a growth 







Table  6-1: Demographic, anthropometry and clinical characteristics 
MPHSDS, mid-parental height SDS; HtSDS, height SDS score; CD, Crohn's Disease. 
 




  Total  
48 (80%) 
Age/year (range)  14.3 
(7.0, 17.7) 
Sex (M) n (%)  35 
(73)  
Ht SDS (range) -1.2 
(-3.0, 0.9)* 
MPH SDS (range)  -0.6 
(-3.1, 1.4)  











6.4.2  Participants response  
The responses from young people and parents to survey
’
s questions are summarised in 
Table 6-2. In total 3 (6%) young people and 5 (11%) parents were very concerned about 
height, 19 (40%) young people and 11 (24%) parents were slightly concerned about height 
and 26 (54%) young people and 29 (63%) parents were not concerned about height(Figure 
6-1). In 31 cases there was agreement with regards to how concerned a child and their 
parent were with the child’s height (κ=0.42 95% CI (0.23 to 0.71)), representing moderate 
agreement.  
The majority of respondents, 42 (88%) young people  and 40 (87%) parent, agreed that 
doctors should try to find a better treatment for growth in CD; 20 (42%) young people and 
25 (54) parents believed that opportunity of gaining extra height was worth a year of daily 
injection. 36 (75%) young children and 34 (74%) parents agreed to attend an extra visit to 
have child’s growth and other things checked (e.g. quality of life) if it sometimes means an 
extra visit (1 or 2 extra in a year). With respect of being comfortable of entering the study 
without being able to choose the treatment; 20 (44%) of parents said yes and 24 young 
people (50%) answered yes. Regardless of concern about height, 21 (44%) young people 
and 22 (48%) parents were willing for RCT participation. 
  




Table  6-2: The responses from young people and parents to survey’s questions 
 
  Total 
 Question Response Parents (n=46) Child(n=48) 













2 Do you think it is worth doctors trying to find 











3 Do you think that the opportunity of gaining 
extra 










4 We have explained that in an RCT you are not 
able to choose which treatment your child 











5 Would you and your child be willing to attend 
to have your child’s growth and other things 
checked (e.g. quality of life) if it sometimes 










6 If the RCT we had in mind was happening 

































6.4.3  Children and parents attitude about height and participation in 
RCT 
Cross-tabulation of questions was examined to understand if a child’s attitude to their height 
influenced their willingness to have injectable treatment. The results of cross-tabulation of 
Question 1 (How concerned are you about your/your child height?) and Question 6 (If the 
RCT we had in mind was happening now, would you be willing for your child to join?) are 
shown in Tables 6-3& 6-4.  
Although they were not concerned about their height, 6/26 (23%) patients were willing to 
participate in an RCT [median Ht SDS (range) for children who were willing, -0.6 (-2.2, 0.2), 
and not willing, -0.7 (-1.5, 0.8), to participate in the RCT, p=0.9]. Moreover, 12/19 (63%) 
young people who were slightly concerned about their height responded that they would be 
happy to participate in the RCT [median (range) Ht SDS was -1.6 (-3.0, -0.07) compared to 
6/19 (31%) who were slightly concerned and not willing to participate, -1.3 (-2.0, -0.6), 
p=0.5]. All very concerned young people were willing to take part if the RCT went forward, 
and they all had heights more than 1 SD below the mean [median (range) Ht SDS -2.1 (-1.2, -
2.5)] (Figure 6-2). 
Although they were not concerned about their children’s growth, 11/29 (38%) parents were 
willing to have their children participate in the RCT. The median (range) Ht SDS of these 
children was -1.2 (-3.0, 0.2) compared to -0.7 (-2.2, 0.9) for children of the 18/29 parents who 
were not concerned and not willing to participate in the RCT, p=0.61]. In contrast, 7/11(64%) 
of parents who were slightly concerned were willing for their children to join the RCT. There 
was no difference in median (range) Ht SDS [-1.4 (-2.3, -0.6) vs -1.1 (-1.6, -0.6) respectively, 
p=0.63] between these two groups. In addition, 4/5 (80%) of very concerned parents were 
willing for their children to participate in the RCT [median (range) Ht SDS -1.8 (-2.5, -1.1)] 
(Figure 6-2). 
 









 Question 6 
 If the RCT we had in mind was happening now, 
would you be willing to join? 
Total 
Question 1 
How concerned are you about your height? 
 No Yes 
















Table  6-4: Cross-tabulation of questions was examined to understand if parent’s attitude to their children height influenced their willingness to have 
injectable treatment 
 Question 6  
If the RCT we had in mind was happening now, would you be 
willing for your child to join? 
Total 
Question 1 
How concerned are you about your child’s height? 
 No Yes 












Missing data for question 1 =1, Missing data for question 6 =1 
 


















Figure  6-2: Yong people (left) and parents (right) attitude on height and willingness to participate in a randomised controlled trial 
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6.4.4 Anthropometric characteristic of children based on their attitude and 
willingness to participate in RCT 
The median Ht SDS [-1.5 (range, -3.0, -0.7)] in concerned young people was lower than in 
the non-concerned group [median (range) Ht SDS -0.7 (-2.2, 0.9); p=0.0009] (Table 6-5; 
Figure. 6-3). However, no differences were found in gender distribution (16M/6F vs. 9M/7F, 
p=0.98) or MPH SDS [-0.6 (-3.1, 0.5) vs. -0.6 (-2.3, 1.4), p=0.82] among concerned and non-
concerned children. The 21 (44%) children who were willing to participate in the RCT were 
shorter [median (range) with a Ht SDS -1.5 (-3.0 to 0.2] than the 27 (56%) who were not 
willing to participate in RCT [median (range) Ht SDS -0.9 (-1.9 to 0.9), p=0.01] (Table 6-5; 
Figure. 6-3). However, there were no differences among the two groups with respect to their 
age and gender, as the median age (range) was 14.7 years (7.0 to 17.3; 14M/7F) in the former 
group and the median age (range) was 14.1 years (10.0 to 17.7, p=0.5; 21M/6F, p=0.39) in 
the latter. 
 




Table  6-5: Different in age, gender and anthropometry between young people according to 





















  Concerned about height(n, 22) 
Slightly concerned (n, 19)+ Very 
concerned(n, 3) 
Not concerned about height 
(n, 26) 





Sex(M/F) (n)  16/6 19/7 








  Willing to participate in RCT 
(n, 21) 
Not willing to participate in RCT 
(n, 27) 




Sex(M/F)(n)  14/7 21/6 
Ht SDS -1.5 
(-3.0, 0.2)* 
-0.9 
( -1.9, 0.9) 




















Figure  6-3: Differences in height (SDS) between young people who were concerned and those who not concerned about their height(Left)and 
different heights (SDS) between young people who willing to participate in randomised controlled trial and those who not willing(Right). 
Ht SDS, height SD score. 
*
p<0.05. 
Ht SDS Ht SDS 
* 
SDS 
Ht SDS Ht SDS 
SDS 
* 






6.4.5 Major factors influencing decision making in willing to join RCT 
The major reasons for not wishing to participate in the RCT were identified by 18 out of 27 
of young people (Figure 6-4): Eight (44%) of them stated the fear of injections; 8 (44%) 
stated that they were not concerned about their height; 1 (6%) participant was already on 
























6% Fear of injections 
Not concerned about height 
Difficult to take off time from college  






6.5 Discussion  
This is the first feasibility study of an RCT in growth promoting therapy in children with 
CD. It is also the first quantitative study to survey the attitude of young people with CD 
and their parents towards endocrine therapy for growth promotion in an RCT. The possible 
treatments, in addition to optimal anti-inflammatory therapy (standard treatment), includes 
daily injections of rhGH; rhIGF-1; or rhGH and rhIGF-1. Many young people with CD and 
their parents would take part in an RCT of growth promoting therapy despite only a 
minority being very concerned about their height. However, answers may differ when 
confronted with consent to an ongoing trial, rather than a hypothetical one. Concerns about 
height were more likely in those who were shorter; and shorter children were more likely 
to consider this additional therapy to promote their growth. The results of our survey are in 
agreement with a preliminary RCT on rhGH in children with IBD (262). 
Reports show that boys are more vulnerable to the psychological burden of being short 
than are girls (317), however, we did not find any gender difference in their concerns over 
height. The majority of our participants were boys (73%), and this may have influenced 
our results. Major reasons for not taking part in the proposed RCT reported by young 
people in the survey were fear of injections and not being concerned about their height. 
Alleviating such concerns in eligible participants may result in higher recruitment rates.  
Regardless of concern about height, majority of young people and parents were willing for 
RCT participation. However, the degree of concern about height correlated with an interest 
in taking part in the proposed RCT, with 100% of very concerned patients willing to 
participate. Similarly, in a survey examining patients’ perceptions of faecal microbiota 
transplantation for UC, all patients with severe UC were willing to take part (318); thus the 
patients most affected by the condition it seems are the most likely to agree to any 
proposed study. 
Although currently there is a lack of conclusive data on rhGH in children with IBD, the 
initial results from the published studies as well as the study described in this thesis 
suggest that rhGH may have a positive effect on growth in the short term (258-262). The 
available evidence has shown the growth-promoting effect of rhGH on children with mild 
disease activity and growth retardation. Thus, the effect of rhGH on CD children with 
intractable inflammation and growth retardation remains unanswered. There is a need to 
perform larger, more conclusive studies of rhGH therapy which explore this issue. 




Given that a substantial proportion of children may  remain short despite use of optimal 
therapy (84) and considering that the abnormality may occur at multiple levels of the GH-
IGF-1 axis, the possible use of other forms of growth-promoting agents such as rhIGF-1, 
either alone or in combination with rhGH for promoting growth, also warrants further 
investigation. The studies of effects of IGF-1 on growth on CD have not been described 
yet, partly because of the theoretical risk of colon cancer in patients with high levels of 
circulating IGF-1. However, by using mathematical modelling to determine the dose of 
rhIGF-1 that could be prescribed to maintain serum IGF-1 level within the physiological 
range study may inform the design of future clinical trials (319). 
One of the limitations of the survey was that exploring the reasons for patients’ concern at 
being short was beyond the scope of a questionnaire on willingness to consent. Mason  et 
al (98) published the first study which showed  that short stature is associated with adverse 
quality of life measured by IMPACT-III in the subdomain of body image. It would, 
therefore, be beneficial to assess the impact on quality of life in any future trial involving 
the use of growth promoting therapies. 
 
6.6 Conclusions 
In summary, this study indicated that it was feasible to consider the initiation of a 
randomised controlled trial of growth therapy in children with CD with the majority of 
those surveyed were interested despite a minority being very concerned about their height. 
By targeting the shorter young people as well as alleviating fears about injections to them, 




















7.1 General discussion  
The studies presented in this thesis investigated the effects of anti-TNF-α and rhGH 
therapy on linear growth and bone health in CD children.  
The impact of anti-TNF-α on linear growth, IGF-1 axis and biomarkers of bone turnover 
were investigated in Chapter-2. My data showed that receiving anti-TNF-α maintenance 
therapy for 12 months was associated with a significant improvement in growth velocity 
and ∆Ht SDS, in those who had potential to grow at time of anti-TNF-α induction, 
although no benefit was seen in more mature patients. These observations are consistent 
with previous data showing that anti-TNF-α therapy is associated with linear growth 
improvement in children with chronically active CD in early puberty (88;240). In 
accordance with these previous reports (88;240), anti-TNF-α therapy was not associated 
with a significant improvement in Ht SDS in my study, may suggest that control of 
inflammation improves growth velocity sufficiently to prevent further deterioration in 
height but is unable to improve overall height. This finding suggests that if anti-TNF-α 
therapy is given to CD patients with growth potential, attained height may still be sub-
optimal of what would be expected in a healthy population. Thus, if growth is of concern, 
the role of adjuvant therapy to boost height in these children is worth further exploration. 
The GH-IGF-1 axis is a crucial signalling pathway that impacts on linear growth, bone, 
and muscle development (73;74). It is assumed that disturbances in the GH–IGF-1 axis are 
one of many factors contributing to growth retardation in CD children (112;114;115). 
However, in the current study no obvious disturbances in this axis were noted.  
Consistent with previous studies (149;150;178), I found a state of low bone turnover at the 
time of starting anti-TNF-α, as indicated by markers of bone formation (BSAP) and bone 
resorption (β-CTX). Marked increases in bone formation biomarkers and moderate 
increases in bone resorption markers were also observed following anti-TNF-α therapy, in 
line with previous evidence (237;243). Whether this improvement in disease status and 
biomarkers of bone metabolism translated to improvement in bone mass was explored 
further in Chapter-3. 
The Chapter-3 prospective study explored the impact of anti-TNF-α on bone mineral 
density and muscle mass and function. BMD was assessed at different body sites including 
TB, LS by DXA, and weight and non-weight bearing limbs by pQCT. Muscle mass was 
assessed at TB by DXA and muscle cross-sectional area was assessed at radius by pQCT. 
Muscle function in the non-dominant hand was assessed by MIGF. My results revealed 
improvement in growth and bone formation following anti-TNF-α and there was 




insufficient evidence to show a change in bone health or muscle mass and function as 
assessed by imaging.  
A recent study of anti-TNF-α therapy in children and adolescents with CD did find an 
improvement, but not normalization, of trabecular bone density and cortical structure using 
pQCT (237). It is of note however, that my study cohort consisted of a group of children 
with a longer duration of disease (3.1 vs. 2.1 years), and a greater degree of lean mass 
deficits. The degree of recovery from cytokine-induced bone growth retardation has been 
demonstrated to be dependent on the duration of exposure (120;248). However, two 
additional studies found no improvement on bone health after anti-TNF-α with disease 
duration similar/longer than our cohort (241;254). Using exclusive enteral nutrition in ten 
newly diagnosed children with CD normalized trabecular density and muscle area using 
pQCT at 12 weeks (223). Pooling my findings with the available evidence raises a question 
about the proper time for intervention to see recovery of bone health in CD children. 
Further studies are needed to determine if there is window for intervention and recovery of 
bone health in CD children. 
Catch-up in bone mass is greater in younger children with CD following controlling the 
inflammation (153;237), and my study consisted of a large proportion of adolescents in 
later stages of puberty, with a limited window for improvement of skeletal growth. 
Additionally, the possibility of a lag between catch-up linear growth and bone growth may 
also explain our results (302). Despite significant improvement in disease activity index in 
our cohort, there is the possibility of persistent mild, chronic inflammation (149). 
Unfortunately, we did not have information of endoscopic re-evaluation or faecal 
calprotectin to inform on this. The findings of low muscle mass and strength in my cohort 
is consistent with previous studies of adolescents with CD (115;153-155;199;200). This 
study also revealed a strong independent positive association between muscle and bone 
density and geometry following anti-TNF-α therapy in paediatric CD. In accordance with 
the mechanostat theory (299), it is possible that sustained muscle deficit may hinder 
skeletal acquisition in paediatric CD following anti-TNF-α therapy. Thus, the role of 
adjuvant interventions to improve muscle strength such as exercise/nutrition may be 
beneficial in CD after controlling inflammation, and warrants further studies. 
Another possible explanation to be considered from our analysis is the positive association 
between ALS SDS and trabecular BMD SDS, and negative association between IGFBP-3 
and tibia cortical thickness SDS. This raises the possibility that the IGF axis may 
contribute to trabecular and cortical geometry impairment seen in CD children. A 
reduction in trabecular BMD and cortical bone volume is present in ALS-Knockout mice, 




which is explained by the inability to form ternary complex, resulting in the marked 
reduction in circulating IGF-1 (77;300). Recently, data from our group, investigating 
women with childhood onset type 1 diabetes mellitus showed a significant inverse 
correlation between ALS and trabecular bone separation (301). This raises the possibility 
that ALS could play a role in the regulation of trabecular bone, and this might be exerted 
via IGF-1 independent mechanisms. However, preclinical studies are needed to verify this 
assumption. Regardless of proposed possible mechanisms behind the lack of improvement 
in bone in this cohort, it seems that inflammation insult to the skeleton is not completely 
removed even with anti-TNF-α therapy. The role of adjuvant therapy to improve 
musculoskeletal development in children with CD such as nutritional, exercise or 
manipulation of the GH/IGF axis requires further exploration. 
In children with CD, systemic abnormalities of the GH-IGF-1 axis are reported, suggesting 
that many may exhibit a range of abnormalities in secretion and sensitivity of the GH-IGF 
axis (101). From the results presented in Chapter-2, and consistent with the existing 
evidence (203;235;239;240;245;249), it seems that targeting cytokines using anti-TNF-α 
therapy leads to statistically significant, but clinically modest, height gain. Therefore, if 
maximising growth is the concern, adjuvant therapy combined with other forms of growth-
promoting therapy may also need to be considered. Given gaps in knowledge on the effect 
of rhGH, especially at higher dose and for long duration, on linear growth and glucose 
homeostasis in children with CD, the third study (Chapter-4) was conducted to investigate 
this question in the cohort of CD children. In the first long term case-controlled study of 
rhGH at 0.067 mg/kg/day, which is almost double the replacement dose, we demonstrated 
a sustained effect on linear growth over a 24-month period, in short pubertal CD children 
compared with untreated control patients. However, findings from this study should be 
interpreted with caution as the sample size was small and puberty is a potential 
confounder. Data may therefore not be applicable to prepubertal CD children. Furthermore, 
it is noteworthy to highlight that the participants in our cohort had mild or inactive disease 
so our finding cannot be applied to those with growth failure and intractable disease. A 
further large RCT will be required to determine whether rhGH therapy can potentially 
improve growth in this population regardless of pubertal progress and disease status. 
It is known that rhGH treatment is associated with a decrease of insulin sensitivity in some 
studies (320). However, my analysis in this study revealed that rhGH therapy for 24 
months was not associated with deleterious effect on glucose homeostasis in this cohort. 
Given that children with inflammatory conditions may also be at risk of developing insulin 
resistance as a result of the inflammatory process (305) as well as the use of concurrent GC 




therapy (259;264), I believe close monitoring of glucose homeostasis is required when 
rhGH therapy is used in this cohort in both a clinical setting and for research purpose. 
Following the findings in Chapter-3, work performed in Chapter-5 aimed to examine the 
role of adjuvant therapy with rhGH on bone health in children with inactive/mild disease 
status. This study is the first report of the results of a 24-months prospective study of rhGH 
therapy on bone health and lean mass, measured by DXA, in a small cohort of children 
with mild/inactive CD. 
Though the sample size was small, my data indicated 24 months of rhGH in paediatric CD 
was not associated with improvement in bone density and body composition, despite an 
increase in biomarkers of bone formation at six months, after adjusted for skeletal 
maturation and improvement linear growth, and the consideration that most of children 
(6/8) had completed their pubertal growth. This may be due to partial recovery of the GH-
IGF-1 axis and/or persistent decreased muscle mass. A state of functional GH insensitivity 
can exist in children with chronic disease (101), and whilst early evidence show that use of 
relatively high dose rhGH may overcome this insensitivity and lead to improvement in 
linear growth (259;260;262), the possibility of differential end organ insensitivity should 
be considered. Whilst serum IGF-1 levels have been shown to increase with rhGH therapy 
in children with CD (283), the observed persistent low systemic IGF-1 SDS, despite supra-
physiological doses of rhGH in this small cohort of children, suggests the possibility of 
partial rescue of GH resistance following rhGH therapy. A study in female rats showed 
that combined rhGH and rhIGF-1 therapy leads to significantly higher systemic IGF-1 
paralleled with improvement in cortical bone mass (321). Thus, normalisation of IGF-1 
with rhIGF-1 therapy (on its own or in combination with rhGH) may result in greater 
improvement of bone deficits, and future research is needed to evaluate this.  
My analysis also confirms potential imperative influence of muscle on bone health (299). 
Thus, the challenge remains for further research to identify management strategies for low 
muscle mass and function in CD and to examine whether addressing lean mass deficit can 
improve bone health. Therefore, future clinical studies assessing mechanical-loading 
interventions are required. It is also possible that DXA bone assessment may not be 
sufficiently detailed to give information on changes of bone structure following rhGH 
therapy in these children. Newer methods of assessment using high-resolution pQCT or 
microMRI may allow non-invasive evaluation of bone microenvironment and should be 
considered in future studies in CD. Finally, as participants in this study had disease of long 
duration, the question of a possible optimal window of recovery is also raised. However, so 




far, there is no general agreement on the relative importance of disease duration on bone 
health recovery.  
Currently there is a lack of conclusive data on rhGH in children with CD, the initial results 
suggest that rhGH may have a positive effect on growth in the short term (258-262). The 
available data are limited by small sample size and are restricted to children with CD who 
only have mild disease activity and growth retardation. Thus, to date, the effect of rhGH on 
CD children with intractable inflammation and growth retardation has not been examined 
and larger, more conclusive studies of rhGH therapy that explore this issue are still needed. 
Work presented in Chapter-6 was the first piece of research that surveyed the attitude of 
young people with CD and their parents towards endocrine therapy for growth promotion 
in an RCT. The participants were questioned about their attitude to take part in one of the 
four proposed arms of the RCT including (1) standard treatment to combat inflammation; 
(2) additional injections of rhGH; (3) additional injections of rhIGF; and (4) a combination 
of tow injections of rhGH and rhIGF-1. Many CD children and their parents would 
participate in an RCT despite only a minority being very concerned about their height. 
Concerns about height were more likely in those who were shorter; and shorter children 
were more likely to consider this additional therapy to promote their growth. Not being 
concerned about their height and fear of injections were foremost explanations stated by 
CD children in the survey for not participating in the proposed RCT. Thus, higher 
recruitment rates may be achieved in eligible participants by alleviating such concerns. 
However, responses could vary when challenged with consent to an on-going trial, rather 
than a hypothetical one. Exploring the explanations for patients’ concern at being short was 
beyond the scope of a survey on willingness to consent. Recently our group (98) published 
the first study which showed that short stature is associated with adverse quality of life 
measured by IMPACT-III in the subdomain of body image. Thus, it would certainly be of 
interest for future research to consider the impact of poor growth, short stature and delayed 
puberty on the quality of life of these children. 
 
7.2 Conclusion  
The data reported in this thesis found that combatting inflammation with anti-TNF-α was 
associated with modest clinical improvement in height, but with no observed beneficial 
effect on musculoskeletal health. Overall, no definitive conclusions can be made regarding 
the effect of anti-TNF-α therapy on bone health, as conclusive data are still lacking. If 
growth is of concern, the data suggest that targeted therapy with rhGH, or in combination 
with rhIGF-1, during critical periods of growth is worthy of further exploration. The use of 




high dose rhGH for 24 months was associated with a growth-promoting effect but no 
influence was observed on bone and body composition. Further larger randomised studies 
are needed to definitively evaluate the effects of rhGH on growth and musculoskeletal 
development in paediatric CD. The careful monitoring of glucose homeostasis while using 
rhGH in children with CD and growth retardation is also recommended. The sustained 
muscle deficit in children with CD hinders skeletal acquisition following anti-TNF and 
rhGH therapy, thus muscle mass and strength are imperative contributors for bone health in 
CD. Interventions to preserve or increase muscle mass can be one of the important 
strategies that may improve bone health. From surveying CD children it seems to be 
feasible to consider the initiation of a randomised controlled trial of growth therapy in 
those children for whom growth is a valid concern. 
 
7.3 Strength and limitations  
Specific strengths and limitations of the thesis results have been comprehensively 
presented in each respective chapter. In summary, the major strengths are the evaluation of 
two treatment strategies in two models of CD, looking at both growth and bone health in 
children with CD in the context of active inflammation by using anti-TNF-α, and the role 
of adjuvant therapy alongside rhGH therapy in children with mild/inactive CD. Chapter-3, 
although preliminary due to sample size constraints, is the first study to have examined the 
effect of anti-TNF-α on IGF-1 and binding protein and related them to bone health in the 
context of paediatric chronic inflammation. Secondly, this study provides a broad view of 
skeletal health at different body sites through the use of DXA and pQCT. Thirdly, this is 
the first study that charts the effect of anti-TNF-α therapy on changes in upper limb muscle 
function in paediatric patients with CD. Chapter-4 and Chapter-5 are important as the first 
study that extensively explored the long-term effect of rhGH on growth, IGF-1, glucose 
homeostasis, biomarkers of bone turnover, bone density and body composition in this 
particular population.  
The main limitation of the studies presented in this thesis related to sample size constraints, 
which restricted the analyses of potential confounding factors on growth and bone health. 
However, we tried to overcome this issue through the use of mixed model regression 
analysis to obtain association between variables. In the anti-TNF-α studies, lack of 
knowledge of drug trough levels may have impacted on our ability to ensure anti-TNF-α 
optimisation, and without a comparable control group, we were unable to examine the 
protective role of anti-TNF-α. In relation to evaluation of bone parameters, although the 
DXA and pQCT methods provided information about BMD and bone geometry at different 




body sites, both methods were insufficient to characterise the microarchitecture of 
trabecular and cortical bone, which are crucial components of bone strength. Furthermore, 
in the absence of data on sex steroid levels, their relationship with changes in bone density 
could not be taken into account. Although, it was more feasible to use validated survey of 
child self-assessment of puberty (Chapter-2 & Chapter-3) instead of investigator 
examination, it potentially leads to misclassification of pubertal stage. However, we 
overcome this limitation by measuring BA and use it for further analysis.  
Measurements of pQCT geometry were adjusted only for height, without taking age into 
consideration, so may yield error when comparing individuals of the same height with 
different age and pubertal maturation, ignoring the influence of sexual hormones on bone 
and muscle development. Moreover, the studies are limited by a reliance on validated 
disease activity index to assess disease status, which is not a valid assessment of mucosal 
healing in comparison with endoscopic re-evaluation and assessment with faecal 
calprotectin.  
 
7.4 Implication for clinical practice and further research  
Given that the majority of CD children present in early or mid-adolescence, there is a 
limited window of opportunity for improvement in growth, and a combined approach may 
be needed that targets both disease and growth. However, in the absence of conclusive 
data, rhGH therapy should be considered only in those with suboptimal growth despite 
controlling inflammation. Because the results of this thesis suggest that inflammation-the 
insult to the skeleton is not completely removed, even with anti-TNF-α therapy, the role of 
adjuvant therapy to improve musculoskeletal development in children with CD such as 
nutrition and exercise may be useful.  
Based on work relating to growth and bone promoting therapy in children with CD, the 
following future research should be considered: 
1. Firstly, an in-depth understanding of the mechanism behind the insult to 
bone cells and the potential for spontaneous recovery following 
proinflammatory cytokines exposure should be addressed through 
preclinical study. Such research may aid clinicians in a more focused 
approach to delivery of management for bone health. 
2. Large prospective studies are still needed to verify the effect of anti-TNF-α 
on bone health. 




3. RCT in children with active CD and growth failure to compare the four 
treatment strategies (combat inflammation, combat inflammation and rhGH 
therapy, combat inflammation and rhIGF-1 or combat inflammation plus 
rhGH and rhIGF-1) on growth and bone health. 
Given the abnormality may occur at multiple levels of the GH-IGF-1 axis (101), the 
possible use of other forms of growth-promoting agents such as rhIGF-1, either alone or in 
combination with rhGH for promoting growth should be considered. There are a number of 
reasons why combination treatment of rhGH with rhIGF-1 may be more beneficial for 
growth and metabolism. Human data has shown that combined therapy resulted in a higher 
serum concentration of IGF-1 compared with IGF-1 alone, probably linked to the negative 
feedback effect of IGF-1 on GH secreted by the pituitary (322). The addition of rhGH to 
rhIGF-1 may reverse the insulin suppressive effects of the latter and may have anti-
catabolic effects on protein synthesis and muscle mass (322-324). Furthermore, 
administration of rhIGF-1 alone results in hypoglycaemia, thus concomitant treatment with 
rhGH may attenuate the glucose-lowering effect of rhIGF-1. An experimental rat model of 
uraemia showed that concomitant treatment with rhIGF-1 and rhGH was more effective in 
improving growth than rhIGF-1 or rhGH therapy alone, and inhibited the hypoglycaemia 
that may occur with use of rhIGF-1 alone (325).  
Finally, the use of IGF-1 may itself counter the insulin-resistant state that can be induced 
by the use of high-dose rhGH therapy in a group of children who may already have a 
degree of insulin resistance, due to their state of chronic inflammation and glucocorticoid 
excess (259). A double-blind placebo-controlled crossover trial of seven pre-pubertal 
cystic fibrosis children showed that rhIGF-1 therapy for 6 months was associated with an 
improvement in glucose homeostasis (326). More recently, Rao et al. (319) reported the 
use of mathematical modelling to determine the dose of rhIGF-1 necessary to maintain 
circulating IGF-1 in the physiological range in children with IBD and growth failure, 
which may aid in selecting therapy dosage for children with CD to maintain IGF-1 level 
within an acceptable range.  
4.  RCT to assess the effect of exercise alone or in combination with rhGH-
IGF-1 therapy on the bone health of children and adolescents with inactive 
CD. 
In keeping with muscle-bone unit theory (299), the results of studies in this thesis 
consistently showed that muscle mass and strength are important contributors to bone 




health of subjects with CD. Thus interventions to encourage physical activity may be 
















Appendix-1: Young People Survey 
 
1. About you: 
a. How old are you?  years,  months (example: 12 years, 8 months) 
b. Are you: Male   Female   
c.  Please tell us your height as measured at today’s clinic (the clinic staff will be happy to tell 
you this if they haven’t already done so) 
Height    centimetres Date measured:  dd  /  mm  / yyyyy  
d. Please can you tell us your parents heights (if they haven’t completed their own form): 
Mother: feet  inches (    centimetres) 
Father:   feet  inches (    centimetres) 
e. Have you ever been treated for a growth problem?  Yes  
 No  
 Don’t know  
If yes, what treatment did you have: 
   
   
   
 
2. About your views: 
a. How concerned are you about your height? Not concerned  
  Slightly 
concerned  
  Very Concerned
  
b.  Do you think it is worth doctors trying to find a better treatment  
for growth in Crohn’s disease? Yes  
  No  
c.  Do you think that the opportunity of gaining extra height 
 is worth a year of daily injections? Yes  
  No  
d. We have explained that in an RCT you are not able to choose which 
treatment you would receive. Would you be comfortable with 
this? Yes  





e.  Would you be willing to attend to have your growth and other  
things checked (e.g. quality of life) if it sometimes means an extra 
clinic visit (1 or 2 extra in a year)? Yes  
  No  
   
f. If the RCT we had in mind was happening now, would you be willing 
to join? Yes  
  No  
You don’t have to give us a reason, but it would help us if you could provide us with more information 




g. Has your mum or dad also completed a survey questionnaire? Yes  
  No  
   
Please add here any information that you think would be helpful to the doctors thinking about 







Thank you for taking the time to complete this survey. Please place the questionnaire in 






Appendix-2: Parent Survey 
 
3. About you: 
a. Are you the parent of a child with Crohn’s disease? Yes  
 No   
  (If no, please do not complete the rest of the survey) 
 
b. Do you also have inflammatory bowel disease? Yes  
 No   
c. Please can you tell us your height and that of the other parent: 
Mother:  feet  inches (    centimetres) 




4. About your child: 
a. Age:  years,  months (example: 12 years, 8 months) 
b. Is your child: Male   Female   
c.  Please tell us your child’s height as measured at today’s clinic (the clinic staff will be 
happy to tell you this if they haven’t already done so) 
Height    centimetres Date measured:  dd  /  mm  / yyyy  
d. Has your child ever been treated for a growth problem?  Yes  
 No  
 Don’t know  
If yes, what treatment was given: 
   
   
   
 
5. About your views: 
a. How concerned are you about your child’s height? Not concerned  
  Slightly 
concerned  
  Very Concerned
  
b.  Do you think it is worth doctors trying to find a better treatment  
for growth in Crohn’s disease? Yes  
  No  
c.  Do you think that the opportunity of gaining extra height 
is worth a year of daily injections? Yes  





d. We have explained that in an RCT you are not able to choose which 
treatment your child would receive. Would you be comfortable with 
this? Yes  
  No  
  
e. Would you and your child be willing to attend to have your childs 
growth and other things checked (e.g. quality of life) if it sometimes 
means an extra clinic visit (1 or 2 extra in a year)? Yes  
  No  
   
f. If the RCT we had in mind was happening now, would you be willing 
for your child to join? Yes  
  No  
You don’t have to give us a reason, but it would help us if you could provide us with more 




g. Has your child also completed a survey questionnaire? Yes  
  No  
   
Please add here any information that you think would be helpful to the doctors thinking about 







Thank you for taking the time to complete this survey. Please place the questionnaire in 
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